VacCiencia

FINLAY EDICIONES

Boletín Científico

No. 18 (1-10 agosto / 2023)

EN ESTE NÚMERO

VacCiencia es una publicación dirigida a investigadores y especialistas dedicados a la vacunología y temas afines, con el objetivo de serle útil. Usted puede realizar sugerencias sobre los contenidos y de esta forma crear una retroalimentación que nos permita acercarnos más a sus necesidades de información.

- Noticias más recientes en la Web sobre vacunas.
- Artículos científicos más recientes de Medline sobre vacunas COVID-19.
- Patentes más recientes en Patentscope sobre vacunas.

IFV INSTITUTO FINLAY DE VACUNAS

SiViFinlay

VaCyT

CUBA

Noticias en la Web

India & Vaccines: Where Are We?

Aug 1. COVID-19 pandemic accelerated the development, manufacture, and distribution of vaccines at an unprecedented speed and scale.

Despite being one of the leading manufacturing hubs, India's vaccination coverage is still below the world average. In 2021, global immunisation coverage was 81 per cent and India's coverage was only 79.6 per cent. However, the number changed drastically to 89.4 per cent in 2022. As seen in Figure 1, the increase in immunisation coverage in India can largely be attributed to an increase in diphtheria and pneumococcal vaccinations.



Data analysis from the above figure also reveals that there is a consistent dip between the nth and the (n+1)th doses of vaccines. For instance, in 2021, the DTP-containing vaccine, 1st dose had a coverage of approx. 87.5 per cent in India, which decreased to about 85.2 per cent in the second dose of the vaccine, and a similar trend followed in the subsequent year for the same vaccination doses. There must be an increased focus from the public sector on ensuring the completion of vaccination doses to achieve optimal vaccine efficacy.

Another cause for concern in the Indian immunisation landscape is the increase in reported cases of typhoid and measles in 2022 (Figure 2). The reported cases for typhoid increased from 0 in 2021 to 4,02,532 in 2022 and for measles, it increased from 5700 in 2021 to 40967 in 2022. The huge increase in typhoid cases was most likely due to the increased drug resistance and low immunisation coverage and not a consequence of poor hygiene or water contamination. However, the high cost of the vaccine continues to be a major roadblock to nationwide adoption.

Thus, the National Technical Advisory Group on Immunisation, or NTAGI, advised the Government of India to include the typhoid conjugate vaccine as a part of its routine immunisation programme as that would lead to improved affordability of the vaccine. The Indian immunisation schedule should incorporate changes that arise

due to endemics and/or pandemics and must rapidly implement the reforms to ensure optimal health coverage. This is crucial for timely action and management of infectious diseases and will help bolster Indian stand in the global immunisation landscape.



COVID-19 vaccines

India has administered over 2.2 billion doses of the COVID-19 vaccine, and the cases have declined steadily. Despite being poised to be the world's most populous country in 2023, India's cumulative confirmed cases of COVID-19 remain lower than that of the US and China (refer to Table 1).

Table 1: Indian COVID-19 Scenario, 2020-2023*

	Confirmed COVID-19 Cases	COVID-19 Deaths	COVID-19 Doses
Global	76,79,84,989	69,43,390	13,39,72,92,784
US	10,34,36,829	11,27,152	66,88,82,018
China	9,92,77,103	1,21,237	3,51,58,72,818
India	4,49,92,960	5,31,892	2,20,67,10,296

*data as of June 14th, 2023

Source: WHO, Frost & Sullivan

The leading reason for not getting vaccinated in India largely was due to the fear of side effects, as it is a newly introduced vaccine. However, as the increased vaccine dose has led to a decline in COVID-19 cases and mortality, the data is likely to bolster improved trust in Indian citizens and increase its uptake in the subsequent years.

Indian vaccine innovation landscape

The COVID-19 pandemic saw the emergence of several indigenous vaccines in India. Bharat Biotech's Covaxin, an inactivated vaccine and Zydus Cadila's Zycov-D, a DNA vaccine, were both approved by the Drug Controller General of India (DCGI). India is also developing its first indigenous mRNA vaccine, HGC019, which is being made by Gennova, Pune, in collaboration with HDT Biotech Corporation, US. Other indigenous vaccines in clinical development include Biological E's BECOV (protein subunit vaccine), Bharat Biotech's BBV154 (non-replicating viral vector vaccine), and Aurobindo's UB-612 (protein subunit vaccine).

Other global manufacturers who received COVID-19 vaccine approvals in India include Serum Institute of India (SII)/AstraZeneca/Oxford, Moderna, Gamaleya, and Janssen. Within the Indian population, Covishield and Covaxin were some of the most administered vaccines.

India is also an exporter of COVID-19 vaccines. As of May 2022, India exported about 140.2 million COVID-19 doses to the world, accounting for about 2.3 per cent of the global COVID-19 vaccine export share (Figure 3). The Union Ministry of External Affairs (MEA), India, reported that SII's Covishield accounted for over 66 per cent of the total COVID-19 exports from India. For instance, SII's Covovax was exported to the Netherlands, and SII's Covishield to Brazil.



Several COVID-19 vaccine candidates are currently undergoing clinical development in India. While most of them are protein subunits and inactivated vaccines, India is likely to witness upcoming regulatory approvals for RNA vaccines as the next emerging technology segment within the COVID-19 space. Some of the key emerging innovators in this space include Bharat Biotech, Biological E, Gennova, and Aurobindo.

The way forward

The COVID-19 pandemic accelerated the development, manufacture, and distribution of vaccines at an unprecedented speed and scale. Global collaborations and rising political pressures were able to shorten the vaccine development time to less than a year as opposed to the standard 10-year time frame. While this was beneficial in the clinical management of the pandemic, the shortened time was often not sufficient to achieve optimal efficacy rates.

For instance, Covaxin had an efficacy rate of about 78 per cent and Moderna's mRNA vaccine had a low antibody titer against the beta-variant of the virus. Furthermore, the efficacy of the COVID-19 vaccines was not fully tested against the new SARS-CoV-2 variants such as delta and omicron. COVID-19 distribution equity across global economies and the impact of COVID-19 vaccination for children were also some of the major causes of global concern and WHO is currently looking to improve vaccine distribution equity globally.

Although 3 vaccines, namely, Corbevax, Covaxin and Covovax, received emergency use regulatory approvals for use in children between 5 and 12 years of age, there is still a lot of concern regarding the long-term impact and side effects of the vaccine in that age group. There is also a need to study the impact of co-morbidities during the administration of COVID-19 vaccines. Additionally, the impact of COVID-19 vaccines should be

studied in pregnant women and infants. Rigorous post approval monitoring of COVID-19 vaccines across different population age groups and demographics will help alleviate the rising concerns for COVID-19 vaccines and help develop more effective products in the future.

India also needs to decrease its large dependency on China for API (active pharmaceutical ingredients) manufacturing to emerge as a stronger leader in the global vaccine industry. The Indian government needs to increase its R&D spending and create a favourable local environment for end-to-end vaccine innovation and manufacturing. Adding innovative vaccine delivery platforms, such as a common viral vector or cell-based delivery platforms, to India's growing vaccine portfolio can also help scale production. Regulatory frameworks should also be redesigned to include platform-based approvals. Then, a single approved platform can be utilised to develop multiple vaccine products, thereby accelerating market entry through a streamlined regulatory process.

Furthermore, India's non-COVID-19 vaccine portfolio is largely restricted to LIC (low-income country), and LMIC (lower middle-income country) sectors. There is a need to tap into HIC (high-income country) markets to accelerate growth in this sector. The Indian vaccine industry should explore technology transfer and contract manufacturing opportunities for vaccines such as conjugate vaccines, pneumococcal vaccines, and rotavirus vaccines to enter the HIC segment. Furthermore, novel applications should also be explored. For instance, vaccines are also likely to enable disease treatment, in cases such as norovirus and HIV infections. These opportunities should be explored further for the growth of the Indian vaccine sector.

International collaborations can also help improve the production and delivery of vaccines at an affordable rate. For instance, the collaboration among the SII, the Bill & Melinda Gates Foundation, and GAVI accelerated the development and delivery of about 200 million COVID-19 vaccine doses at the cost of about $3 per dose. There is a need to develop a process that formalises such collaboration going forward and enables accelerated response to endemics and/or pandemics.

Global vaccine manufacturing is largely restricted to large pharmaceuticals such as Pfizer, Sanofi, GSK, and Novartis. However, IP licensing programmes and modular manufacturing approaches can enable Indian manufacturing of global vaccines and thereby provide improved access. Indian public and private sectors should explore these strategies to grow in this industry sector.

The public sector manufacturing capacity in India remains underutilised. According to the National Health Profile of the Government of India, the share of the public sector share in total installed capacity decreased from 22.8 per cent in 2006 to about 10.2 per cent in 2019. This was also accompanied by a steep decline in public sector demand for Universal Immunisation Programme (UIP) vaccines. The government also began to direct UIP vaccine demand to the private sector, which now accounts for over 95 per cent of the UIP demand. However, there are only about 25 vaccine manufacturers, and they are unlikely to meet the rising demand for vaccines in the coming years through indigenous manufacturing hubs. Hence, India will continue to rely increasingly on imports for vaccine demands.

While India's vaccines provide greater value for money when compared to its global counterparts and enabled its exports to low- and middle-income economies, COVID-19 adversely impacted India's position as a global vaccine exporter. It also provided an opportunity for China to emerge as one of the leading participants in the global vaccine landscape.

However, the pandemic also fueled Indian manufacturers such as Bharat Biotech to develop novel vaccines

and enter the global vaccine market. There are several other indigenous participants that are developing novel vaccines across newer technology segments, such as mRNA vaccines for COVID-19. Growing participation from the public sector and the optimal utilisation of India's manufacturing capabilities can not only enable India to become self-sufficient but also help India regain its dominant position in the global vaccine market.

Fuente: BioSpectrum. Disponible en https://goo.su/L6LT88i

Group B Streptococcus Vaccine Shows Promise in Phase 2 Study

Aug 1. Pfizer Inc. has announced positive findings from a phase 2 study that analyzed its hexavalent capsular polysaccharide (CPS) conjugate of the Group B Streptococcus (GBS) vaccine. GBS is a form of bacteria that can cause harmful diseases in infants in the first 3 months of life. Some of these diseases include sepsis, pneumonia, and meningitis. Approximately 1 in 4 pregnant individuals carry GBS and may pass the bacteria to their infant before childbirth, according to Pfizer.

Image credit: Dr_Microbe - stock.adobe.com

"Annually, there are nearly 400,000 cases of infant disease and approximately 138,000 stillbirths and infant deaths worldwide due to GBS," said Annaliesa Anderson, PhD, senior vice president and chief scientific officer at vaccine research and development from Pfizer, said in a press release.

The researchers evaluated CPS and a genetically detoxified diphtheria toxin cross reactive material (CRM) to develop 197 glycoconjugate (GBS6) to protect infants against the disease. The study was divided into 3 stages, with stage 1 focused on studying the safety and immunogenicity of 66 healthy individuals in South Africa who were not pregnant, based on a parallel natural history study conducted in South Africa.

Stage 2 focused on The New England Journal of Medicine's (NEJM) publication that assessed the safety and immunogenicity in 360 healthy pregnant individuals and their infants. The individuals ranged in age from 18-40 years, resided in South Africa, and were administered a random, single dose of GBS6, prepared at 5, 10, or 20 µg/serotype. This was given with or without an AlPO4 adjuvantor placebo during the later side of the second trimester. Stage 3 focused on evaluating 216 healthy individuals who were pregnant, residing in South Africa, the United States, and the UK.

Pfizer stated that in stage 2, the groups who received the vaccine versus the placebo had similar reactions regarding the safety in both the mothers and infants. The study showed that 2%-8% of the individuals who received the GBS6 vaccine reported a fever, compared with 5% administered the placebo. Further, 45%-70% of pregnant individuals reported adverse effects (AE) from GBS6 that were dependent on the dose compared with 61% with the placebo; however, between both groups, the most common AEs were related to pregnancy.

Despite the AEs, stage 2 of the GBS6 vaccine provided maternal antibodies to fight the GBS CPS serotypes. The antibodies in the vaccine were subsequently transferred to the infants to fight off the bacteria produced by GBS.

"The findings published in NEJM provide hope that maternal vaccination with GBS6 may protect infants against GBS, potentially helping to prevent thousands of cases of illness annually, if it is successfully developed and approved. Building on decades of expertise and knowledge in vaccines, we are committed to helping protect newborns and young infants through maternal immunization," Anderson said in the release.

The findings suggest that the GBS6 vaccine could protect infants from being affected by the GBS disease, based on evidence expanded from the NEJM study, according to the investigators.

Fuente: Pharmacy Times. Disponible en https://goo.su/aczwbZ

China recomienda a personas mayores vacunas especializadas contra la variante XBB de COVID-19

2 ago. Para prepararse mejor ante un posible aumento de contagios de COVID-19 durante las temporadas de otoño e invierno de este año, el Mecanismo Conjunto de Prevención y Control del Consejo de Estado de China anunció un aviso el martes, pidiendo vacunarse a sectores clave de la población, como las personas mayores, y recomendando vacunas que contengan los componentes del antígeno de la variante XBB como dosis priorizadas.

Una trabajadora médica administra una vacuna en un centro de vacunación en la estación de servicio de salud comunitaria de Honglian en la calle Guanganwai, distrito de Xicheng, Beijing, capital de China, el 3 de enero de 2021. Foto: Xinhua.

Según una actualización de la cuenta de WeChat de la Administración Nacional de Control y Prevención de Enfermedades, la población objetivo son personas de 60 años o más, o de 18 a 59 años con afecciones de salud subyacentes graves y sistemas inmunológicos afectados. También se incluyen las personas con alto riesgo de infección.

La población objetivo también debe haber completado la inmunización básica o haber sido infectada previamente por COVID-19, dice el aviso.

Como la variante XBB sigue siendo la prevalente en China, se recomienda encarecidamente priorizar las vacunas que contienen el componente de antígeno de esta variante, especialmente para las temporadas de otoño e invierno de este año.

La administración ha recomendado una vacuna recombinante trivalente de proteína trimérica contra la COVID-19 desarrollada por WestVac Biopharma y West China Medical Center en la Universidad de Sichuan, que es efectiva contra las variantes XBB, BA.5 y Delta, y que recibió la aprobación de uso de emergencia en China en junio, marcando la primera vacuna aprobada del mundo dirigida a combatir la XBB.

Los miembros de la población objetivo que hayan completado la inmunización básica o hayan sido infectados por COVID-19 pueden recibir una dosis de la vacuna especializada contra la XBB, ya sea de tres a seis meses después de su última vacunación o seis meses después de su infección más reciente.

Para aquellos que ya han recibido una vacuna que contiene el componente de antígeno variante de la XBB, actualmente no se les recomienda ponerse otros tipos de vacunas.

El aviso ha instado a los departamentos relevantes de todo el país a alentar activamente a la población objetivo a recibir vacunas voluntariamente, con especial énfasis en aumentar la tasa de vacunación entre los ancianos.

En marzo, China aprobó su primera vacuna contra la COVID-19 de ARNm desarrollada por CSPC Pharmaceutical Group Ltd, corrigiendo la ausencia de esta nueva tecnología de vacuna para uso público. La vacuna se puso inicialmente en uso en mayo.

Los hospitales comunitarios de Shanghai introdujeron nuevas vacunas contra la COVID-19 que cubren las variantes de Omicron a fines de mayo, incluida la vacuna de subunidades de proteínas y la vacuna de ARNm, que están disponibles para personas mayores de 18 años.

Fuente: Spanish.China.org.cn. Disponible en https://goo.su/PM3BOgk

Moderna raises Covid vaccine outlook despite sharp drop in quarterly sales



Aug 3. Moderna on Thursday hiked its full-year outlook for its Covid vaccine, its only marketable product, despite reporting a loss and sharp drop in revenue for the second quarter.

Here's what Moderna reported compared with Wall Street's expectations, based on a survey of analysts by Refinitiv:

Loss per share: $3.62, vs. $4.04 expected

Revenue: $344 million, vs. $319.6 million expected

The biotech company generated second-quarter sales of $344 million, with sales of its Covid shot dropping 94%. Total revenue plunged from the $4.75 billion it recorded in the same period a year ago, when Covid cases still trended higher in the U.S.

Moderna posted a net loss of $1.38 billion, or $3.62 per share, for the quarter. That compares with $2.20 billion in net income, or $5.24 per share, reported during the same quarter last year.

But Moderna hopes to end the sales slump on strong demand for its updated Covid vaccine targeting the omicron subvariant XBB.1.5. The company is slated to roll the shot out this fall in the U.S. commercial market, but is still waiting for the Food and Drug Administration to approve the jab.

Moderna expects $6 billion to $8 billion in sales for its Covid shot this year, up from its previous forecast of $5 billion.

The "biggest factor" that will determine whether sales are within that range is vaccination rates in the U.S. from September to December, Moderna's chief commercial officer, Arpa Garay, said during an earnings call.

She noted that the company expects U.S. demand of 50 million to 100 million doses this fall, but

acknowledged that it's "difficult to accurately predict market volumes and predict how many Americans will come in this fall for their shots."

The new sales forecast includes around $4 billion in previously announced Covid vaccine purchase agreements and $2 billion to $4 billion in "signed and anticipated" contracts in the U.S. and other markets like Japan and the European Union.

The company is in talks with other purchasers in the U.S., EU and other parts of the world for more potential orders. However, Moderna said $1 billion in previously anticipated 2023 sales from signed government contracts was pushed to 2024.

Moderna's stock price closed flat on Thursday. The Massachusetts-based company's stock has dropped more than 38% this year, putting its market value at around $42 billion.

Cost of sales for the quarter came in at $731 million. That included a $464 million write-off for vaccines that have exceeded their shelf life and a $135 million charge from unused manufacturing capacity, among other expenses.

The charges were primarily driven by a shift in product demand to the monovalent XBB.1.5 shot, which rendered the remaining inventory of Moderna's previous bivalent vaccine obsolete. Bivalent means the shot targeted two strains of the virus, while a monovalent jab only targets one.

Moderna, Pfizer and Novavax have all seen sales of their Covid-related products plummet as much of the world moves on from the pandemic and depends less on protective vaccines and treatments.

But people are still dying from Covid every day and the virus isn't fully going away anytime soon, so the drugmakers are investing in new products to fight it.

This fall will be an important milestone for Moderna and its rivals.

The U.S. government will shift Covid products to the commercial market, which means drugmakers will start selling vaccines and treatments directly to health-care providers rather than to the government.

Pfizer on Tuesday warned that Covid shot sales in the commercial market are uncertain, adding that vaccination rates will help the company better predict sales for 2023 and beyond.

Pfizer, Moderna and Novavax haven't disclosed when they expect their new shots to be available to the public.

But new CDC Director Mandy Cohen told NPR on Monday that the new vaccines could be available by the "early October time frame."

Moderna has said it hopes to offer a new set of lifesaving vaccines targeting cancer, heart disease and other conditions by 2030.

That lineup includes Moderna's experimental vaccine that targets respiratory syncytial virus. The company expects to file for full approval of the shot for adults age 60 and older this quarter.

The pipeline also includes Moderna's personalized cancer vaccine, a highly anticipated mRNA shot being developed with Merck to target different tumor types, along with a flu vaccine.

Fuente: CNBC. Disponible en https://goo.su/mDJ8m

Hipra venderá su vacuna contra la COVID-19 en Reino Unido de la mano de Accord Healthcare

4 ago. Hipra ha recibido luz verde por parte de la Agencia Reguladora de Medicamentos y Productos Sanitarios de Reino Unido (MHRA) para su vacuna contra la COVID-19, Bimervax. Ahora la farmacéutica tendrá la posibilidad de vender su suero en el país inglés. Para ello, ha firmado un acuerdo con Accord Healthcare, que se encargará de distribuir el suero de manera exclusiva.

Reino Unido ha autorizado Bimervax como un refuerzo para la inmunización activa para prevenir el Coronavirus en personas de 16 años o más que hayan recibido previamente una vacuna de ARN mensajero. La autorización de la agencia reguladora inglesa se produjo tras concluir que se disponía de suficientes datos sólidos sobre la calidad, la inmunogenicidad y la seguridad del suero.

"Estamos encantados de colaborar con Hipra para poner a disposición una vacuna COVID-19 basada en proteína recombinante en Reino Unido. Esto proporciona una opción adicional para ayudar a combatir lo que sigue siendo una amenaza para la salud", indica el vicepresidente ejecutivo de Accord Healthcare, Paul Tredwell. "Con estructuras y capacidades que van desde la investigación más básica y desarrollo a la producción de vacunas en el país es un factor clave para poder soportar una respuesta rápida ante futuras emergencias sanitarias y refuerza la autonomía estratégica de Europa en el ámbito de la salud", recalca el director general de Hipra Human Health, Carles Fábrega.

En marzo de 2023, la Agencia Europea del Medicamento (EMA) abrió sus puertas a la vacuna de la farmacéutica española al superar la evaluación. La opinión positiva se basó en los resultados del ensayo que comparó la respuesta inmunitaria provocada por la vacuna de Hipra frente a la provocada por la vacuna de Pfizer y BioNtech. Cabe recordar que se trata de un suero bivalente con adyuvante que contiene una proteína recombinante.

Antes de recibir la autorización, Hipra firmó un acuerdo de venta con la Comisión Europea bajo el cuál se ponían a disposición hasta 250 millones de dosis, pero los catorce países que participaron (Bélgica, Dinamarca, Irlanda, España, Francia, Italia, Chipre, Letonia, Luxemburgo, Países bajos, Austria, Portugal, Suecia y Noruega) no estaban obligados a realizar ningún pedido. A fecha de hoy -cinco meses después de recibir luz verde – solo España ha comprado 3,2 millones de dosis.

Por otro lado, cabe recordar que Hipra se encuentra dentro de la lista de las cinco farmacéuticas que en caso de emergencia serán las encargadas de producir vacunas bajo la tecnología de proteína. En concreto, su papel consiste en garantizar todo el proceso de desarrollo, desde la fabricación de la sustancia activa hasta el envasado y sellado de los viales. Las otras compañías que conforman el listado son Zendal, Reig Jofre, Pfizer y Bilthoven Biological.

Hipra ganó 55,7 millones de euros en 2022, un 11% más respecto al año anterior que registró 50,2 millones. El incremento se debía a la evolución de las ventas de salud humana. Sin embargo, el resultado bruto de explotación experimentó una caída del 20,4% frente al ejercicio de 2021 (84,7 millones). Además, la farmacéutica facturó 396,7 millones. Esta cifra supuso un 14% más respecto al ejercicio anterior que ingresó 347,9 millones.

Para el presente año, es decir, 2023, la compañía prevé un crecimiento de la cifra de negocio y una mejora de la rentabilidad. Además, vaticina una expansión significativa del ebitda*.

*ebitda: indicador financiero del beneficio bruto de explotación calculado antes de deducir los gastos financieros.

Fuente: El Economista. Disponible en https://goo.su/n2qWz

La Ciencia logra las vacunas contra la COVID-19 y la investigación estudia también los efectos secundarios adversos



5 ago. Está documentado que mujeres otomanas vendían en Estambul costras de pústulas de personas que habían sufrido la viruela. Disolvían las costras en cáscaras de nuez y en agua, les hacían pequeñas heridas a los niños y les aplicaban la pasta en esas heridas. Algunos niños no mostraban ningún tipo de reacción; otros daban una reacción febril y la mayoría si no todos, se tornaban resistentes a la viruela. Fue la primera vacuna y en principio solo al alcance de los que pudieran pagarla.

El fundamento de cualquier vacuna, la de la viruela y la de la COVID-19, es en esencia muy sencillo: se trata de provocar una respuesta inmune específica frente a un virus o una bacteria pero sin que se desarrolle la enfermedad que ese virus o esa bacteria produce.

La respuesta inmune que desencadena la vacuna suele ir acompañada de los síntomas propios de la primoinfección: malestar general, dolores articulares y fiebre que suelen remitir en un par de días. Pocas veces, en sujetos hipersensibles (que en principio no se pueden identificar) pueden dar lugar a reacciones más adversas y en casos extremos y rarísimos provocar incluso la muerte.

La covid-19 fue una pandemia provocada por el SARS Cov2, un virus cuyo material genético es ARN de cadena sencilla, que sometió a los sistemas de salud durante dos eternos años a una presión y un estrés como hacía un siglo (con la mal llamada "gripe española") que no ocurría. Fue de irrupción tan inesperada y tan súbita, tan brutal, que las medidas que se tomaban eran sobre la marcha y con la incertidumbre de no haber experiencia previa. Aun así la gestión fue más que aceptable. Confinamiento estricto al principio, para luego ir relajando las medidas a la espera de que llegara la tan ansiada vacuna.

Va quedando en el recuerdo crítico, pero abril y mayo de 2020 fueron particularmente dramáticos. Hubo semanas en las que fallecieron hasta 900 personas al día.

Cuando alguien en una residencia de ancianos se infectaba era una auténtica catástrofe y morían muchos, sobre todo en la comunidad autónoma en la que fueron abandonados a su suerte.

El desarrollo de tres vacunas efectivas y seguras, en tan solo 8 meses, puso de manifiesto lo necesaria que es la investigación básica. A pesar de lo rápido de su desarrollo, las vacunas cumplían por supuesto, todos los estándares de seguridad y eficacia que exige la OMS porque de lo contrario no hubieran podido administrarse.

De no ser por todo el conocimiento acumulado disponible que había en biología molecular, biología celular, inmunología, microbiología, farmacología... hubiera sido imposible un logro semejante.

Cuando la inoculación cogió el ritmo adecuado el número de muertes cayó en picado y en el caso de las residencias de ancianos fue realmente espectacular.

Se estima que la vacunación masiva evitó solo en el tercer trimestre de 2021 un mínimo de 3.500 fallecimientos.

Pero, obviamente, el solo ventajas no existe y las vacunas no son una excepción; a veces se presentan complicaciones y efectos secundarios adversos.

El establecer una relación causal entre un agente y una enfermedad puede parecer sencillo pero en realidad no lo es tanto. Por ejemplo, se sabe que el hábito de fumar cigarrillos es un factor predisponente para desarrollar cáncer de pulmón y para sufrir infarto de miocardio. Hay personas que sin ser fumadores han sufrido una de esas patologías. ¿Cómo saber entonces si una persona fumadora que tiene un cáncer de pulmón o ha sufrido un infarto ha sido por ser fumador? La respuesta es que no se puede saber para esa persona en concreto.

Lo que sí se sabe es que, estudiados dos grupos de personas lo suficientemente numerosos y lo más parecidos posible (mismo sexo, misma edad, misma profesión, mismo etnia...), y que uno de los grupos esté formado por fumadores y el otro por no fumadores, en el grupo de fumadores la incidencia de cáncer de pulmón y de infartos de miocardio es significativamente mayor.

Lo mismo para poder relacionar una vacuna con potenciales secuelas que pueda tener esa vacuna. Solo cuando la incidencia de tales patologías sea significativamente superior en grupos de personas vacunadas con respecto a grupos de personas no vacunadas se podrá decir que esa vacuna predispone a esas secuelas. Por abundar en ejemplos, la píldora anticonceptiva aumenta el riesgo de accidentes embólicos, la aspirina aumenta ligeramente el riesgo de úlceras gastrodudenales y los fármacos antidislipémicos dan lugar a dolores musculares que pueden ser intensos.

Leer los prospectos de los fármacos que nos prescriben algunas veces asusta. Quimioterapia y radioterapia en pacientes oncológicos tienen graves efectos secundarios, pero no hay alternativa mejor. Como siempre, se trata entonces de ponderar los beneficios y los riesgos.

Por ejemplo, se ha encontrado un incremento estadísticamente significativo entre la vacuna contra la covid y el Síndrome de Taquicardia Postural Ortostática. Un incremento de un 0,22%, o lo que es lo mismo, hay 22 individuos más con este síndrome en 10.000 vacunados de los que hay en 10.000 individuos no vacunados. Pero la vacuna es protectora hasta un 93% de una patología potencialmente grave y hasta mortal. Se ha evidenciado también un ligero aumento de un tipo concreto de trombosis (trombosis inmunomediada con trombocitopenia) en sujetos a los que se les administró la vacuna de AstraZeneca con

respecto a individuos no inoculados. Por precaución se interrumpió su inoculación.

Solo hay que plantearse, ¿cuánta gente hubiera muerto si no hubiera habido vacunas? ¿Cuánta COVID-19 persistente se ha evitado con las vacunas? ¿Cuántas secuelas poscovid se hubieran producido en personas que hubieran desarrollado la enfermedad y que no se han infectado por estar vacunadas? Las estadísticas y los números son contundentes, solo hay que ver fallecidos antes de la vacunación y fallecidos tras la vacunación de casi toda la población.

Hay que seguir investigando porque hay interrogantes que aún quedan por contestar. Por ejemplo, ¿por qué un paciente con 28 años en principio sin ningún riesgo falleció de COVID-19 tras la temida tormenta de citoquinas, mientras otro infectado con 90 años permaneció asintomático? La clave está en la propia constitución genética de ambos y su relación con la forma en que responden al virus. Pero eso es algo que de momento no es abordable esclarecer aunque ya se están investigando tratamientos personalizados, es decir tratamientos para una persona determinada.

Queda mucho por hacer desde luego, pero el camino que se ha recorrido es largo. También eso hay que reconocerlo.

Fuente: Público. Disponible en https://goo.su/X3FRYTj

¿Cuál es la vacuna contra la COVID-19 más segura y eficaz?

6 ago. Un estudio en adultos mayores estadounidenses dirigido por investigadores de la Universidad Brown ha descubierto que el riesgo de efectos negativos de las vacunas de ARNm de Moderna y Pfizer-BioNTech es excepcionalmente bajo, pero el más bajo es con la vacuna Moderna, según anuncian sus autores en la revista 'JAMA Network Open'.

Mientras que las vacunas de ARNm contra el COVID-19 han demostrado ser seguras y eficaces para la población general, la evidencia en profundidad sobre la seguridad y eficacia para los adultos mayores y las personas con enfermedades crónicas es más limitada.

Para subsanar esta carencia, un equipo dirigido por investigadores de la Universidad de Brown llevó a cabo el mayor estudio comparativo de las dos vacunas de ARNm aprobadas por la Administración de Alimentos y Medicamentos de Estados Unidos (FDA): las vacunas Moderna y Pfizer-BioNTech. Los resultados mostraron que, en el caso de los adultos mayores, la vacuna Moderna se asociaba a un riesgo ligeramente inferior de acontecimientos adversos que la vacuna Pfizer-BioNTech.

"Los resultados de este estudio pueden ayudar a los expertos en salud pública a sopesar qué vacuna de ARNm podría ser preferible para los adultos mayores y los subgrupos de mayor edad, como los que presentan una mayor fragilidad", apunta el autor principal del estudio, Daniel Harris, epidemiólogo y científico investigador del Centro de Gerontología e Investigación Sanitaria de la Facultad de Salud Pública de la Universidad Brown.

El estudio analizó a más de seis millones de adultos mayores, con una edad media de 76 años, que fueron vacunados contra la COVID-19 utilizando una de las dos vacunas de ARNm, Moderna y Pfizer-BioNTech. Las vacunas presentan sutiles diferencias de fabricación, administración y respuesta inmunitaria.

El estudio confirmó que para los adultos mayores de ambos grupos de vacunas, el riesgo de acontecimientos adversos graves era muy bajo. Los investigadores también observaron que la vacuna de

Moderna se asociaba a un riesgo un 4% menor de embolia pulmonar, que es una obstrucción repentina de los vasos sanguíneos pulmonares, y a un riesgo un 2% menor de tromboembolias, definidas como diversas afecciones relacionadas con la coagulación de la sangre.

La vacuna de Moderna también se asoció a un riesgo un 15% menor de diagnóstico de COVID-19 en comparación con la vacuna de Pfizer-BioNTech.

Harris enfatiza que el riesgo de efectos adversos de una infección natural por SARS-CoV-2, el virus que causa el COVID-19, es sustancialmente mayor que el riesgo de efectos adversos de cualquiera de las dos vacunas de ARNm. Pero ahora que más del 70% de la población mundial ha recibido un tipo de vacuna contra el COVID-19 y que el suministro de vacunas es menos preocupante, afirma que es necesario disponer de información detallada sobre los efectos y la seguridad de las vacunas para orientar la toma de decisiones.

"La inmunización con cualquiera de las dos vacunas de ARNm es sustancialmente mejor y más segura que no vacunarse en absoluto --recuerda Harris--, pero en un mundo ideal en el que podamos elegir qué producto vacunal se utiliza, queríamos ver si una vacuna se asociaba con un mejor rendimiento para los adultos mayores y aquellos con mayor fragilidad".

Añade que también es necesario comprender el rendimiento de las vacunas en poblaciones del mundo real. Señala que los adultos mayores, que a menudo padecen enfermedades crónicas, tienden a quedar excluidos de los ensayos clínicos o a estar representados en un número reducido.

Esto es especialmente importante si se tiene en cuenta que los adultos mayores, sobre todo los que viven en residencias de ancianos, tienen un mayor riesgo de desarrollar COVID-19 grave. Los adultos mayores con fragilidad también pueden tener diferencias en sus respuestas inmunitarias a las vacunas, indica Harris, por lo que es importante entender cómo estas vacunas funcionan para los adultos mayores frágiles en comparación con sus homólogos no frágiles.

Esta investigación formaba parte de un proyecto denominado IMPACT Collaboratory, dirigido por investigadores de la Universidad Brown y de Hebrew SeniorLife, que está permitiendo un seguimiento masivo de la seguridad y eficacia a largo plazo de las vacunas para los beneficiarios de Medicare, en colaboración con cadenas de farmacias.

"Como disponíamos de estos datos reales y de una cohorte que incluía a millones de ancianos, pudimos distinguir diferencias potencialmente muy pequeñas en la seguridad y eficacia de la vacuna y realizar análisis de subgrupos clínicos importantes", comenta Harris.

Según el equipo de investigación, la mayor seguridad de la vacuna Moderna en relación con algunos acontecimientos adversos, como la embolia pulmonar, podría deberse a su mayor protección contra la COVID-19, especialmente en el caso de los adultos mayores no frágiles.

"Creemos que estas dos cosas, seguridad y eficacia, están interrelacionadas --explica Harris--. El riesgo, ligeramente menor, de embolia pulmonar y otros acontecimientos adversos que observamos en las personas que recibieron Moderna puede deberse a que la vacuna Moderna también fue más eficaz para reducir el riesgo de COVID-19".

Sin embargo, el estudio no pudo concluir de forma definitiva si las diferencias en los acontecimientos adversos se debían a la seguridad o a la eficacia, y los investigadores recomendaron realizar más

investigaciones en este ámbito. Además, el estudio sólo analizó la primera dosis de las vacunas de ARNm, por lo que otro posible paso siguiente podría consistir en realizar comparaciones similares para vacunaciones posteriores.

"Podemos imaginar la actualización periódica de este tipo de análisis a medida que se desarrollen nuevas vacunas --afirma Harris--. Dependiendo de cuál salga mejor parada, incluso a muy pequeña escala, podría tener grandes implicaciones a nivel de población y dar preferencia a esa vacuna en particular".

Fuente: La Voz del Tajo. Disponible en https://goo.su/tpmCTO

BioNTech prevé facturar con la vacuna del Covid en 2023 tres veces menos que en 2022

7 ago. El laboratorio alemán BioNTech, responsable junto a la estadounidense Pfizer de una de las vacunas de ARN mensajero contra la Covid-19, espera facturar alrededor de 5.000 millones de euros este año, una cifra sustancialmente por debajo de los algo más de 17.000 millones de euros contabilizados en 2022 con las ventas de este tratamiento, según ha informado la compañía.

Por otro lado, la farmacéutica ha revisado a la baja su previsión de gasto en I+D en el conjunto del ejercicio, hasta un rango de entre 2.000 y 2.200 millones de euros, frente a la anterior horquilla de entre 2.400 y 2.600 millones.

En los seis primeros meses del ejercicio, las ventas de la empresa germana sumaron un total de 1.444,7 millones de euros, un 84,9% menos, incluyendo una caída del 94,7% en el segundo trimestre, hasta 167,7 millones.

A este respecto, BioNTech explicó que la caída de sus ingresos trimestrales refleja las cancelaciones por parte de su socio, Pfizer, lo que redujo significativamente la participación en las ganancias brutas de la empresa en el segundo trimestre y, por lo tanto, influyeron negativamente en sus ingresos durante los tres meses finalizados el 30 de junio de 2023.

De este modo, en el segundo trimestre del ejercicio, BioNTech registró pérdidas de 190,4 millones de euros, frente al beneficio neto de 1.672 millones de euros registrado entre abril y junio del año pasado, lo que en los primeros seis meses del ejercicio implicó una caída del 94,2% de las ganancias del laboratorio hasta los 311,8 millones de euros, frente a los 5.370,8 millones.

"Entramos en la segunda mitad de 2023 con una posición financiera sólida", dijo Jens Holstein, director financiero de BioNTech, para quien el mercado de la vacuna Covid-19 sigue siendo muy dinámico y difícil de predecir.

"Con cierta incertidumbre en la línea de ingresos, también estamos observando cuidadosamente nuestros gastos revisando nuestra base de costes mientras nos mantenemos enfocados en cumplir con nuestros objetivos estratégicos y brindar valor al público y a nuestros accionistas", añadió.

Fuente: BolsaManía. Disponible en https://goo.su/didI282

New COVID-19 vaccine expected by end of September

Aug 9. With COVID-19 cases resurging and the world entering its fourth year of grappling with this highly contagious disease, the initial batch of updated vaccines for the upcoming fall season is anticipated to be ready by the end of September.

Moderna, Pfizer, and Novavax plan to release updated vaccines this fall, potentially making them accessible for most ages.



Photo by: Steve Helber / AP

However, they must wait for the Food and Drug Administration and the Centers for Disease Control and Prevention to authorize or approve the updated COVID-19 vaccines.

The new vaccines are aimed at protecting against the XBB variants, which are strains descended from the original Omicron variant.

According to drugmakers Pfizer and Moderna, they could be the first to get the FDA's approval.

"What we expect is that we will have approval by the end of August. And we are ready with products already now," Pfizer's CEO Albert Bourla said last week.

Moderna filed for authorization of its updated vaccine on June 22.

Novavax's President of Research and Development, Filip Dubovsky, said on Tuesday that they are still working on their submission for a new emergency use authorization for the updated vaccine and expect to deliver the product for authorization "by the end of September."

Accordingto the CDC, about 81% of the U.S. population has had at least one dose of the vaccine, 69.5% have completed the primary series, and only around 17% have received a dose of the updated booster from last fall.

Fuente: KTVH. Disponible en https://goo.su/6wY47e

AstraZeneca pursues mRNA, signs vaccine manufacturing deal with China's CanSino

Aug 9. Despite a Moderna partnership that turned sour, AstraZeneca still wants a piece of the mRNA game.

The British pharma company has signed a new mRNA manufacturing deal with China's CanSino Biologics, CanSino said in a securities filing (PDF) Tuesday.

The supply agreement will last at least 10 years. Under the deal, CanSino will use its mRNA manufacturing platform to support AZ on the R&D of certain vaccines, the filing shows. The pair may further collaborate on R&D and commercialization in the future.

No financial details were disclosed. It's not clear what diseases AZ is planning to target with the mRNA

tech, or whether the shots made by CanSino will be supplied to countries outside of China.

The deal comes a year after AZ axed an mRNA partnership with Moderna on AZD8601. The mid-stage heart failure candidate sought to use mRNA encoding VEGF-A to repair and regenerate the heart. AZ also terminated an immuno-oncology project with Moderna, cutting MEDI1191, an mRNA drug for IL-12, from its pipeline.

AstraZeneca lists mRNA as an area of interest under nucleotide-based therapeutics. (China News Service/Getty Images)

As of its latest earnings update two weeks ago, AZ had no clinical mRNA candidates. But the company's website still lists mRNA as an area of interest under nucleotide-based therapeutics, a larger field that also includes a broad antisense collaboration with Ionis.

For its part, Moderna in July inked a memorandum of understanding and a land collaboration agreement with the Shanghai government to potentially study, develop and manufacture mRNA medicines in China. All products produced through that deal will be exclusively for China, according to Moderna.

Fuente: Fierce Pharma. Disponible en https://goo.su/URpeXV

La doble mutación Flip de la variante Eris de la COVID-19 provoca un repunte de casos leves este verano

9 ago. Una nueva variante del virus de la COVID-19, la EG.5.1 y bautizada como Eris, tiene una capacidad superior de contagio frente a otras variantes XBB del SARS-CoV 2 por una doble mutación llamada Flip que ha hecho aumentar los casos, aunque no reportan gravedad ni se considera un hecho preocupante.

La Sociedad Española de Médicos de Atención Primaria (SEMERGEN) ha puesto de manifiesto que se está produciendo un aumento de la incidencia de COVID-19 aunque insiste en que los cuadros clínicos son más leves que durante la pandemia debido a la vacunación.

"Este verano se están produciendo más casos de resfriados, gripe A y COVID-19, aunque con cuadros más leves que durante la pandemia", ha apuntado Carlos Montalvá, responsable del grupo de trabajo de urgencias en SEMERGEN, a la Cadena SER. No obstante "el virus más preocupante ahora es el de la gripe, que está dando cuadros mucho más agudos" que el resto, y asimismo apunta que hay más catarros por el aumento de las temperaturas y el uso de aires acondicionados.

Asimismo, tras el incipiente aumento de la incidencia de Covid está una nueva variante del virus, la EG.5.1, que tiene una capacidad superior de contagio frente a otras variantes XBB del SARS-CoV 2 por una doble mutación llamada Flip que ha hecho aumentar los casos, aunque no reportan gravedad.

Antonio Zapatero, jefe de Servicio de Medicina Interna del Hospital de Fuenlabrada, en Madrid, explica en twitter que su circulación es todavía baja,en torno al 2%, pero algunos países como Brasil y España los porcentajes son más altos; en España, concretamente, está entre el 15 y el 20%.

"EG.5.1, presenta una doble mutación, F456L y L455F, mutaciones entre F y L y L y F, de ahí el nombre de FLip, que hace que se una más y mejor al receptor del aparato respiratorio y justifique el incremento de casos y de su presencia en aguas residuales", continúa Zapatero, responsable del área de Asistencia Sanitaria y Salud Pública del Partido Popular desde que dejó su cargo como viceconsejero de Salud Pública y Plan COVID-19 de Madrid.

Fuente: Expansión. Disponible en https://goo.su/48yPfU

Advancing vaccine design: potential of peptide mimicry

Aug 10. In a new development, a recent paper published in Biology Methods & Protocols by Oxford University Press has highlighted a promising avenue for enhancing vaccine efficacy against infectious pathogens like the COVID-19 virus. Since December 2019, SARS-CoV-2 (COVID-19) infection has become a worldwide urgent public health concern.1 The study reveals a novel bioinformatic approach and tool that holds the potential to empower researchers in designing vaccines capable of inducing a stronger immune response. By selecting specific segments of proteins that elicit robust immune reactions, these vaccines could offer enhanced protection against diseases.



Bioinformatics and Biostatistics Concept - New Tools and Systems for Understanding Complex Biological Datasets - Computer Science Applied to Biology and Medicine - Conceptual Illustration

Peptide mimicry and immune recognition

The immune system of humans and other vertebrates is naturally adept at distinguishing between self and non-self-structures, allowing it to launch targeted attacks against foreign invaders. Key players in this immune response are the T cells, which identify peptides—short chains of amino acids—present in non-self-proteins, such as those found in viruses or bacteria but absent in the host's proteins. To evade detection by the host's T cells, parasitic organisms have evolved to eliminate unnecessary peptides from their proteins, often mutating these peptides to mimic those found in the host's proteins.

Testing the peptide mimicry theory

The researchers embarked on testing a crucial aspect of the peptide mimicry theory—whether they could predict a parasite's ability to provoke an immune response based on the absence of certain peptides in the host's body. Leveraging detailed mapping of T-cell clones related to the SARS-CoV-2 virus, the team investigated the overlap between the actual T-cell response targets and a list of potential T-cell recognition targets—peptides present in SARS-CoV-2 but absent in the human body.

Empowering vaccine development

Through sophisticated computer simulations, the researchers made a significant discovery. The actual T-cell recognition targets demonstrated a substantially higher proportion of pentapeptides and hexapeptides (peptides consisting of five and six amino acids, respectively) that were not found in human proteins. This

newly developed method, based on solid immunological theory, exhibited four times greater efficiency in detecting targets compared to conventional methods grounded in empirical observations. The implications of this finding are far-reaching, as it holds the potential to revolutionize vaccine design.

Designing tailored vaccines

Armed with this cutting-edge knowledge, researchers can now focus on developing vaccines specifically tailored to recognise and target the protein segments of parasites that trigger the most robust immune responses. By honing in on these critical regions, vaccines can be engineered to prompt a more potent and targeted defence against infectious pathogens.

Jaroslav Flegr, the lead author of the paper, shared his excitement about the unforeseen practical implications of their peptide mimicry theory. Originally conceived as fundamental research, the theory's application in vaccine construction has emerged as a promising avenue. Flegr expressed hope that their findings will not only deepen our understanding of disease evolution and pathogen transmission but also provide valuable insights for enhancing vaccine design and the global fight against infectious diseases.

The paper marks a milestone in vaccine development by unlocking the potential of peptide mimicry in eliciting stronger immune responses. This newfound understanding of how parasites adapt their peptide vocabulary to evade the host's immune system opens up exciting possibilities for creating more effective vaccines against a wide range of infectious diseases. As researchers delve deeper into this realm of bioinformatics and immunology, we can anticipate transformative advancements that may redefine the landscape of global healthcare, bringing us closer to a world where infectious diseases pose less of a threat.

Fuente: Drug Target Review. Disponible en https://goo.su/r8WOzH

Artículos científicos publicados en Medline

Filters activated: Publication date from 2023/07/21 to 2023/07/31. “Covid-19 vaccine” (Title/Abstract) 484 records.

COVID Vaccine-Associated Uveitis.
Habot-Wilner Z, Neri P, Okada AA, Agrawal R, Xin Le N, Cohen S, Fischer N, Kilmartin F, Coman A, Kilmartin D. Ocul Immunol Inflamm. 2023 Aug;31(6):1198-1205. doi: 10.1080/09273948.2023.2200858. Epub 2023 May 5. PMID: 37145198

Batch-dependent safety of the BNT162b2 mRNA COVID-19 vaccine.
Schmeling M, Manniche V, Hansen PR. Eur J Clin Invest. 2023 Aug;53(8):e13998. doi: 10.1111/eci.13998. Epub 2023 Apr 9. PMID: 36997290

Iron and iron-related proteins in COVID-19.
Suriawinata E, Mehta KJ. Clin Exp Med. 2023 Aug;23(4):969-991. doi: 10.1007/s10238-022-00851-y. Epub 2022 Jul 18. PMID: 35849261

COVID-19 Vaccination and Cardiac Arrhythmias: A Review.
Pari B, Babbili A, Kattubadi A, Thakre A, Thotamgari S, Gopinathannair R, Olshansky B, Dominic P. Curr Cardiol Rep. 2023 Aug 2. doi: 10.1007/s11886-023-01921-7. Online ahead of print. PMID: 37530946

The Race for COVID-19 Vaccines: The Various Types and Their Strengths and Weaknesses.
Muhar BK, Nehira J, Malhotra A, Kotchoni SO. J Pharm Pract. 2023 Aug;36(4):953-966. doi: 10.1177/08971900221097248. Epub 2022 Jun 18. PMID: 35723017

Neuro-Ophthalmic Complications of COVID-19 Infection and Vaccination.
Alotaibi K, Badeeb N, Karanjia R. Adv Ophthalmol Optom. 2023 Aug;8(1):281-298. doi: 10.1016/j.yaoo.2023.03.004. Epub 2023 Mar 6. PMID: 37350847

Aerosol pulmonary immune engineering.
Sudduth ER, Trautmann-Rodriguez M, Gill N, Bomb K, Fromen CA. Adv Drug Deliv Rev. 2023 Aug;199:114831. doi: 10.1016/j.addr.2023.114831. Epub 2023 Apr 24. PMID: 37100206

Risk aversion and COVID-19 vaccine hesitancy.
Lepinteur A, Borga LG, Clark AE, Vögele C, D'Ambrosio C. Health Econ. 2023 Aug;32(8):1659-1669. doi: 10.1002/hec.4693. Epub 2023 May 5. PMID: 37146156

Barriers to COVID-19 Vaccines and Strategies to Improve Acceptability and Uptake.
Nawas GT, Zeidan RS, Edwards CA, El-Desoky RH. J Pharm Pract. 2023 Aug;36(4):900-904. doi: 10.1177/08971900221081621. Epub 2022 Apr 23. PMID: 35465688

COVID-19 vaccine acceptance among people living with HIV: A systematic review and meta-analysis.
Ejamo JY, Legese GL, Tesfaye YA, Liben FE. Trop Med Int Health. 2023 Aug;28(8):601-611. doi: 10.1111/tmi.13908. Epub 2023 Jul 4. PMID: 37402693

Broadly neutralizing antibodies against COVID-19.
Zhou D, Ren J, Fry EE, Stuart DI. Curr Opin Virol. 2023 Aug;61:101332. doi: 10.1016/j.coviro.2023.101332. Epub 2023 Jun 6. PMID: 37285620

Prevalence of COVID-19 vaccine acceptance among migrant and refugee groups: A systematic review and *meta*-analysis.
Alimoradi Z, Sallam M, Jafari E, Potenza MN, Pakpour AH. Vaccine X. 2023 Aug;14:100308. doi: 10.1016/j.jvacx.2023.100308. Epub 2023 May 6. PMID: 37223070

Risk of all-cause and cardiac-related mortality after vaccination against COVID-19: A meta-analysis of self-controlled case series studies.
Marchand G, Masoud AT, Medi S. Hum Vaccin Immunother. 2023 Aug 1;19(2):2230828. doi: 10.1080/21645515.2023.2230828. PMID: 37534766

Pediatricians' perspectives on COVID-19 and HPV vaccine hesitancy.
Ryan GW, Miotto MB, McReynolds C, Lemon SC, Pbert L, Trivedi M. Hum Vaccin Immunother. 2023 Aug 1;19(2):2225388. doi: 10.1080/21645515.2023.2225388. PMID: 37347712

COVID-19 vaccine intention: Prospective and concurrent tests of a disposition-belief-motivation framework.
Bogg T, Milad E, Godfrey O. Health Psychol. 2023 Aug;42(8):521-530. doi: 10.1037/hea0001200. Epub 2022 Jun 27. PMID: 35759005

Clinical features, diagnosis, and management of COVID-19 vaccine-associated Vogt-Koyanagi-Harada disease.
Xu K, Gao B, Li J, Xiang Y, Cao L, Zhao M. Hum Vaccin Immunother. 2023 Aug 1;19(2):2220630. doi: 10.1080/21645515.2023.2220630. Epub 2023 Jun 6. PMID: 37282614

Determinants of influenza and COVID-19 vaccine intent or uptake in Lebanon: a scoping review of the literature.
Salam M, Honein-AbouHaidar G. BMC Infect Dis. 2023 Aug 6;23(1):511. doi: 10.1186/s12879-023-08478-4. PMID: 37544988

Development and validation of a multi-dimensional COVID-19 vaccine hesitancy questionnaire.
Hammoud H, Albayat SS, Mundodan J, Alateeg S, Adli N, Sabir D, Bendari T, Al-Romaihi HE, Bougmiza I. Vaccine X. 2023 Aug;14:100286. doi: 10.1016/j.jvacx.2023.100286. Epub 2023 Mar 23. PMID: 36994092

SARS-CoV-2 Infection and Response to COVID-19 Vaccination in Patients With Primary Immunodeficiencies.
Paris R. J Infect Dis. 2023 Aug 4;228(Suppl 1):S24-S33. doi: 10.1093/infdis/jiad145. PMID: 37539759

Urological complications after COVID 19 vaccine according to age, sex and manufacturer.
Shim SR, Kim KT, Park E, Pyun JH, Kim JH, Chung BI. World J Urol. 2023 Aug;41(8):2255-2263. doi: 10.1007/s00345-023-04481-1. Epub 2023 Jul 3. PMID: 37400660

The mRNA Vaccine Revolution: COVID-19 Has Launched the Future of Vaccinology.

Ye Z, Harmon J, Ni W, Li Y, Wich D, Xu Q. ACS Nano. 2023 Aug 3. doi: 10.1021/acsnano.2c12584. Online ahead of print. PMID: 37535899

Temporal trends and determinants of COVID-19 vaccine series initiation after recent pregnancy.
Török E, Dhinsa T, Dimanlig-Cruz S, Alton GD, Sprague AE, Dunn SI, Shah PS, El-Chaâr D, Regan AK, Wilson K, Buchan SA, Kwong JC, Håberg SE, Gravel CA, Okun N, Walker MC, MacDonald SE, Wilson SE, Barrett J, Fell DB. Hum Vaccin Immunother. 2023 Aug 1;19(2):2215150. doi: 10.1080/21645515.2023.2215150. Epub 2023 May 30. PMID: 37249316

The Global Network COVID-19 studies: a review.
Naqvi S, Saleem S, Billah SM, Moore J, Mwenechanya M, Carlo WA, Esamai F, Bucher S, Derman RJ, Goudar SS, Somannavar M, Patel A, Hibberd PL, Figueroa L, Krebs NF, Petri WA, Lokangaka A, Bauserman M, Koso-Thomas M, McClure EM, Goldenberg RL. BJOG. 2023 Aug 2. doi: 10.1111/1471-0528.17610. Online ahead of print. PMID: 37530467

The Intersection of COVID-19 and Rheumatoid Arthritis: Shared Mechanisms, Treatment Challenges, and Potential Therapeutic Approaches.
Xiao J, Liang C, Zhang L, Li J, Liu S. Aging Dis. 2023 Aug 1;14(4):1196-1213. doi: 10.14336/AD.2023.0406. PMID: 37163438

Exploring COVID-19 Vaccine Confidence with People from Black and Asian Backgrounds in England.
Eberhardt J, Ling J, Horsley L, Cunnett J, Fryer-Smith E, Lant J, Edwards S, Ross E. J Racial Ethn Health Disparities. 2023 Aug;10(4):1899-1909. doi: 10.1007/s40615-022-01372-w. Epub 2022 Aug 1. PMID: 35913541

Opportunities and challenges of leveraging COVID-19 vaccine innovation and technologies for developing sustainable vaccine manufacturing capabilities in Africa.
Kana BD, Arbuthnot P, Botwe BK, Choonara YE, Hassan F, Louzir H, Matsoso P, Moore PL, Muhairwe A, Naidoo K, Ndomondo-Sigonda M, Madhi SA. Lancet Infect Dis. 2023 Aug;23(8):e288-e300. doi: 10.1016/S1473-3099(22)00878-7. Epub 2023 Jun 5. PMID: 37290473

COVID-19 outcomes among people with HIV and COVID-19 in New York City.
Braunstein SL, Wahnich A, Lazar R. J Infect Dis. 2023 Aug 3:jiad311. doi: 10.1093/infdis/jiad311. Online ahead of print. PMID: 37534822

SARS-CoV-2 antibody response in SARS survivors with and without the COVID-19 vaccine.
Xia CS, Zhan M, Liu Y, Yue ZH, Song Y, Zhang F, Wang H. Int J Antimicrob Agents. 2023 Aug 4:106947. doi: 10.1016/j.ijantimicag.2023.106947. Online ahead of print. PMID: 37544384

Health literacy as a social vaccine in the COVID-19 pandemic.
Okan O, Messer M, Levin-Zamir D, Paakkari L, Sørensen K. Health Promot Int. 2023 Aug 1;38(4):daab197. doi: 10.1093/heapro/daab197. PMID: 35022721

Vaccine hesitancy and acceptance: an examination of predictive factors in COVID-19 vaccination in Saudi Arabia.
Fadhel FH. Health Promot Int. 2023 Aug 1;38(4):daab209. doi: 10.1093/heapro/daab209. PMID: 34967862

Scleritis and Episcleritis following Coronavirus Disease (COVID-19) Vaccination.
Sanjay S, Handa A, Kawali A, Shetty R, Bhakti Mishra S, Mahendradas P. Ocul Immunol Inflamm. 2023 Aug;31(6):1184-1190. doi: 10.1080/09273948.2023.2182324. Epub 2023 Mar 8. PMID: 36884356

COVID-19 vaccine hesitancy among first-generation immigrants living in Sweden.
Svallfors S, Larsson EC, Puranen B, Ekström AM. Eur J Public Health. 2023 Aug 1;33(4):687-694. doi: 10.1093/eurpub/ckad073. PMID: 37229599

Impact of COVID-19 and vaccination on first and second trimester screening results.
Hantoushzadeh S, Younesi S, Mahdi Taheri Amin M, Saadati P, Jamali S, Nassiri S, Modarresi MH, Savad S, Delshad S, Soleiman Meiguni Z, Amidi S, Navidpour F, Yazdani B, Karimi Farani A, Saleh M, Ghafouri-Fard S. Cytokine. 2023 Aug;168:156228. doi: 10.1016/j.cyto.2023.156228. Epub 2023 May 22. PMID: 37224577

COVID-19 vaccine uptake rates, perceptions, and attitudes among dialysis patients: Experience across a national sample.
Balzan D, Agius SM, Farrugia E, Buttigieg J. Ther Apher Dial. 2023 Aug;27(4):726-734. doi: 10.1111/1744-9987.13983. Epub 2023 Mar 27. PMID: 36919384

COVID-19 vaccine uptake trends in SARS-CoV-2 previously infected cancer patients.
Shahid Z, Patrick AL, Wallander ML, Donahue EE, Trufan SJ, Tan AR, Hwang JJ, Burgess EF, Ragon B, Ghosh N, Grunwald MR, Voorhees PM, Copelan EA, Raghavan D. Vaccine X. 2023 Aug;14:100289. doi: 10.1016/j.jvacx.2023.100289. Epub 2023 Mar 30. PMID: 37020982

Knowledge and confidence gains after a COVID-19 vaccine continuing education program developed for nurse practitioners.
Roberts EN, Carrico R, Garrett JH, Scalzo P. J Am Assoc Nurse Pract. 2023 Aug 1;35(8):494-502. doi: 10.1097/JXX.0000000000000871. PMID: 37159448

Trajectory of COVID-19 vaccine hesitancy post-vaccination and public's intention to take booster vaccines: A cross-sectional analysis.
Salman M, Mallhi TH, Khan YH, Mustafa ZU, Khan MT, Khan FU, Butt MH, Shehzadi N, Farrukh MJ, Waheed M, Azmat F, Saeed A, Mazhar SA, Ali A, Ashfaq A, Hussain K. Hum Vaccin Immunother. 2023 Aug 1;19(2):2225990. doi: 10.1080/21645515.2023.2225990. Epub 2023 Jun 23. PMID: 37350298

Safety profile of inactivated COVID-19 vaccine in indonesian adults.
Satari HI, Kaswandani N, Medise BE, Sundoro J, Hadinegoro SR, Leonard E, Putra A, Angkasa PF. Vaccine X. 2023 Aug;14:100331. doi: 10.1016/j.jvacx.2023.100331. Epub 2023 Jun 10. PMID: 37346082

Efficacy and safety of a fourth dose of the COVID-19 vaccine in kidney transplant recipients: A systematic review and meta-analysis.
Kuniduzi Y, Chen B, Zeng J, Sun X, Chen T, Qian X, Wang J, Liang F, Abuduxukuer R, Yusufu M, Xu S, Zhang X. Transpl Immunol. 2023 Aug;79:101864. doi: 10.1016/j.trim.2023.101864. Epub 2023 May 23. PMID: 37230397

Choice preference and willingness to pay for COVID-19 vaccination in Namibia.
Konstantinus A, Konstantinus I. Vaccine X. 2023 Aug;14:100324. doi: 10.1016/j.jvacx.2023.100324. Epub 2023 Jun 8. PMID: 37333055

Survey of COVID-19 Vaccine Attitudes in Predominately Minority Pregnant Women.
Bonilla E, Fogel J, Hubley R, Anand R, Liu PC. South Med J. 2023 Aug;116(8):677-682. doi: 10.14423/SMJ.0000000000001587. PMID: 37536694

Family size and vaccination among older individuals: The case of COVID-19 vaccine.
Bonsang E, Pronkina E. Econ Hum Biol. 2023 Aug;50:101256. doi: 10.1016/j.ehb.2023.101256. Epub 2023 May 5. PMID: 37301172

SARS-CoV-2 and male infertility: from short- to long-term impacts.
Dai P, Qiao F, Chen Y, Chan DYL, Yim HCH, Fok KL, Chen H. J Endocrinol Invest. 2023 Aug;46(8):1491-1507. doi: 10.1007/s40618-023-02055-x. Epub 2023 Mar 14. PMID: 36917421

Adenoviral-vectored next-generation respiratory mucosal vaccines against COVID-19.
Afkhami S, Kang A, Jeyanathan V, Xing Z, Jeyanathan M. Curr Opin Virol. 2023 Aug;61:101334. doi: 10.1016/j.coviro.2023.101334. Epub 2023 May 11. PMID: 37276833

Association between Bisphosphonate use and COVID-19 related outcomes.
Thompson J, Wang Y, Dreischulte T, Barreiro O, Gonzalez RJ, Hanč P, Matysiak C, Neely HR, Rottenkolber M, Haskell T, Endres S, von Andrian UH. Elife. 2023 Aug 3;12:e79548. doi: 10.7554/eLife.79548. Online ahead of print. PMID: 37534876

COVID-19 vaccination and leprosy-A UK hospital-based retrospective cohort study.
de Barros B, Pierce R, Sprenger C, Ong ELH, Walker SL. PLoS Negl Trop Dis. 2023 Aug 4;17(8):e0011493. doi: 10.1371/journal.pntd.0011493. Online ahead of print. PMID: 37540711

Dynamic Trends and Underlying Factors of COVID-19 Vaccine Booster Hesitancy in Adults: Cross-Sectional Observational Study.
Wu J, Ma M, Li Q, Guo X, Tarimo CS, Jia S, Zhou X, Wang M, Gu J, Miao Y, Ye B. JMIR Public Health Surveill. 2023 Aug 1;9:e44822. doi: 10.2196/44822. PMID: 37526963

Human monkeypox virus in the shadow of the COVID-19 pandemic.
Khamees A, Awadi S, Al-Shami K, Alkhoun HA, Al-Eitan SF, Alsheikh AM, Saeed A, Al-Zoubi RM, Zoubi MSA. J Infect Public Health. 2023 Aug;16(8):1149-1157. doi: 10.1016/j.jiph.2023.05.013. Epub 2023 May 13. PMID: 37269693

The Incidence of Graves' Hyperthyroidism Before and After COVID-19 Messenger RNA Vaccination.
Endo M, Pinto J, Roth MY, Hoofnagle AN, Failor RA, Tylee TS. Endocr Pract. 2023 Aug;29(8):618-622. doi: 10.1016/j.eprac.2023.05.005. Epub 2023 Jun 29. PMID: 37391042

Social processes, practical issues, and COVID-19 vaccination among hesitant adults.
Willis DE, Reece S, Gurel-Headley M, Selig JP, Li J, Zimmerman S, Cornett LE, McElfish PA. Vaccine. 2023 Aug 7;41(35):5150-5158. doi: 10.1016/j.vaccine.2023.07.006. Epub 2023 Jul 7. PMID: 37423799

COVID-19 vaccine-associated vitiligo: A cross-sectional study in a tertiary referral center and systematic review.
Tsai TF, Ng CY. J Dermatol. 2023 Aug;50(8):982-989. doi: 10.1111/1346-8138.16799. Epub 2023 Apr 26. PMID: 37186102

Burden of influenza in the elderly: a narrative review.
Conrad A, Valour F, Vanhems P. Curr Opin Infect Dis. 2023 Aug 1;36(4):296-302. doi: 10.1097/QCO.0000000000000931. Epub 2023 Jun 22. PMID: 37431557

The Burden of COVID-19 in the Immunocompromised Patient: Implications for Vaccination and Needs for the Future.
Antinori A, Bausch-Jurken M. J Infect Dis. 2023 Aug 4;228(Suppl 1):S4-S12. doi: 10.1093/infdis/jiad181. PMID: 37539764

Correlates of COVID-19 vaccine uptake among U.S. College students.
Soulakova JN, Crockett LJ, Schmidt-Owens M, Schrimshaw EW. Prev Med Rep. 2023 Aug;34:102232. doi: 10.1016/j.pmedr.2023.102232. Epub 2023 May 19. PMID: 37234565

Factors related to COVID-19 vaccination intention and uptake among childbearing women.
Preis H, Mahaffey B, Lobel M. Health Psychol. 2023 Aug;42(8):567-576. doi: 10.1037/hea0001221. Epub 2022 Sep 8. PMID: 36074594

Conspiracy beliefs, COVID-19 vaccine uptake and adherence to public health interventions during the pandemic in Europe.
Regazzi L, Lontano A, Cadeddu C, Di Padova P, Rosano A. Eur J Public Health. 2023 Aug 1;33(4):717-724. doi: 10.1093/eurpub/ckad089. PMID: 37290405

Correlates of uptake of COVID-19 vaccines and motivation to vaccinate among Malawian adults.
Whitehead HS, Songo J, Phiri K, Kalande P, Lungu E, Phiri S, van Oosterhout JJ, Hoffman RM, Moucheraud C. Hum Vaccin Immunother. 2023 Aug 1;19(2):2228168. doi: 10.1080/21645515.2023.2228168. Epub 2023 Jul 2. PMID: 37394430

Understanding COVID-19 Vaccine Confidence in People Living with HIV: A pan-Canadian Survey.
Costiniuk CT, Singer J, Needham J, Yang Y, Qian H, Chambers C, Burchell AN, Samji H, Colmegna I, Del Canto S, Godin GH, Habanyama M, Hui C, Kroch A, Mandarino E, Margolese S, Martin C, Owino M, Mohammadi T, Zhang W, Pelaez S, Kovacs C, Benko E, Vulesevic B, Cooper CL, Anis AH. AIDS Behav. 2023 Aug;27(8):2669-2680. doi: 10.1007/s10461-023-03991-8. Epub 2023 Feb 4. PMID: 36738344

Benefit-risk assessment of Covid-19 vaccine, MRNA (MRNA-1273) for males age 18-64 years.
Yogurtcu ON, Funk PR, Forshee RA, Anderson SA, Marks PW, Yang H. Vaccine X. 2023 Aug;14:100325. doi: 10.1016/j.jvacx.2023.100325. Epub 2023 Jun 2. PMID: 37324525

COVID-19 Vaccination in Patients With Cancer and Patients Receiving HSCT or CAR-T Therapy: Immune Response, Real-World Effectiveness, and Implications for the Future.
Hall VG, Teh BW. J Infect Dis. 2023 Aug 4;228(Suppl 1):S55-S69. doi: 10.1093/infdis/jiad174. PMID: 37539765

Effectiveness of homologous or heterologous immunization regimens against SARS-CoV-2 after two doses of inactivated COVID-19 vaccine: A systematic review and meta-analysis.
Zhang X, Xia J, Jin L, Wu Y, Zheng X, Cao X, Meng X, Li J, Zhu F. Hum Vaccin Immunother. 2023 Aug 1;19(2):2221146. doi: 10.1080/21645515.2023.2221146. PMID: 37344370

Acute Uveitis Following AstraZeneca COVID-19 Vaccination.
Cho SK, Wu XN, Amaratunge C. Ocul Immunol Inflamm. 2023 Aug;31(6):1295-1298. doi: 10.1080/09273948.2023.2189456. Epub 2023 Apr 6. PMID: 37023373

Immunogenicity and reactogenicity of heterologous COVID-19 vaccination in pregnant women.
Chayachinda C, Watananirun K, Phatihattakorn C, Anuwutnavin S, Niyomnaitham S, Phongsamart W, Lapphra K, Wittawatmongkol O, Rungmaitree S, Jansarikit L, Boonnak K, Wongprompitak P, Senawong S, Upadhya A, Toh ZQ, Licciardi PV, Chokephaibulkit K. Hum Vaccin Immunother. 2023 Aug 1;19(2):2228670. doi: 10.1080/21645515.2023.2228670. Epub 2023 Jul 13. PMID:

mRNA: A promising platform for cancer immunotherapy.
Kong B, Kim Y, Kim EH, Suk JS, Yang Y. Adv Drug Deliv Rev. 2023 Aug;199:114993. doi: 10.1016/j.addr.2023.114993. Epub 2023 Jul 4. PMID: 37414361

Reports of New and Recurrent Keratitis following mRNA-based COVID-19 Vaccination.
Shah PP, Glidai Y, Braunstein R, Gorski M, Lee J, Anwar F, Schrier A, Winokur J, Steiner AS. Ocul Immunol Inflamm. 2023 Aug;31(6):1169-1174. doi: 10.1080/09273948.2022.2133730. Epub 2022 Nov 7. PMID: 36345233

COVID-19 and Global Distributive Justice: 'Health Diplomacy' of India and South Africa for the TRIPS waiver.
Singh B, Chattu VK, Kaur J, Mol R, Gauttam P, Singh B. J Asian Afr Stud. 2023 Aug;58(5):747-765. doi: 10.1177/00219096211069652. Epub 2022 Jan 18. PMID: 37461426

Otolaryngologic Side Effects After COVID-19 Vaccination.
Ahsanuddin S, Jin R, Dhanda AK, Georges K, Baredes S, Eloy JA, Fang CH. Laryngoscope. 2023 Aug 4. doi: 10.1002/lary.30923. Online ahead of print. PMID: 37539984

Modelling the Factors That Predict the Intention to Take COVID-19 Vaccine in Nigeria.
Apuke OD, Asude Tunca E. J Asian Afr Stud. 2023 Aug;58(5):664-680. doi: 10.1177/00219096211069642. Epub 2022 Jan 7. PMID: 37461427

Dacryoadenitis post COVID-19 infection and immunization.
Singh S, Gandhi A, Das S. Indian J Ophthalmol. 2023 Aug;71(8):3100-3102. doi: 10.4103/IJO.IJO_30_23. PMID: 37530288

Safety surveillance of the NVX-CoV2373 COVID-19 vaccine among Koreans aged 18 years and over.
Kim S, Ko M, Heo Y, Lee YK, Kwon Y, Choi SK, Bahng E. Vaccine. 2023 Aug 7;41(35):5066-5071. doi: 10.1016/j.vaccine.2023.06.077. Epub 2023 Jun 27. PMID: 37422379

Bioinformatics and systems biology analysis revealed PMID26394986-Compound-10 as potential repurposable drug against covid-19.
Nisar H, Wajid B, Anwar F, Ahmad A, Javaid A, Attique SA, Nisar W, Saeed A, Shahid S, Sadaf S. J Biomol Struct Dyn. 2023 Aug 3:1-14. doi: 10.1080/07391102.2023.2242500. Online ahead of print. PMID: 37534820

Halal or Haram? The COVID-19 Vaccine Discussion Among Twitter users in Malaysia.
Mohd Jenol NA, Ahmad Pazil NH. J Relig Health. 2023 Aug;62(4):2933-2946. doi: 10.1007/s10943-023-01798-4. Epub 2023 Mar 24. PMID: 36964281

Foreword: Preventing COVID-19 Among the Immunocompromised Population.
Willicombe M. J Infect Dis. 2023 Aug 4;228(Suppl 1):S1-S3. doi: 10.1093/infdis/jiad106. PMID: 37539760

Mix-and-match COVID-19 vaccines trigger high antibody response after the third dose vaccine in Moroccan health care workers.
Amellal H, Assaid N, Akarid K, Maaroufi A, Ezzikouri S, Sarih M. Vaccine X. 2023 Aug;14:100288. doi: 10.1016/j.jvacx.2023.100288. Epub 2023 Mar 25. PMID: 37008956

COVID-19 vaccination and hybrid immunity in older adults.
Ruiz JG, Andrew MK. Lancet Healthy Longev. 2023 Aug;4(8):e364-e365. doi: 10.1016/S2666-7568(23)00112-5. Epub 2023 Jul 14. PMID: 37459880

The influence of sociodemographic factors on COVID-19 vaccine certificate acceptance: A cross-sectional study.
Smith D, Zhu DT, Hawken S, Bota AB, Mithani SS, Marcon A, Pennycook G, Greyson D, Caulfield T, Graves F, Smith J, Wilson K. Hum Vaccin Immunother. 2023 Aug 1;19(2):2220628. doi: 10.1080/21645515.2023.2220628. PMID: 37291793

Effect of COVID-19 vaccination and booster on maternal-fetal outcomes: a retrospective cohort study.
Piekos SN, Hwang YM, Roper RT, Sorensen T, Price ND, Hood L, Hadlock JJ. Lancet Digit Health. 2023 Aug 1:S2589-7500(23)00093-6. doi: 10.1016/S2589-7500(23)00093-6. Online ahead of print. PMID: 37537121

Challenges and Progress in Designing Broad-Spectrum Vaccines Against Rapidly Mutating Viruses.
Bedi R, Bayless NL, Glanville J. Annu Rev Biomed Data Sci. 2023 Aug 10;6:419-441. doi: 10.1146/annurev-biodatasci-020722-041304. Epub 2023 May 17. PMID: 37196356

Attitude and influencing factors to receive the COVID-19 vaccine among university students in Sichuan Province, China: A cross-sectional study.
Yang K, Chi Y, Wan J, Qing X, Peng Y, Chen H, Li J, Jiang X. Nurs Open. 2023 Aug;10(8):5149-5164. doi: 10.1002/nop2.1751. Epub 2023 Apr 18. PMID: 37071667

COVID-19 vaccine hesitancy in Latin America and Africa: a scoping review.
Gonçalves BA, Matos CCSA, Ferreira JVDS, Itagyba RF, Moço VR, Couto MT. Cad Saude Publica. 2023 Aug 7;39(8):e00041423. doi: 10.1590/0102-311XPT041423. eCollection 2023. PMID: 37556613

Leveraging lessons from the COVID-19 pandemic to strengthen low-income and middle-income country preparedness for future global health threats.
Alakija A. Lancet Infect Dis. 2023 Aug;23(8):e310-e317. doi: 10.1016/S1473-3099(23)00279-7. Epub 2023 Jun 5. PMID: 37290474

The attitude and knowledge of pediatricians and family physicians toward COVID-19 vaccination in children: A cross-sectional study.
Alfaqih MA, Ababneh EY, Almansi GA, Marashdeh SA, Khazandar AA, Said AM, Mustafa AG. Hum Vaccin Immunother. 2023 Aug 1;19(2):2230104. doi: 10.1080/21645515.2023.2230104. Epub 2023 Jul 3. PMID: 37395614

Susceptibility to COVID-19 and Immunologic Response to Vaccination in Patients With Immune-Mediated Inflammatory Diseases.
Finckh A, Ciurea A, Raptis CE, Rubbert-Roth A. J Infect Dis. 2023 Aug 4;228(Suppl 1):S13-S23. doi: 10.1093/infdis/jiad148. PMID: 37539758

Corticosteroid-refractory autoimmune hepatitis after COVID-19 vaccination: a case report and literature review.
Ueno M, Takabatake H, Itakura J, Fujita R, Kayahara T, Morimoto Y, Notohara K, Mizuno M. Clin J Gastroenterol. 2023 Aug;16(4):554-558. doi: 10.1007/s12328-023-01794-x. Epub 2023 Apr 7. PMID: 37029249

Vaccine effectiveness of primary and booster COVID-19 vaccinations against SARS-CoV-2 infection in the Netherlands from July 12, 2021 to June 6, 2022: A prospective cohort study.
Huiberts AJ, de Gier B, Hoeve CE, de Melker HE, Hahné SJM, den Hartog G, Grobbee DE, van de Wijgert JHHM, van den Hof S, Knol MJ. Int J Infect Dis. 2023 Aug;133:36-42. doi: 10.1016/j.ijid.2023.04.401. Epub 2023 Apr 20. PMID: 37086863

The association between COVID-19 vaccination and idiopathic sudden sensorineural hearing loss, clinical manifestation and outcomes.
Fisher R, Tarnovsky Y, Hirshoren N, Kaufman M, Stern Shavit S. Eur Arch Otorhinolaryngol. 2023 Aug;280(8):3609-3613. doi: 10.1007/s00405-023-07869-2. Epub 2023 Feb 17. PMID: 36799975

COVID-19 vaccination hesitancy in adults in the United Kingdom: Barriers and facilitators to uptake.
Husted M, Gibbons A, Cheung WY, Keating S. Health Psychol. 2023 Aug;42(8):584-592. doi: 10.1037/hea0001256. Epub 2023 Jan 12. PMID: 36633991

Predictors and prevalence of COVID-19 vaccination in patients with focal epilepsy following resection surgery.
Yang Y, Lv J, He C, Shen C, Xu S, Guo Y, Ding Y, Zheng Z, Zhu J, Wang S, Ding M, Wang S. Epilepsy Behav. 2023 Aug;145:109344. doi: 10.1016/j.yebeh.2023.109344. Epub 2023 Jul 3. PMID: 37459719

Omicron variant evolution on vaccines and monoclonal antibodies.
Sabbatucci M, Vitiello A, Clemente S, Zovi A, Boccellino M, Ferrara F, Cimmino C, Langella R, Ponzo A, Stefanelli P, Rezza G. Inflammopharmacology. 2023 Aug;31(4):1779-1788. doi: 10.1007/s10787-023-01253-6. Epub 2023 May 19. PMID: 37204696

Analysis of the institutional landscape and proliferation of proposals for global vaccine equity for COVID-19: too many cooks or too many recipes?
Geiger S, McMahon A. J Med Ethics. 2023 Aug;49(8):583-590. doi: 10.1136/medethics-2021-107684. Epub 2021 Nov 30. PMID: 34848492

Introduction to the special issue on vaccine hesitancy and refusal.
Bednarczyk RA, Dew MA, Hart TA, Freedland KE, Kaufmann PG. Health Psychol. 2023 Aug;42(8):511-515. doi: 10.1037/hea0001302. PMID: 37486374

The Influence of Racism in Healthcare: COVID-19 Vaccine Hesitancy Among Black Mothers in Chicago.
Harris M, Sherrod D, Walsh JL, Hunt BR, Jacobs J, Valencia J, Baumer-Mouradian S, Quinn KG. J Racial Ethn Health Disparities. 2023 Aug 2. doi: 10.1007/s40615-023-01708-0. Online ahead of print. PMID: 37531019

Bibliometric and visual analysis of vaccination hesitancy research from 2013 to 2022.
Chen C, Yang Q, Tian H, Wu J, Chen L, Ji Z, Zheng D, Chen Y, Li Z, Lu H. Hum Vaccin Immunother. 2023 Aug 1;19(2):2226584. doi: 10.1080/21645515.2023.2226584. Epub 2023 Jun 30. PMID: 37387233

Disparities in COVID-19 vaccine hesitancy among a diverse community-based sample in Connecticut, United States.
Eger WH, Suttiratana SC, Herbst RL, Behringer H, Ibrahim E, Jones BA. Prev Med Rep. 2023 Aug;34:102263. doi: 10.1016/j.pmedr.2023.102263. Epub 2023 May 24. PMID: 37252068

Determinants of COVID-19 immunisation uptake in a country with high mortality and a low vaccination rate.
Aksentijevic D, Tanner R, Lazović-Pita L, Peštek A, Abdić A. J Infect Public Health. 2023 Aug;16(8):1322-1331. doi: 10.1016/j.jiph.2023.06.001. Epub 2023 Jun 3. PMID: 37343504

The backfiring effects of monetary and gift incentives on Covid-19 vaccination intentions.
Zhang X, Lane T. China Econ Rev. 2023 Aug;80:102009. doi: 10.1016/j.chieco.2023.102009. Epub 2023 Jun 16. PMID: 37351337

How does nudging the COVID-19 vaccine play out in people who are in doubt about vaccination?
de Ridder D, Adriaanse M, van Gestel L, Wachner J. Health Policy. 2023 Aug;134:104858. doi: 10.1016/j.healthpol.2023.104858. Epub 2023 Jun 12. PMID: 37327707

A Case of Neuroretinitis Following COVID-19 Vaccination.
Yoshida N, Tsukada A. Ocul Immunol Inflamm. 2023 Aug;31(6):1261-1264. doi: 10.1080/09273948.2022.2137047. Epub 2022 Oct 28. PMID: 36306430

Association of Sources of COVID-19 Information with Vaccine Uptake, Preventive Behaviors, and Perceived Severity of COVID-19.
Kim Y, Kim J, Li Y. J Am Med Dir Assoc. 2023 Aug;24(8):1143-1150. doi: 10.1016/j.jamda.2023.05.024. Epub 2023 Jun 7. PMID: 37400059

Rational design of a booster vaccine against COVID-19 based on antigenic distance.
Hu YF, Yuen TT, Gong HR, Hu B, Hu JC, Lin XS, Rong L, Zhou CL, Chen LL, Wang X, Lei C, Yau T, Hung IF, To KK, Yuen KY, Zhang BZ, Chu H, Huang JD. Cell Host Microbe. 2023 Aug 9;31(8):1301-1316.e8. doi: 10.1016/j.chom.2023.07.004. Epub 2023 Jul 31. PMID: 37527659

Impact of pandemics and disruptions to vaccination on infectious diseases epidemiology past and present.
Hamson E, Forbes C, Wittkopf P, Pandey A, Mendes D, Kowalik J, Czudek C, Mugwagwa T. Hum Vaccin Immunother. 2023 Aug 1;19(2):2219577. doi: 10.1080/21645515.2023.2219577. Epub 2023 Jun 8. PMID: 37291691

Updated guidance regarding the risk of allergic reactions to COVID-19 vaccines and recommended evaluation and management: A GRADE assessment and international consensus approach.
Greenhawt M, Dribin TE, Abrams EM, Shaker M, Chu DK, Golden DBK, Akin C, Anagnostou A, ALMuhizi F, Alqurashi W, Arkwright P, Baldwin JL, Banerji A, Bégin P, Ben-Shoshan M, Bernstein J, Bingemann TA, Bindslev-Jensen C, Blumenthal K, Byrne A, Cahill J, Cameron S, Campbell D, Campbell R, Cavender M, Chan ES, Chinthrajah S, Comberiati P, Eastman JJ, Ellis AK, Fleischer DM, Fox A, Frischmeyer-Guerrerio PA, Gagnon R, Garvey LH, Grayson MH, Isabwe GAC, Hartog N, Hendron D, Horner CC, Hourihane JO, Iglesia E, Kan M, Kaplan B, Katelaris CH, Kim H, Kelso JM, Khan DA, Lang D, Ledford D, Levin M, Lieberman JA, Loh R, Mack DP, Mazer B, Mody K, Mosnaim G, Munblit D, Mustafa SS, Nanda A, Nathan R, Oppenheimer J, Otani IM, Park M, Pawankar R, Perrett KP, Peter J, Phillips EJ, Picard M, Pitlick M, Ramsey A, Rasmussen TH, Rathkopf MM, Reddy H, Robertson K, Rodriguez Del Rio P, Sample S, Sheshadri A, Sheik J, Sindher SB, Spergel JM, Stone CA, Stukus D, Tang MLK, Tracy JM, Turner PJ, Vander Leek TK, Wallace DV, Wang J, Wasserman S, Weldon D, Wolfson AR, Worm M, Yacoub MR. J Allergy Clin Immunol. 2023 Aug;152(2):309-325. doi: 10.1016/j.jaci.2023.05.019. Epub 2023 Jun 7. PMID: 37295474

Multiple Evanescent White Dot Syndrome Following Adenovirus Vector-Based COVID-19 Vaccine (Covishield).
Baharani A, Reddy RR. Ocul Immunol Inflamm. 2023 Aug;31(6):1299-1304. doi: 10.1080/09273948.2023.2192271. Epub 2023 Apr 12. PMID: 37043615

Access to Health Care Improves COVID-19 Vaccination and Mitigates Health Disparities Among Medicare Beneficiaries.
Lane J, Palacio A, Chen LE, McCarter D, Tamariz L, Chen CJ Jr, Ghany R. J Racial Ethn Health Disparities. 2023 Aug;10(4):1569-1575. doi: 10.1007/s40615-022-01343-1. Epub 2022 Sep 28. PMID: 36171495

Vaccine-hesitant individuals accumulate additional COVID-19 risk due to divergent perception and behaviors related to SARS-CoV-2 testing: a population-based, cross-sectional study.
Wratil PR, Kotter K, Bischof ML, Hollerbach S, Apak E, Kalteis AL, Nayeli-Pflantz T, Kaderali L, Adorjan K, Keppler OT. Infection. 2023 Aug;51(4):909-919. doi: 10.1007/s15010-022-01947-z. Epub 2022 Nov 10. PMID: 36355269

Natural and vaccine-induced immunity are equivalent for the protection against SARS-CoV-2 infection.
Franchi M, Pellegrini G, Cereda D, Bortolan F, Leoni O, Pavesi G, Galli M, Valenti G, Corrao G. J Infect Public Health. 2023 Aug;16(8):1137-1141. doi: 10.1016/j.jiph.2023.05.018. Epub 2023 May 20. PMID: 37267680

Medical Mistrust, Perceived Discrimination, and Race: a Longitudinal Analysis of Predictors of COVID-19 Vaccine Hesitancy in US Adults.
Morgan KM, Maglalang DD, Monnig MA, Ahluwalia JS, Avila JC, Sokolovsky AW. J Racial Ethn Health Disparities. 2023 Aug;10(4):1846-1855. doi: 10.1007/s40615-022-01368-6. Epub 2022 Aug 1. PMID: 35913543

Vaccine effectiveness against severe COVID-19 during the Omicron wave in Germany: results from the COViK study.
Stoliaroff-Pepin A, Peine C, Herath T, Lachmann J, Hellenbrand W, Perriat D, Dörre A, Nitsche A, Michel J, Grossegesse M, Hofmann N, Rinner T, Kohl C, Brinkmann A, Meyer T, Stern D, Treindl F, Dorner BG, Hein S, Werel L, Hildt E, Gläser S, Schühlen H, Isner C, Peric A, Ghouzi A, Reichardt A, Janneck M, Lock G, Huster D, Grünewald T, Schaade L, Wichmann O, Harder T. Infection. 2023 Aug;51(4):1093-1102. doi: 10.1007/s15010-023-02012-z. Epub 2023 Mar 13. PMID: 36913112

Intention to receive COVID-19 vaccine and its health belief model (HBM)-based predictors: Comment.
Kleebayoon A, Wiwanitkit V. Hum Vaccin Immunother. 2023 Aug 1;19(2):2219181. doi: 10.1080/21645515.2023.2219181. Epub 2023 Jun 4. PMID: 37271581

Recent trends in vaccine coverage and confidence: A cause for concern.
Eagan RL, Larson HJ, de Figueiredo A. Hum Vaccin Immunother. 2023 Aug 1;19(2):2237374. doi: 10.1080/21645515.2023.2237374. PMID: 37526111

A non-transmissible live attenuated SARS-CoV-2 vaccine.
Adler JM, Martin Vidal R, Voß A, Kunder S, Nascimento M, Abdelgawad A, Langner C, Vladimirova D, Osterrieder N, Gruber AD, Kunec D, Trimpert J. Mol Ther. 2023 Aug 2;31(8):2391-2407. doi: 10.1016/j.ymthe.2023.05.004. Epub 2023 May 26. PMID: 37263272

COVID-19 mRNA vaccines as hypothetical epigenetic players: Results from an in silico analysis, considerations and perspectives.
Talotta R. Vaccine. 2023 Aug 7;41(35):5182-5194. doi: 10.1016/j.vaccine.2023.07.007. Epub 2023 Jul 13. PMID: 37453842

Axillary Lymphadenopathy After a COVID-19 Vaccine Booster Dose: Time to Resolution on Ultrasound Follow-Up and Associated Factors.
Mema E, Lane EG, Drotman MB, Eisen CS, Thomas C, Prince MR, Dodelzon K. AJR Am J Roentgenol. 2023 Aug;221(2):175-183. doi: 10.2214/AJR.22.28970. Epub 2023 Mar 8. PMID: 36883774

Vaccination and mortality from COVID-19: a comparative study between hemodialysis, peritoneal dialysis, and non-dialysis adult population in Panama.
Courville KJ, Bustamante NE, Nuñez-Samudio V, Pecchio M, Landires I, Viggiano C, Durán H, Novoa N, Alvarado E, Vargas F, Salado D, Manzanares J, Haughton K, Cuero C, Niedda M, Valdés R. Int Urol

Nephrol. 2023 Aug;55(8):2091-2098. doi: 10.1007/s11255-023-03529-w. Epub 2023 Feb 24. PMID: 36828920

Comments on "Assessing the self-reported after events following immunization of COVID-19 vaccines in Turkey and Bangladesh" by Sultana et al. (2023) (10.1007/s11356-023-25527-2).
Das Sharmi P, Rony MKK. Environ Sci Pollut Res Int. 2023 Aug;30(37):88233-88234. doi: 10.1007/s11356-023-28831-z. Epub 2023 Jul 17. PMID: 37460890

Bivalent COVID-19 booster vaccines and the absence of BA.5-specific antibodies.
Carreño JM, Singh G, Simon V, Krammer F; PVI study group. Lancet Microbe. 2023 Aug;4(8):e569. doi: 10.1016/S2666-5247(23)00118-0. Epub 2023 May 1. PMID: 37141905

Assessing the credibility of COVID-19 vaccine mis/disinformation in online discussion.
Savolainen R. J Inf Sci. 2023 Aug;49(4):1096-1110. doi: 10.1177/01655515211040653. Epub 2021 Aug 19. PMID: 37461399

Vaccine perceptions among Black adults with long COVID.
Dell'Imperio SG, Aboul-Hassan D, Batchelor R, Chambers-Peeple K, Clauw DJ, DeJonckheere M, Bergmans RS. Ethn Health. 2023 Aug;28(6):853-873. doi: 10.1080/13557858.2023.2191914. Epub 2023 Apr 2. PMID: 37005013

Vaccination, human mobility, and COVID-19 health outcomes: Empirical comparison before and during the outbreak of SARS-Cov-2 B.1.1.529 (Omicron) variant.
Hu S, Xiong C, Zhao Y, Yuan X, Wang X. Vaccine. 2023 Aug 7;41(35):5097-5112. doi: 10.1016/j.vaccine.2023.05.056. Epub 2023 May 29. PMID: 37270367

COVID-19 in patients with chronic kidney disease: a 2-year study of incidence and mortality in relation to the variants of concern waves in Brazil.
Almeida NBF, Filgueiras PS, Lourenço AJ, Bicalho CMF, Corsini CA, de Miranda DAP, Gomes SVC, Vilela RVR, Grenfell RFQ. Trans R Soc Trop Med Hyg. 2023 Aug 3;117(8):606-608. doi: 10.1093/trstmh/trad019. PMID: 37042271

Real-time forecasting of COVID-19 spread according to protective behavior and vaccination: autoregressive integrated moving average models.
Cheng C, Jiang WM, Fan B, Cheng YC, Hsu YT, Wu HY, Chang HH, Tsou HH. BMC Public Health. 2023 Aug 8;23(1):1500. doi: 10.1186/s12889-023-16419-8. PMID: 37553650

Retinal Vasculitis Following COVID-19 Vaccination: Causation or Coincidence?
Yi Z, Chen L, Zheng H, Chen C. Ocul Immunol Inflamm. 2023 Aug;31(6):1283-1285. doi: 10.1080/09273948.2023.2176887. Epub 2023 Feb 17. PMID: 36799876

COVID-19 Vaccine Safety Surveillance in Early Pregnancy in the United States: Design Factors Affecting the Association Between Vaccine and Spontaneous Abortion.
Vazquez-Benitez G, Haapala JL, Lipkind HS, DeSilva MB, Zhu J, Daley MF, Getahun D, Klein NP, Vesco KK, Irving SA, Nelson JC, Williams JTB, Hambidge SJ, Donahue J, Fuller CC, Weintraub ES, Olson C,

Kharbanda EO. Am J Epidemiol. 2023 Aug 4;192(8):1386-1395. doi: 10.1093/aje/kwad059. PMID: 36928091

Tixagevimab/cilgavimab for the prevention of COVID-19 in vaccine-refractory patients with autoimmune diseases: a prospective cohort study.
Minopoulou I, Tascilar K, Corte G, Mutlu MY, Schmidt K, Bohr D, Hartmann F, Manger K, Manger B, Korn K, Kleyer A, Simon D, Harrer T, Schett G, Fagni F. Rheumatology (Oxford). 2023 Aug 2:kead391. doi: 10.1093/rheumatology/kead391. Online ahead of print. PMID: 37531288

Self-reported symptoms after COVID-19 vaccination. Distinct sex, age, and geographical outcomes in Lebanese and Italian cohorts.
Khalil M, Bonfrate L, Di Ciaula A, Portincasa P; LEITvax Group^. Intern Emerg Med. 2023 Aug;18(5):1463-1475. doi: 10.1007/s11739-023-03321-9. Epub 2023 Jun 15. PMID: 37322183

Concordance between COVID-19 mortality statistics derived from clinical audit and death certificates in Östergötland county, Sweden.
Spreco A, Andersson C, Sjödahl R, Timpka T. Public Health. 2023 Aug;221:46-49. doi: 10.1016/j.puhe.2023.06.007. Epub 2023 Jun 9. PMID: 37399611

Impacts of the COVID-19 pandemic on immunization with pneumococcal vaccines in children and older adults in Brazil.
Novaes JVLC, de Freitas Faria FM, de Bragança BSC, Dos Santos LI. Prev Med. 2023 Aug;173:107602. doi: 10.1016/j.ypmed.2023.107602. Epub 2023 Jul 7. PMID: 37423475

General publics' perception toward COVID-19 vaccines in Afghanistan, 2021.
Hakim MS, Mansoor GF, Walizada AW, Saeed KMI, Naeemi S, Fazil FA. Hum Vaccin Immunother. 2023 Aug 1;19(2):2228164. doi: 10.1080/21645515.2023.2228164. Epub 2023 Jul 7. PMID: 37417006

Delayed cutaneous hypersensitivities to COVID-19 vaccination: Phenotypic distribution and tolerability of vaccine rechallenge.
De Luca JF, Awad A, Vogrin S, Waldron JL, McInnes K, Gibney G, Hall R, Douglas AP, Chua KYL, Holmes NE, Trubiano JA. J Allergy Clin Immunol Pract. 2023 Aug;11(8):2605-2607.e2. doi: 10.1016/j.jaip.2023.04.045. Epub 2023 May 11. PMID: 37178767

Sapovirus infections in Japan before and after the emergence of the COVID-19 pandemic: An alarming update.
Hoque SA, Pham NTK, Onda-Shimizu Y, Nishimura S, Sugita K, Kobayashi M, Islam MT, Okitsu S, Khamrin P, Maneekarn N, Hayakawa S, Ushijima H. J Med Virol. 2023 Aug;95(8):e29023. doi: 10.1002/jmv.29023. PMID: 37543991

A Call to Action: Current Challenges and Considerations for COVID-19 Vaccination in Immunocompromised Populations.
Bonanni P, Ceddia F, Dawson R. J Infect Dis. 2023 Aug 4;228(Suppl 1):S70-S76. doi: 10.1093/infdis/jiad150. PMID: 37539763

The effect of COVID-19 vaccination on anticoagulation stability in adolescents and young adults using vitamin K antagonists.
Visser C, Yousefi A, Nierman MC, Huisman MV, Gulpen AJW, van Ommen CH, Kruip MJHA; Dutch COVID and Thrombosis Coalition. Thromb Res. 2023 Aug;228:121-127. doi: 10.1016/j.thromres.2023.06.005. Epub 2023 Jun 12. PMID: 37321159

Effectiveness of mRNA and inactivated COVID-19 vaccines: A test-negative study in an infection-naïve Hong Kong population.
Ng RWY, Sze RKH, Chong KC, Zhao S, Ling L, Lui G, Leung ASY, Yeung ACM, Ho WCS, Wong MCS, Chen Z, Boon SS, Hui DSC, Chan PKS. J Infect. 2023 Aug;87(2):136-143. doi: 10.1016/j.jinf.2023.05.020. Epub 2023 May 26. PMID: 37245544

Routine vaccination for influenza and pneumococcal disease and its effect on COVID-19 in a population of Dutch older adults.
Taks EJM, Föhse K, J C F M Moorlag S, Hoogerwerf J, van Crevel R, van Werkhoven CH, Netea MG, Ten Oever J. Vaccine X. 2023 Jul 6;14:100344. doi: 10.1016/j.jvacx.2023.100344. eCollection 2023 Aug. PMID: 37484869

Experiences of American Health Departments, Health Systems, and Community Organizations in COVID-19 Vaccine Provision for Refugee, Immigrant, and Migrant Communities.
Thomas CM, Yun K, Mudenge NU, Abudiab S, de Acosta D, Fredkove WM, Garcia Y, Hoffman SJ, Karim S, Mann E, Smith MK, Yu K, Dawson-Hahn E. Am J Trop Med Hyg. 2023 Jul 10;109(2):471-479. doi: 10.4269/ajtmh.23-0034. Print 2023 Aug 2. PMID: 37429571

Kikuchi-Fujimoto Disease Following COVID-19 Vaccination: Experience at a Population-Based Referral Center.
Craig JW, Farinha P, Jiang A, Lytle A, Skinnider B, Slack GW. Am J Clin Pathol. 2023 Aug 1;160(2):114-118. doi: 10.1093/ajcp/aqad032. PMID: 37526500

Bivalent COVID-19 mRNA vaccine against omicron subvariants in immunocompromised patients.
Solera JT, Ierullo M, Arbol BG, Mavandadnejad F, Kurtesi A, Qi F, Hu Q, Gingras AC, Ferreira VH, Humar A, Kumar D. Lancet Infect Dis. 2023 Aug;23(8):e266-e267. doi: 10.1016/S1473-3099(23)00357-2. Epub 2023 Jun 20. PMID: 37352879

Advancements in the development of nucleic acid vaccines for syphilis prevention and control.
Li S, Li W, Jin Y, Wu B, Wu Y. Hum Vaccin Immunother. 2023 Aug 1;19(2):2234790. doi: 10.1080/21645515.2023.2234790. PMID: 37538024

Cutaneous reactions after COVID-19 vaccination in Turkey: Questions and answers.
Cebeci Kahraman F, Temiz SA. J Cosmet Dermatol. 2023 Aug;22(8):2368-2369. doi: 10.1111/jocd.15711. Epub 2023 Mar 8. PMID: 36891626

Intentions to receive COVID-19 vaccines in the united states: Sociodemographic factors and personal experiences with COVID-19.
Warren AM, Bennett MM, da Graca B, Waddimba AC, Gottlieb RL, Douglas ME, Powers MB. Health Psychol. 2023 Aug;42(8):531-540. doi: 10.1037/hea0001225. Epub 2022 Sep 5. PMID: 36066860

Vaccination intention and uptake within the Black community in Appalachia.
Brumbaugh JT, Sokoto KC, Wright CD, Francis SE, Hubbard J, Alexander L, McNeil DW. Health Psychol. 2023 Aug;42(8):557-566. doi: 10.1037/hea0001264. Epub 2023 Feb 13. PMID: 36780275

Myocarditis following COVID-19 mRNA vaccinations: Twin and sibling case series.
Shenton P, Cheng DR, Simm P, Jones B, Crawford NW. Vaccine X. 2023 Jul 7;14:100350. doi: 10.1016/j.jvacx.2023.100350. eCollection 2023 Aug. PMID: 37484868

COVID-19 Vaccination Among Patients Receiving Maintenance Renal Replacement Therapy: Immune Response, Real-World Effectiveness, and Implications for the Future.
Rouphael N, Bausch-Jurken M. J Infect Dis. 2023 Aug 4;228(Suppl 1):S46-S54. doi: 10.1093/infdis/jiad162. PMID: 37539761

"Why rush to get vaccinated earlier?": Regulatory focus and COVID-19 vaccination.
Ku X, Cha SE, Jeong J, Kim N, Kim Y, Kim JH, Choi I. Health Psychol. 2023 Aug;42(8):615-623. doi: 10.1037/hea0001237. Epub 2022 Sep 8. PMID: 36074596

A population-based assessment of avoidable hospitalizations and resource use of non-vaccinated patients with COVID-19.
Bagshaw SM, Abbott A, Beesoon S, Bowker SL, Zuege DJ, Thanh NX. Can J Public Health. 2023 Aug;114(4):547-554. doi: 10.17269/s41997-023-00777-2. Epub 2023 May 10. PMID: 37165140

Optimal vaccination strategies for COVID-19 in population migration between two regions scenario.
Zuo C, Ling Y, Guo Y, Zhang M, Meng Z, Xiang G. Hum Vaccin Immunother. 2023 Aug 1;19(2):2223108. doi: 10.1080/21645515.2023.2223108. Epub 2023 Jun 23. PMID: 37350470

Vaccine hesitancy promotes emergence of new SARS-CoV-2 variants.
Jing S, Milne R, Wang H, Xue L. J Theor Biol. 2023 Aug 7;570:111522. doi: 10.1016/j.jtbi.2023.111522. Epub 2023 May 18. PMID: 37210068

Mushroom β-glucans: application and innovation for food industry and immunotherapy.
Timm TG, Costa TM, Alberton MD, Helm CV, Tavares LBB. Appl Microbiol Biotechnol. 2023 Aug;107(16):5035-5049. doi: 10.1007/s00253-023-12656-4. Epub 2023 Jul 6. PMID: 37410138

Self-reported long COVID-19 symptoms are rare among vaccinated healthcare workers.
AlBahrani S, AlBarrak A, AlGubaisi N, Alkurdi H, Alburaiki D, AlGhamdi A, AlOthaiqy M, Tayeb S, Tayeb N, Abdraboh S, Khairi A, Alshareef L, AlHarbi A, AlRabeeah S, Alqahtani AS, Alqahtani JS, Hakami FH, Al-Maqati TN, Alkhrashi SA, Almershad MM, AlAbbadi A, Hakami MH, Faqihi O, Altawfiq KJA, Jebakumar AZ, Al-Tawfiq JA. J Infect Public Health. 2023 Aug;16(8):1276-1280. doi: 10.1016/j.jiph.2023.05.037. Epub 2023 Jun 5. PMID: 37315430

Reduction in the risk of progression of solid organ transplant recipients infected by SARS-CoV-2 treated with monoclonal antibodies.
Candel FJ, Salavert M, Lorite Mingot D, Manzano Crespo M, Pérez Portero P, Cuervo Pinto R. Rev Esp Quimioter. 2023 Aug;36(4):380-391. doi: 10.37201/req/023.2023. Epub 2023 Apr 24. PMID: 37089055

Sickness absence due to mandatory COVID-19 certificates in the workplace.
Wanger S, Weber E. BMC Public Health. 2023 Aug 3;23(1):1482. doi: 10.1186/s12889-023-16415-y. PMID: 37537556

Impact of customer incivility on restaurant employee stress spread and turnover: COVID-19 vaccination mandate.
Kim B, Yu H, Huang Y, Lee S. Int J Hosp Manag. 2023 Aug;113:103522. doi: 10.1016/j.ijhm.2023.103522. Epub 2023 May 29. PMID: 37284333

"In general people aren't excited about the vaccine...": Frontline perspectives on COVID-19 vaccine hesitancy across Syria.
Alhaffar M, Douedari Y, Howard N. Hum Vaccin Immunother. 2023 Aug 1;19(2):2235239. doi: 10.1080/21645515.2023.2235239. PMID: 37489270

The protective effect of COVID-19 vaccines on developing multisystem inflammatory syndrome in children (MIS-C): a systematic literature review and meta-analysis.
Hamad Saied M, van der Griend L, van Straalen JW, Wulffraat NM, Vastert S, Jansen MHA. Pediatr Rheumatol Online J. 2023 Aug 7;21(1):80. doi: 10.1186/s12969-023-00848-1. PMID: 37550719

Highly Attenuated Poxvirus-Based Vaccines Against Emerging Viral Diseases.
Perdiguero B, Pérez P, Marcos-Villar L, Albericio G, Astorgano D, Álvarez E, Sin L, Gómez CE, García-Arriaza J, Esteban M. J Mol Biol. 2023 Aug 1;435(15):168173. doi: 10.1016/j.jmb.2023.168173. Epub 2023 Jun 8. PMID: 37301278

Public trust is earned: Historical discrimination, carceral violence, and the COVID-19 pandemic.
Anderson A, Lewis DF 4th, Shafer P, Anderson J, LaVeist TA. Health Serv Res. 2023 Aug;58 Suppl 2(Suppl 2):218-228. doi: 10.1111/1475-6773.14187. Epub 2023 Jun 6. PMID: 37279782

Comparison of self-reported symptoms in COVID-19 patients who had or had not previously received COVID-19 mRNA vaccination.
Hara M, Furue T, Fukuoka M, Iwanaga K, Matsuishi E, Miike T, Sakamoto Y, Mukai N, Kinugasa Y, Shigyo M, Sonoda N, Tanaka M, Arase Y, Tanaka Y, Nakashima H, Irie S, Hirota Y. Hum Vaccin Immunother. 2023 Aug 1;19(2):2226575. doi: 10.1080/21645515.2023.2226575. PMID: 37357433

Why some people do not get vaccinated against COVID-19: Social-cognitive determinants of vaccination behavior.
Han Q, Zheng B, Abakoumkin G, Leander NP, Stroebe W. Appl Psychol Health Well Being. 2023 Aug;15(3):825-845. doi: 10.1111/aphw.12411. Epub 2022 Nov 8. PMID: 36345695

Emerging zoonotic diseases and COVID-19 pandemic: global Perspective and Indian Scenario.
Bardhan M, Ray I, Roy S, Bhatt P, Patel S, Asri S, Shariff S, Shree A, Mitra S, Roy P, Anand A. Ann Med Surg (Lond). 2023 Jul 7;85(8):3997-4004. doi: 10.1097/MS9.0000000000001057. eCollection 2023 Aug. PMID: 37554903

Public Opinions About Palliative and End-of-Life Care During the COVID-19 Pandemic: Twitter-Based Content Analysis.

Wang Y, Chukwusa E, Koffman J, Curcin V. JMIR Form Res. 2023 Aug 7;7:e44774. doi: 10.2196/44774. PMID: 37368840

Factors Associated with COVID-19 Vaccine Uptake Among High School Students in a Large, Diverse Metropolitan Area.
Qi JZ, Weller SC. J Sch Health. 2023 Aug 1. doi: 10.1111/josh.13379. Online ahead of print. PMID: 37528550

Differences in non-positive intention to accept the COVID-19 booster vaccine between three countries in the cross-border region Meuse-Rhine Euroregion: The Netherlands, Belgium, and Germany.
van Bilsen CJA, Stabourlos C, Moonen CPB, Brinkhues S, Demarest S, Hanssen DAT, van Loo IHM, Savelkoul PHM, Philippsen D, van der Zanden BAM, Dukers-Muijrers NHTM, Hoebe CJPA. Vaccine X. 2023 Aug;14:100306. doi: 10.1016/j.jvacx.2023.100306. Epub 2023 Apr 20. PMID: 37113740

A Psychosocial Model of COVID-19 Vaccination: Antecedent and Concurrent Effects of Demographics, Traits, Political Beliefs, Vaccine Intention, Information Sources, Mandates, and Flu Vaccine History.
Godfrey O, Bogg T, Milad E. Ann Behav Med. 2023 Aug 4:kaad043. doi: 10.1093/abm/kaad043. Online ahead of print. PMID: 37540839

The Association Between Receiving the Flu and COVID-19 Vaccines and Related Factors, Data from the StopFlu Campaign in Eight States and the District of Columbia, 2022.
Garza N, Leibensperger M, Bonnevie E. J Community Health. 2023 Aug;48(4):731-739. doi: 10.1007/s10900-023-01213-9. Epub 2023 Mar 31. PMID: 37002473

Susceptibility to SARS-CoV-2 Infection and Immune Responses to COVID-19 Vaccination Among Recipients of Solid Organ Transplants.
Subramanian V. J Infect Dis. 2023 Aug 4;228(Suppl 1):S34-S45. doi: 10.1093/infdis/jiad152. PMID: 37539762

A phase I COVID-19 vaccine trial among SARS-CoV-2 seronegative and seropositive individuals in Uganda utilizing a self-amplifying RNA vaccine platform: Screening and enrollment experiences.
Kitonsa J, Kamacooko O, Ruzagira E, Nambaziira F, Abaasa A, Serwanga J, Gombe B, Lunkuse J, Naluyinda H, Tukamwesiga N, Namata T, Kigozi A, Kafeero P, Basajja V, Joseph S, Pierce BF, Shattock R, Kaleebu P. Hum Vaccin Immunother. 2023 Aug 1;19(2):2240690. doi: 10.1080/21645515.2023.2240690. PMID: 37553178

Covid-19: Latin America defies nationalism and circumstance to develop its own vaccines.
De Ambrosio M. BMJ. 2023 Aug 7;382:1351. doi: 10.1136/bmj.p1351. PMID: 37549974

Effect of COVID-19 vaccinations on menstrual cycle and postmenopausal bleeding among health care workers: A cross-sectional study.
Farah S, Hijazi M, Aoun E, Boueri M, Nasr E, Chlala W, Salem MJ, Moufawad G, Farah D, El Hayek P, Jallad K, Ghaname W, Ziadeh H. Int J Gynaecol Obstet. 2023 Aug;162(2):532-540. doi: 10.1002/ijgo.14809. Epub 2023 May 3. PMID: 37132636

Factors associated with COVID-19 vaccination uptake in community health center patients.

Buscemi J, Arteaga N, O'Donnell A, Takgbajouah M, Bushnell A, Mirich C, Sagan D, Riley E, Harley P, Cabbler A. Health Psychol. 2023 Aug;42(8):551-556. doi: 10.1037/hea0001241. Epub 2022 Oct 10. PMID: 36222648

Best Practices for Implementation of an Employee Health COVID-19 Vaccine Clinic-A Model for Future Pandemic Preparedness.
Green-McKenzie J, Field-Flowers C, Peairs K, Barnes K, Shofer F, Kuter BJ. J Occup Environ Med. 2023 Aug 1;65(8):621-626. doi: 10.1097/JOM.0000000000002860. Epub 2023 Apr 11. PMID: 37043395

Herpesviruses reactivation following COVID-19 vaccination: a systematic review and meta-analysis.
Shafiee A, Amini MJ, Arabzadeh Bahri R, Jafarabady K, Salehi SA, Hajishah H, Mozhgani SH. Eur J Med Res. 2023 Aug 10;28(1):278. doi: 10.1186/s40001-023-01238-9. PMID: 37559096

Correspondence on immune responses, rheumatoid arthritis and third dose of mRNA COVID-19 vaccine.
Kleebayoon A, Wiwanitkit V. Semin Arthritis Rheum. 2023 Aug;61:152222. doi: 10.1016/j.semarthrit.2023.152222. Epub 2023 May 9. PMID: 37217405

Self-reported side effects following COVID-19 vaccination in athletes: A retrospective study.
Komici K, Verderosa S, D'Amico F, Guerra G. Hum Vaccin Immunother. 2023 Aug 1;19(2):2234788. doi: 10.1080/21645515.2023.2234788. PMID: 37470390

Acceptability for the influenza virus vector COVID-19 vaccine for intranasal spray: A cross-sectional survey in Beijing, China.
Ma Y, Li J, Cao Y, Li W, Shi R, Jia B, Wang H, Yan L, Suo L, Yang W, Wu J, Feng L. Hum Vaccin Immunother. 2023 Aug 1;19(2):2235963. doi: 10.1080/21645515.2023.2235963. PMID: 37450312

Lethality of SARS-CoV-2 infection-a comparative autopsy study focusing on COVID-19 development and virus variants.
Schwab C, Merle U, Schirmacher P, Longerich T. Histopathology. 2023 Aug;83(2):242-251. doi: 10.1111/his.14931. Epub 2023 May 5. PMID: 37145111

Association of herpes zoster with COVID-19 vaccination: A systematic review and meta-analysis.
Chen IL, Chiu HY. J Am Acad Dermatol. 2023 Aug;89(2):370-371. doi: 10.1016/j.jaad.2023.03.031. Epub 2023 Mar 30. PMID: 37001732

Explaining COVID-19 vaccination intention in younger adults using protection motivation theory.
Eberhardt J, Ling J. Health Psychol. 2023 Aug;42(8):577-583. doi: 10.1037/hea0001231. Epub 2022 Aug 18. PMID: 35980723

Possible COVID-19 MRNA Vaccine-Induced Case of Unilateral Central Retinal Vein Occlusion.
Takacs A, Ecsedy M, Nagy ZZ. Ocul Immunol Inflamm. 2023 Aug;31(6):1145-1150. doi: 10.1080/09273948.2022.2094811. Epub 2022 Aug 1. PMID: 35914296

Bilateral Atypical Optic Neuritis following ChAdOx1 nCoV-19 Vaccination: A Putative Plausibility.
Saluja P, Kohli GM, More A, Shetty SB, Sen A. Ocul Immunol Inflamm. 2023 Aug;31(6):1250-1253. doi: 10.1080/09273948.2022.2137044. Epub 2022 Oct 18. PMID: 36256905

Humoral and cellular immunity in three different types of COVID-19 vaccines against SARS-CoV-2 variants in a real-world data analysis.
Song YC, Liu SJ, Lee HJ, Liao HC, Liu CT, Wu MY, Yen HR. J Microbiol Immunol Infect. 2023 Aug;56(4):705-717. doi: 10.1016/j.jmii.2023.03.008. Epub 2023 Mar 31. PMID: 37055256

Prospective cohort of COVID-19 patients requiring hospital admission in Douala, Cameroon.
Tchamgoué S, Ntep Eboko M, Makamté A, Ngagnia A, Talla-Mba F, Nitcheu Wendi O, Kafando E, Tengang B, Sandjon JP, Tattevin P. Infect Dis Now. 2023 Aug;53(5):104713. doi: 10.1016/j.idnow.2023.104713. Epub 2023 Apr 26. PMID: 37116614

Longitudinal analysis of memory Tfh cells and antibody response following CoronaVac vaccination.
Zhou P, Cao C, Ji T, Zheng T, Dai Y, Liu M, Jiang J, Sun D, Bai Z, Lu X, Gong F. JCI Insight. 2023 Aug 8;8(15):e168437. doi: 10.1172/jci.insight.168437. PMID: 37384407

Impact of COVID vaccine and comorbidities in patients receiving casirivimab-imdevimab monoclonal antibody during SARS-CoV-2 B.1.617.2 (Delta) surge: A real-world study.
Agrawal P, Damania D, Cseh A, Grab J, Strom L, Frank B, Patel D, Clyatt G. Vaccine. 2023 Aug 7;41(35):5195-5200. doi: 10.1016/j.vaccine.2023.07.011. Epub 2023 Jul 13. PMID: 37451874

Frontline Worker Safety in the Age of COVID-19: A Global Perspective.
Kavanagh KT, Maiwald M, Pontus C, Cimiotti JP, Palmieri PA, Cormier LE. J Patient Saf. 2023 Aug 1;19(5):293-299. doi: 10.1097/PTS.0000000000001132. Epub 2023 May 10. PMID: 37162150

Impact of prior SARS-COV-2 infection and vaccination on COVID-19 hospital admission and mortality amongst nursing home residents.
España PP, Bilbao-González A, Larrea N, Castillo-Sintes I, García-Gutiérrez S, Portuondo J, Villanueva A, Uranga A, Legarreta MJ, Gascon M, Quintana JM; COVID-Health Basque Country Research Group. Aging Clin Exp Res. 2023 Aug;35(8):1771-1778. doi: 10.1007/s40520-023-02446-3. Epub 2023 May 30. PMID: 37249860

Association between community-level political affiliation and peripartum vaccination.
Post S, Lynch CD, Costantine MM, Fox B, Wu J, Kiefer MK, Rood KM, Landon MB, Grobman WA, Venkatesh KK. Am J Obstet Gynecol MFM. 2023 Aug;5(8):101007. doi: 10.1016/j.ajogmf.2023.101007. Epub 2023 May 6. PMID: 37156464

The effects of COVID-19 infection on the mortality of patients receiving rituximab therapy.
Ekin A, Coskun BN, Dalkilic E, Pehlivan Y. Ir J Med Sci. 2023 Aug;192(4):1959-1973. doi: 10.1007/s11845-022-03193-6. Epub 2022 Oct 19. PMID: 36258064

Sweet syndrome induced by SARS-CoV-2 vaccines: A systematic review of patient-report studies.
Jia Y, Fu B, Dong L, Zhao M. Hum Vaccin Immunother. 2023 Aug 1;19(2):2217076. doi: 10.1080/21645515.2023.2217076. PMID: 37313726

Applying the Hornik & Woolf Approach to Identify Messaging Themes and Improve COVID-19 Vaccine Confidence Among Federally Qualified Health Centers' Workforce in Wisconsin.

Yang S, Shen L, Gregory S, Probst B, Farrar-Edwards D, Passmore SR. J Health Commun. 2023 Aug 3;28(8):507-525. doi: 10.1080/10810730.2023.2230929. Epub 2023 Jul 7. PMID: 37417770

COVID-19 Vaccination Program for Undocumented Migrants: Notes from the Field of a Regional Center of General Medicine and Public Health, Canton of Vaud, Switzerland.
Morisod K, Nikles J, Miauton A, Maussang LB, Vermeulen BP, Bodenmann P. J Immigr Minor Health. 2023 Aug;25(4):953-957. doi: 10.1007/s10903-023-01479-0. Epub 2023 Apr 20. PMID: 37079242

Henoch-Schönlein purpura in a 6-year-old boy after initial COVID-19 vaccination.
de Souza Campos Fernandes RC, Nunes DV, de Almeida NF, da Cruz Assad Monteiro N, Pimenta LAM, Medina-Acosta E. Vaccine X. 2023 Aug;14:100333. doi: 10.1016/j.jvacx.2023.100333. Epub 2023 Jun 20. PMID: 37362023

Immune response after two doses of the BNT162b2 COVID-19 vaccine and risk of SARS-CoV-2 breakthrough infection in Tyrol, Austria: an open-label, observational phase 4 trial.
Seekircher L, Bánki Z, Kimpel J, Rössler A, Schäfer H, Falkensammer B, Bante D, Forer L, Schönherr S; Shieldvacc-2 Study Group; Harthaller T, Sacher M, Ower C, Tschiderer L, Ulmer H, Krammer F, von Laer D, Borena W, Willeit P. Lancet Microbe. 2023 Aug;4(8):e612-e621. doi: 10.1016/S2666-5247(23)00107-6. Epub 2023 Jun 21. PMID: 37354911

COVID-19 Vaccine Hesitancy in Trinidad and Tobago: A Qualitative Study.
Motilal S, Ward D, Mahabir K, Lopez T, Logan R, Maharaj S, Maloney J, Marson M, Marcelle C. Cureus. 2023 Aug 8;15(8):e43171. doi: 10.7759/cureus.43171. eCollection 2023 Aug. PMID: 37560056

Cardiovascular Assessment up to One Year After COVID-19 Vaccine-Associated Myocarditis.
Yu CK, Tsao S, Ng CW, Chua GT, Chan KL, Shi J, Chan YY, Ip P, Kwan MY, Cheung YF. Circulation. 2023 Aug;148(5):436-439. doi: 10.1161/CIRCULATIONAHA.123.064772. Epub 2023 Jul 31. PMID: 37523760

Addressing Racial Capitalism's Impact on Black Essential Workers During the COVID-19 Pandemic: Policy Recommendations.
Brown JL. J Racial Ethn Health Disparities. 2023 Aug;10(4):1597-1604. doi: 10.1007/s40615-022-01346-y. Epub 2022 Jun 10. PMID: 35689156

Frequency of vaccine hesitancy among patients with advanced cancer.
Tang M, Heung Y, Fellman B, Bruera E. Palliat Support Care. 2023 Aug 1:1-7. doi: 10.1017/S147895152300113X. Online ahead of print. PMID: 37525556

Hydroxychloroquine reduces T cells activation recall antigen responses.
Kowatsch MM, Lajoie J, Mwangi L, Omollo K, Oyugi J, Hollett N, Kimani J, Fowke KR. PLoS One. 2023 Aug 2;18(8):e0287738. doi: 10.1371/journal.pone.0287738. eCollection 2023. PMID: 37531383

Predictors of COVID-19 vaccine uptake among adults in South Africa: multimethod evidence from a population-based longitudinal study.
Maughan-Brown B, Eyal KC, Njozela L, Buttenheim AM. BMJ Glob Health. 2023 Aug;8(8):e012433. doi: 10.1136/bmjgh-2023-012433. PMID: 37541692

A lack of an association between COVID-19 vaccination and corneal graft rejection: results of a large multi-country population based study.
Roberts HW, Wilkins MR, Malik M, Talachi-Langroudi M, Myerscough J, Pellegrini M, Yu AC, Busin M. Eye (Lond). 2023 Aug;37(11):2316-2319. doi: 10.1038/s41433-022-02341-7. Epub 2022 Dec 8. PMID: 36481958

Clinical features, management and outcomes of peritoneal dialysis patients during Delta and Omicron waves of COVID-19 infections.
Htay H, Foo MWY, Jayaballa M, Johnson DW, Oei EL, Tan BH, Wang W, Wu SY, Tan CS. Int Urol Nephrol. 2023 Aug;55(8):2075-2081. doi: 10.1007/s11255-023-03496-2. Epub 2023 Feb 23. PMID: 36820945

Frequency of vaccine hesitancy among patients with advanced cancer.
Tang M, Heung Y, Fellman B, Bruera E. Palliat Support Care. 2023 Aug 1:1-7. doi: 10.1017/S147895152300113X. Online ahead of print. PMID: 37525556

Hydroxychloroquine reduces T cells activation recall antigen responses.
Kowatsch MM, Lajoie J, Mwangi L, Omollo K, Oyugi J, Hollett N, Kimani J, Fowke KR. PLoS One. 2023 Aug 2;18(8):e0287738. doi: 10.1371/journal.pone.0287738. eCollection 2023. PMID: 37531383

Predictors of COVID-19 vaccine uptake among adults in South Africa: multimethod evidence from a population-based longitudinal study.
Maughan-Brown B, Eyal KC, Njozela L, Buttenheim AM. BMJ Glob Health. 2023 Aug;8(8):e012433. doi: 10.1136/bmjgh-2023-012433. PMID: 37541692

A lack of an association between COVID-19 vaccination and corneal graft rejection: results of a large multi-country population based study.
Roberts HW, Wilkins MR, Malik M, Talachi-Langroudi M, Myerscough J, Pellegrini M, Yu AC, Busin M. Eye (Lond). 2023 Aug;37(11):2316-2319. doi: 10.1038/s41433-022-02341-7. Epub 2022 Dec 8. PMID: 36481958

Clinical features, management and outcomes of peritoneal dialysis patients during Delta and Omicron waves of COVID-19 infections.
Htay H, Foo MWY, Jayaballa M, Johnson DW, Oei EL, Tan BH, Wang W, Wu SY, Tan CS. Int Urol Nephrol. 2023 Aug;55(8):2075-2081. doi: 10.1007/s11255-023-03496-2. Epub 2023 Feb 23. PMID: 36820945

Topics in Antivax and Provax Discourse: Yearlong Synoptic Study of COVID-19 Vaccine Tweets.
Zaidi Z, Ye M, Samon F, Jama A, Gopalakrishnan B, Gu C, Karunasekera S, Evans J, Kashima Y. J Med Internet Res. 2023 Aug 8;25:e45069. doi: 10.2196/45069. PMID: 37552535

Optic Neuritis Following the BNT162b2 mRNA COVID-19 Vaccine in a Patient with Systemic Lupus Erythematosus Uncovering the Diagnosis of Neuromyelitis Optica Spectrum Disorders.
Shirah B, Mulla I, Aladdin Y. Ocul Immunol Inflamm. 2023 Aug;31(6):1213-1215. doi: 10.1080/09273948.2022.2089901. Epub 2022 Jul 18. PMID: 35849732

[COVID-19 vaccination status, sources of used information and socio-demographic characteristics-results of the CoSiD study].
Haß W, Orth B, von Rüden U. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2023 Aug;66(8):846-856. doi: 10.1007/s00103-023-03736-x. Epub 2023 Jul 12. PMID: 37438645

Management of cardiovascular symptoms after Pfizer-BioNTech COVID-19 vaccine in teenagers in the emergency department.
Liao YF, Tseng WC, Wang JK, Chen YS, Chen CA, Lin MT, Lu CW, Wu MH, Chiu SN. J Formos Med Assoc. 2023 Aug;122(8):699-706. doi: 10.1016/j.jfma.2022.12.004. Epub 2022 Dec 13. PMID: 36564302

How can COVID-19 vaccines benefit people? A study based on the theory of the commons.
Su Y, Li Y, Zhang S, Chen X. Hum Vaccin Immunother. 2023 Aug 1;19(2):2225991. doi: 10.1080/21645515.2023.2225991. Epub 2023 Jun 20. PMID: 37340788

Current health care experiences, medical trust, and COVID-19 vaccination intention and uptake in Black and White Americans.
Martin KJ, Stanton AL, Johnson KL. Health Psychol. 2023 Aug;42(8):541-550. doi: 10.1037/hea0001240. Epub 2022 Oct 13. PMID: 36227310

Evaluation of non-clinical toxicity studies of COVID-19 vaccines.
Schilder NKM, Tiesjema B, Theunissen PT, Rengerink KO, van der Laan JW. Regul Toxicol Pharmacol. 2023 Aug;142:105438. doi: 10.1016/j.yrtph.2023.105438. Epub 2023 Jun 23. PMID: 37356612

Phase 4 clinical trials in the era of the Coronavirus Disease (COVID-19) pandemic and their importance to optimize the COVID-19 vaccination.
Ralise AEG, Camargo TM, Marson FAL. Hum Vaccin Immunother. 2023 Aug 1;19(2):2234784. doi: 10.1080/21645515.2023.2234784. PMID: 37449956

Corneal Allograft Endothelial Rejection after Sinopharm COVID-19 Vaccination; Report of Six Cases.
Ghiasian L, Pourmousa Z, Hadi Y, Abdolalizadeh P. Semin Ophthalmol. 2023 Aug;38(6):565-571. doi: 10.1080/08820538.2023.2169579. Epub 2023 Jan 23. PMID: 36688666

The Recent Outbreak of COVID-19 in China During the Omicron Variant Predominance: Clinical Features and Outcomes in Patients with Autoimmune Inflammatory Rheumatic Diseases.
Geng Y, Fan Y, Deng X, Wang Y, Zhao J, Ji L, Song Z, Li G, Zhang X, Sun X, Huang H, Xie W, Zhang Z. Rheumatol Ther. 2023 Aug;10(4):1039-1053. doi: 10.1007/s40744-023-00569-7. Epub 2023 Jun 19. PMID: 37335431

Acute Idiopathic Maculopathy Following SARS-CoV-2 Vaccination.
Bleicher ID, Brill D, Wu F, Sobrin L, Patel N. Ocul Immunol Inflamm. 2023 Aug;31(6):1232-1235. doi: 10.1080/09273948.2022.2114915. Epub 2022 Sep 2. PMID: 36053888

Vaccination Beliefs and Attitudes of Lactating People During the SARS-CoV-2 Pandemic.
Mark EG, Demirci JR, Megli C, Martin JM, Rick AM. J Hum Lact. 2023 Aug;39(3):415-425. doi: 10.1177/08903344231159640. Epub 2023 Apr 3. PMID: 37009722

Racial/Ethnic Inequity in Transit-Based Spatial Accessibility to COVID-19 Vaccination Sites.
Liu D, Kwan MP, Kan Z, Song Y, Li X. J Racial Ethn Health Disparities. 2023 Aug;10(4):1533-1541. doi: 10.1007/s40615-022-01339-x. Epub 2022 Jun 9. PMID: 35679013

Factors influencing Australian nursing and midwifery students COVID-19 vaccination intentions.
Ford A, Heidke P, Kurup C, Wirihana L, Kroll J, Calleja P. Vaccine X. 2023 Jul 8;14:100352. doi: 10.1016/j.jvacx.2023.100352. eCollection 2023 Aug. PMID: 37519775

Why is it necessary to improve COVID-19 vaccination coverage in older people? How to improve the vaccination coverage?
Zhu KW. Hum Vaccin Immunother. 2023 Aug 1;19(2):2229704. doi: 10.1080/21645515.2023.2229704. PMID: 37433429

Vulval Aphthous Ulcers in Adolescents Following COVID-19 Vaccination-Analysis of an International Case Series.
Rudolph A, Savage DR. J Pediatr Adolesc Gynecol. 2023 Aug;36(4):383-392. doi: 10.1016/j.jpag.2023.03.006. Epub 2023 Mar 17. PMID: 36934803

Incidence and clinical characteristics of adverse neurological events and stroke-like syndrome associated with immune stress-related response after COVID-19 vaccination in 2021 from Thailand.
Sirisuk W, Limvorapitak W, Lolekha P, Methaset K, Kulkantrakorn K. Clin Neurol Neurosurg. 2023 Aug;231:107804. doi: 10.1016/j.clineuro.2023.107804. Epub 2023 May 29. PMID: 37295197

Editorial Comment: Duration of Axillary Lymphadenopathy After COVID-19 Vaccine Booster Administration.
Mullen LA. AJR Am J Roentgenol. 2023 Aug;221(2):183. doi: 10.2214/AJR.23.29309. Epub 2023 Mar 22. PMID: 36946901

Concerns related to the interactions between COVID-19 vaccination and cancer/cancer treatment were barriers to complete primary vaccination series among Chinese cancer patients: A multicentre cross-sectional survey.
Zhang L, Yang J, Su R, Du X, Wang Y, Chen S, Chan PS, Wang Z, Xu J. Hum Vaccin Immunother. 2023 Aug 1;19(2):2222648. doi: 10.1080/21645515.2023.2222648. Epub 2023 Jun 14. PMID: 37314490

The effects of methotrexate on the immune responses to the COVID-19 vaccines in the patients with immune-mediated inflammatory disease: A systematic review of clinical evidence.
Al-Haideri MT, Mannani R, Kaboli R, Gharebakhshi F, Darvishzadehdeldari S, Tahmasebi S, Faramarzi F, Cotrina-Aliaga JC, Khorasani S, Alimohammadi M, Darvishi M, Akhavan-Sigari R. Transpl Immunol. 2023 Aug;79:101858. doi: 10.1016/j.trim.2023.101858. Epub 2023 May 24. PMID: 37236514

Fear, Anxiety, and Coping Self-efficacy of Individuals With Cancer During COVID-19 and Predictive Risk Factors: A Descriptive and Correlational Study.
Karataş T, Ayaz-Alkaya S, Özdemir N. Semin Oncol Nurs. 2023 Aug;39(4):151420. doi: 10.1016/j.soncn.2023.151420. Epub 2023 Mar 14. PMID: 37037701

[Recurrent livedo-like skin lesions following a vector-based COVID-19 vaccine].

Kränke T, Cerpes U, Legat F, Arbab E, Kränke B. Dermatologie (Heidelb). 2023 Aug;74(8):614-617. doi: 10.1007/s00105-023-05160-3. Epub 2023 May 26. PMID: 37237145

Combining aggregate and individual-level data to estimate individual-level associations between air pollution and COVID-19 mortality in the United States.
Woodward SM, Mork D, Wu X, Hou Z, Braun D, Dominici F. PLOS Glob Public Health. 2023 Aug 2;3(8):e0002178. doi: 10.1371/journal.pgph.0002178. eCollection 2023. PMID: 37531330

Promising Practices Observed in High-Throughput COVID-19 Vaccination Sites in the United States, February-May 2021.
McColloch CE, Samson ME, Parris K, Stewart A, Robinson JA, Cooper B, Galloway E, Garcia R, Gilani Z, Jayapaul-Philip B, Lucas P, Nguyen KH, Noe RS, Trudeau AT, Kennedy ED. Am J Public Health. 2023 Aug;113(8):909-918. doi: 10.2105/AJPH.2023.307331. PMID: 37406267

Evaluation of an Audio-Visual Novela to Improve COVID-19 Knowledge and Safe Practices Among Spanish-Speaking Individuals with Schizophrenia.
Kopelowicz A, Lopez SR, Molina GB, Baron M, Franco R, Mayer D. J Immigr Minor Health. 2023 Aug;25(4):889-898. doi: 10.1007/s10903-023-01456-7. Epub 2023 Feb 4. PMID: 36738379

Serologic response to COVID-19 vaccines in patients with inflammatory bowel disease: a prospective study.
Martín Arranz MD, García-Ramírez L, Martín Arranz E, Montero Vega D, Rueda García JL, Sánchez-Azofra M, Poza Cordón J, Noci Belda J, Verges Martínez-Meco T, Blanco San Miguel P, Suárez-Ferrer C. Rev Esp Enferm Dig. 2023 Aug;115(8):444-449. doi: 10.17235/reed.2022.9101/2022. PMID: 36645081

Immune Responses 6 Months After mRNA-1273 COVID-19 Vaccination and the Effect of a Third Vaccination in Patients with Inborn Errors of Immunity.
van Leeuwen LPM, Grobben M, GeurtsvanKessel CH, Ellerbroek PM, de Bree GJ, Potjewijd J, Rutgers A, Jolink H, van de Veerdonk FL, van Gils MJ, de Vries RD, Dalm VASH; VACOPID Research Group. J Clin Immunol. 2023 Aug;43(6):1104-1117. doi: 10.1007/s10875-023-01514-7. Epub 2023 May 26. PMID: 37231290

Changes in haemostasis and inflammatory markers after mRNA BNT162b2 and vector Ad26.CoV2.S SARS-CoV-2 vaccination.
Ivanko I, Ćelap I, Margetić S, Marijančević D, Josipović J, Gaćina P. Thromb Res. 2023 Aug;228:137-144. doi: 10.1016/j.thromres.2023.06.008. Epub 2023 Jun 14. PMID: 37329722

Wells' Syndrome associated with COVID-19 vaccination.
Bocchi C, Marzola E, Pedriali M, Borghi A, Corazza M. Ital J Dermatol Venerol. 2023 Aug;158(4):374-375. doi: 10.23736/S2784-8671.23.07591-6. PMID: 37539510

Pseudomonas aeruginosa infection following COVID-19 vaccination.
Martora F, Fabbrocini G, Villani A, Martora L, Battista T. Ital J Dermatol Venerol. 2023 Aug;158(4):371-372. doi: 10.23736/S2784-8671.23.07558-8. PMID: 37539508

Early impact of COVID-19 vaccination on older populations in four countries of the Americas, 2021.

Jarquin C, Quezada LF, Gobern L, Balsells E, Rondy M. Rev Panam Salud Publica. 2023 Aug 10;47:e122. doi: 10.26633/RPSP.2023.122. eCollection 2023. PMID: 37564919

A systematic review of nudges on hand hygiene against the spread of COVID-19.
Tzikas A, Koulierakis G. J Behav Exp Econ. 2023 Aug;105:102046. doi: 10.1016/j.socec.2023.102046. Epub 2023 May 30. PMID: 37274754

Risk stratification through extensive allergy work-up in COVID-19-mRNA vaccine allergic reactions.
Soria A, Labella M, Doña I, Nicaise-Roland P, Chollet-Martin S, Autegarden JE, Castagna J, Le Thai C, de Chaisemartin L, Torres MJ, Barbaud A. Allergy. 2023 Aug;78(8):2320-2323. doi: 10.1111/all.15715. Epub 2023 Mar 27. PMID: 36971457

The role of zinc sulfate in enhancing cellular and humoral immune responses to foot-and-mouth disease vaccine.
Ko MK, Kim HW, Park SH, Park JH, Kim SM, Lee MJ. Virus Res. 2023 Aug 8;335:199189. doi: 10.1016/j.virusres.2023.199189. Online ahead of print. PMID: 37536380

Individual and structural determinants of COVID-19 vaccine uptake in a marginalized community in the United States.
Campbell J, Kaur A, Gamino D, Benoit E, Amos B, Windsor L. Vaccine. 2023 Aug 5:S0264-410X(23)00923-4. doi: 10.1016/j.vaccine.2023.07.077. Online ahead of print. PMID: 37550145

Sociodemographic and psychosocial factors associated with vaccine hesitancy - results from a longitudinal study in Singapore.
Subramaniam M, Abdin E, Shafie S, Shahwan S, Zhang Y, Satghare P, Devi F, Lun P, Yuxuan Ni M, Chong SA. Hum Vaccin Immunother. 2023 Aug 1;19(2):2235964. doi: 10.1080/21645515.2023.2235964. Epub 2023 Jul 25. PMID: 37489273

Application of Protection Motivation Theory to COVID-19 vaccination among a predominantly Hispanic sample of adolescents.
Unger JB, Herzig E, Rodriguez V, Soto D, Lee R, Sood N. Prev Med Rep. 2023 Aug;34:102245. doi: 10.1016/j.pmedr.2023.102245. Epub 2023 May 19. PMID: 37252067

COVID-19 pandemic stress and cancer symptom burden.
Ballesteros O, Mark S, Block A, Mackin L, Paul S, Cooper B, Abbott M, Chang S, Hammer MJ, Levine J, Pozzar R, Snowberg K, Tsai K, Van Blarigan E, Van Loon K, Miaskowski CA. BMJ Support Palliat Care. 2023 Aug 4:spcare-2023-004319. doi: 10.1136/spcare-2023-004319. Online ahead of print. PMID: 37541779

The use of Health Belief Model (HBM) to explain factors underlying people to take the COVID-19 vaccine in Indonesia.
Adiyoso W, Wilopo W, Mondry, Nurbaiti B, Suprapto FA. Vaccine X. 2023 Aug;14:100297. doi: 10.1016/j.jvacx.2023.100297. Epub 2023 Apr 8. PMID: 37063303

Platform adaptive trial of novel antivirals for early treatment of COVID-19 In the community (PANORAMIC): protocol for a randomised, controlled, open-label, adaptive platform trial of community novel antiviral treatment of COVID-19 in people at increased risk of more severe disease.
Gbinigie O, Ogburn E, Allen J, Dorward J, Dobson M, Madden TA, Yu LM, Lowe DM, Rahman N, Petrou S, Richards D, Hood K, Patel M, Saville BR, Marion J, Holmes J, Png ME, Hayward G, Lown M, Harris V, Jani B, Hart N, Khoo S, Rutter H, Chalk J, Standing JF, Breuer J, Lavallee L, Hadley E, Cureton L, Benysek M, Andersson MI, Francis N, Thomas NPB, Evans P, van Hecke O, Koshkouei M, Coates M, Barrett S, Bateman C, Davies J, Raymundo-Wood I, Ustianowski A, Nguyen-Van-Tam J, Carson-Stevens A, Hobbs R, Little P, Butler CC. BMJ Open. 2023 Aug 7;13(8):e069176. doi: 10.1136/bmjopen-2022-069176. PMID: 37550022

COVID-19 vaccination experience in patients with rheumatoid arthritis treated at a single VA medical center.
Abi Doumeth S, Gong J, Silversteyn L, O'Mara M, Singh S, Anthony DD, Mattar M. Vaccine X. 2023 Aug;14:100295. doi: 10.1016/j.jvacx.2023.100295. Epub 2023 Apr 4. PMID: 37051228

Effectiveness of a bivalent mRNA vaccine booster dose to prevent severe COVID-19 outcomes: a retrospective cohort study.
Arbel R, Peretz A, Sergienko R, Friger M, Beckenstein T, Duskin-Bitan H, Yaron S, Hammerman A, Bilenko N, Netzer D. Lancet Infect Dis. 2023 Aug;23(8):914-921. doi: 10.1016/S1473-3099(23)00122-6. Epub 2023 Apr 14. PMID: 37062302

Restoring Trust: The Need for Precision Medicine in Infectious Diseases, Public Health and Vaccines.
Equils O, Bakaj A, Wilson-Mifsud B, Chatterjee A. Hum Vaccin Immunother. 2023 Aug 1;19(2):2234787. doi: 10.1080/21645515.2023.2234787. Epub 2023 Jul 19. PMID: 37465958

Observational Study of Patients Hospitalized With Neurologic Events After SARS-CoV-2 Vaccination, December 2020-June 2021.
Kim CY, McNeill EN, Young C, King F, Clague M, Caldwell M, Boruah A, Zucker J, Thakur KT. Neurol Clin Pract. 2023 Aug;13(4):e200166. doi: 10.1212/CPJ.0000000000200166. Epub 2023 May 25. PMID: 37251368

Effectiveness of bivalent mRNA booster vaccines against COVID-19: methodological and public health considerations.
Stoliaroff-Pepin A, Harder T. Lancet Infect Dis. 2023 Aug;23(8):881-882. doi: 10.1016/S1473-3099(23)00187-1. Epub 2023 Apr 14. PMID: 37062303

Safety and adverse effects of the coronavirus disease 2019 vaccine among the general Japanese adult population.
Lu X, Masuda S, Horlad H, Katoh T. Vaccine. 2023 Aug 7;41(35):5090-5096. doi: 10.1016/j.vaccine.2023.04.053. Epub 2023 Apr 26. PMID: 37455163

Prospective interpretation of Covid vaccines. A cross sectional study, Ordu province experience.
Çoruh Akyol B, Turgut B, İşcanlı MD, Kaya M, Çankaya S, Enginyurt Ö. Hum Vaccin Immunother. 2023 Aug 1;19(2):2222649. doi: 10.1080/21645515.2023.2222649. Epub 2023 Jun 29. PMID: 37381762

'Getting the vaccine makes me a champion of it': Exploring perceptions towards peer-to-peer communication about the COVID-19 vaccines amongst Australian adults.
Karras J, Harrison M, Seale H. Health Expect. 2023 Aug;26(4):1505-1513. doi: 10.1111/hex.13751. Epub 2023 May 3. PMID: 37132297

Preparing the Allergist/Immunologist for the Next Pandemic.
Williams PV, Fasano MB, Fleisher T. J Allergy Clin Immunol Pract. 2023 Aug 2:S2213-2198(23)00811-5. doi: 10.1016/j.jaip.2023.07.037. Online ahead of print. PMID: 37541618

Unilateral Acute Idiopathic Blind Spot Enlargement following Second Dose of Covid-19 mRNA Vaccine.
Shen C, Tennant M. Ocul Immunol Inflamm. 2023 Aug;31(6):1219-1221. doi: 10.1080/09273948.2022.2090964. Epub 2022 Jul 8. PMID: 35801911

Bivalent mRNA COVID-19 Vaccine-Related Pericarditis on 18 F-FDG PET/CT.
Wu YC, Kao CH, Liao CW, Sun SS, Hsieh TC. Clin Nucl Med. 2023 Aug 1;48(8):e396-e397. doi: 10.1097/RLU.0000000000004711. Epub 2023 May 26. PMID: 37256729

Antibody neutralization capacity after COVID-19 vaccination in people with HIV (CIHR Canadian HIV trials network 328).
Costiniuk CT, Singer J, Lee T, Galipeau Y, McCluskie PS, Arnold C, Langlois MA, Needham J, Jenabian MA, Burchell AN, Samji H, Chambers C, Walmsley S, Ostrowski M, Kovacs C, Tan DHS, Harris M, Hull M, Brumme ZL, Lapointe HR, Brockman MA, Margolese S, Mandarino E, Samarani S, Vulesevic B, Lebouche B, Angel JB, Routy JP, Cooper CL, Anis AH; COVAXHIV Study Group. AIDS. 2023 Aug 3. doi: 10.1097/QAD.0000000000003680. Online ahead of print. PMID: 37534695

COVID-19 omicron variant outbreak in a hematopoietic stem cell transplant unit.
Gilioli A, Bresciani P, Franceschini E, Messerotti A, Pioli V, Colasante C, Bettelli F, Giusti D, Forghieri F, Morselli M, Colaci E, Potenza L, Gennari W, Pecorari M, Marasca R, Candoni A, Mussini C, Trenti T, Comoli P, Luppi M, Cuoghi A. Int J Hematol. 2023 Aug 2. doi: 10.1007/s12185-023-03638-3. Online ahead of print. PMID: 37532827

Phytochemical drug discovery for COVID-19 using high-resolution computational docking and machine learning assisted binder prediction.
Wang Z, Belecciu T, Eaves J, Reimers M, Bachmann MH, Woldring D. J Biomol Struct Dyn. 2023 Aug-Sep;41(14):6643-6663. doi: 10.1080/07391102.2022.2112976. Epub 2022 Aug 22. PMID: 35993534

An update on studies characterizing adaptive immune responses in SARS-CoV-2 infection and COVID-19 vaccination.
da Silva Antunes R, Grifoni A, Frazier A, Weiskopf D, Sette A. Int Immunol. 2023 Aug 7;35(8):353-359. doi: 10.1093/intimm/dxad014. PMID: 37148294

Autoantibodies Neutralizing Type I IFNs in the Bronchoalveolar Lavage of at Least 10% of Patients During Life-Threatening COVID-19 Pneumonia.
Philippot Q, Fekkar A, Gervais A, Le Voyer T, Boers LS, Conil C, Bizien L, de Brabander J, Duitman JW, Romano A, Rosain J, Blaize M, Migaud M, Jeljeli M, Hammadi B, Desmons A, Marchal A; ArtDECO consortium; COVID HGE consortium; Mayaux J, Zhang Q, Jouanguy E, Borie R, Crestani B, Luyt CE,

Adle-Biassette H, Sene D, Megarbane B, Cobat A, Bastard P, Bos LDJ, Casanova JL, Puel A. J Clin Immunol. 2023 Aug;43(6):1093-1103. doi: 10.1007/s10875-023-01512-9. Epub 2023 May 20. PMID: 37209324

Safety and immunogenicity of heterologous boosting with orally aerosolised or intramuscular Ad5-nCoV vaccine and homologous boosting with inactivated vaccines (BBIBP-CorV or CoronaVac) in children and adolescents: a randomised, open-label, parallel-controlled, non-inferiority, single-centre study.
Huang T, Zhang S, Dai DF, Wang BS, Zhuang L, Huang HT, Wang ZF, Zhao JS, Li QP, Wu SP, Wang X, Zhang WD, Zhao ZH, Li H, Zhang YP, Yang XL, Jiang XY, Gou JB, Hou LH, Gao LD, Feng ZC. Lancet Respir Med. 2023 Aug;11(8):698-708. doi: 10.1016/S2213-2600(23)00129-7. Epub 2023 May 17. PMID: 37209700

Intraocular inflammation following COVID-19 vaccination: the clinical presentations.
Li S, Ho M, Mak A, Lai F, Brelen M, Chong K, Young A. Int Ophthalmol. 2023 Aug;43(8):2971-2981. doi: 10.1007/s10792-023-02684-4. Epub 2023 Mar 31. PMID: 37000311

Barriers to COVID-19 vaccination of migrant populations: A qualitative interview study of immunisation providers in Victoria, Australia.
Tuckerman J, Kaufman J, Overmars I, Holland P, Danchin M. Vaccine. 2023 Aug 7;41(35):5085-5089. doi: 10.1016/j.vaccine.2023.07.001. Epub 2023 Jul 3. PMID: 37460355

Skin reaction following SARS-CoV-2 vaccine BNT162b2.
Russo F, Santi F, Sirchio A, Lazzeri L, DE Piano E, Taddeucci P, Rubegni P. Ital J Dermatol Venerol. 2023 Aug;158(4):360-361. doi: 10.23736/S2784-8671.23.07429-7. Epub 2023 Jun 30. PMID: 37387638

Robots in travel clinics: building on tourism's use of technology and robots for infection control during a pandemic.
Bauer IL. Trop Dis Travel Med Vaccines. 2023 Aug 1;9(1):10. doi: 10.1186/s40794-023-00197-7. PMID: 37525269

Comparative Risks of Potential Adverse Events Following COVID-19 mRNA Vaccination Among Older US Adults.
Harris DA, Hayes KN, Zullo AR, Mor V, Chachlani P, Deng Y, McCarthy EP, Djibo DA, McMahill-Walraven CN, Gravenstein S. JAMA Netw Open. 2023 Aug 1;6(8):e2326852. doi: 10.1001/jamanetworkopen.2023.26852. PMID: 37531110

Induction of neutralizing antibodies in CLL patients after SARS-CoV-2 mRNA vaccination: a monocentric experience.
Baratè C, Caruso T, Mavilia F, Sammuri P, Pratesi F, Motta G, Guerri V, Galimberti S, Migliorini P. Clin Exp Med. 2023 Aug;23(4):1197-1203. doi: 10.1007/s10238-022-00877-2. Epub 2022 Sep 8. PMID: 36074205

What matters to us: Bridging research and accurate information through dialogue (BRAID) to build community trust and cultivate vaccine confidence.
Stephenson-Hunter C, Yusuf Y, Larson R, Campanella J, Gutnick DN. Prev Med Rep. 2023 Aug;34:102253. doi: 10.1016/j.pmedr.2023.102253. Epub 2023 May 20. PMID: 37252070

Anti-SARS-CoV-2 IgG antibody titer after BNT162b2 mRNA COVID-19 vaccination in Japanese patients who underwent renal replacement therapy, hemodialysis, peritoneal dialysis, and kidney transplantation.
Iwabuchi R, Harada M, Yamada A, Aomura D, Yamada Y, Sonoda K, Nakazawa H, Sakai K, Mizukami E, Hashimoto K, Kamijo Y. Clin Exp Nephrol. 2023 Aug;27(8):660-671. doi: 10.1007/s10157-023-02348-8. Epub 2023 Apr 24. PMID: 37095343

Association of vaccination, international travel, public health and social measures with lineage dynamics of SARS-CoV-2.
Yang L, Wang Z, Wang L, Vrancken B, Wang R, Wei Y, Rader B, Wu CH, Chen Y, Wu P, Li B, Lin Q, Dong L, Cui Y, Shi M, Brownstein JS, Stenseth NC, Yang R, Tian H. Proc Natl Acad Sci U S A. 2023 Aug 15;120(33):e2305403120. doi: 10.1073/pnas.2305403120. Epub 2023 Aug 7. PMID: 37549270

Virus-induced breath biomarkers: A new perspective to study the metabolic responses of COVID-19 vaccinees.
Cen Z, Lu B, Ji Y, Chen J, Liu Y, Jiang J, Li X, Li X. Talanta. 2023 Aug 1;260:124577. doi: 10.1016/j.talanta.2023.124577. Epub 2023 Apr 22. PMID: 37116359

Third and Fourth Vaccine Doses Broaden and Prolong Immunity to SARS-CoV-2 in Adult Patients with Immune-Mediated Inflammatory Diseases.
Cheung MW, Dayam RM, Shapiro JR, Law JC, Chao GYC, Pereira D, Goetgebuer RL, Croitoru D, Stempak JM, Acheampong L, Rizwan S, Lee JD, Jacob L, Ganatra D, Law R, Rodriguez-Castellanos VE, Kern-Smith M, Delgado-Brand M, Mailhot G, Haroon N, Inman RD, Piguet V, Chandran V, Silverberg MS, Watts TH, Gingras AC. J Immunol. 2023 Aug 1;211(3):351-364. doi: 10.4049/jimmunol.2300190. PMID: 37326480

The contribution of rural primary health care to the coronavirus (COVID-19) vaccination program.
McIntosh K, Hyett N. Aust Health Rev. 2023 Aug;47(4):502-508. doi: 10.1071/AH23044. PMID: 37429818

Hilar lymphadenopathy, development of tubulointerstitial nephritis, and dense deposit disease following Pfizer-BioNTech COVID-19 vaccination.
Nakamura H, Ueda M, Anayama M, Makino M, Makino Y. CEN Case Rep. 2023 Aug;12(3):287-291. doi: 10.1007/s13730-022-00762-7. Epub 2022 Dec 13. PMID: 36513952

Translatability scoring in prospective and retrospective COVID drug development cases.
Wendler A, Wehling M. Eur J Clin Pharmacol. 2023 Aug;79(8):1051-1071. doi: 10.1007/s00228-023-03517-0. Epub 2023 Jun 6. PMID: 37278822

Impact of COVID-19 vaccination or infection on disease activity in a radiologically isolated syndrome cohort: The VaxiRIS study.
Cohen M, Thomel-Rocchi O, Siva A, Okuda DT, Karabudak R, Efendi H, Terzi M, Carra-Dalliere C, Durand-Dubief F, Thouvenot E, Ciron J, Zephir H, Bourre B, Casez O, De Seze J, Moreau T, Neau JP, Pelletier D, Kantarci O, Tutuncu M, Derache N, Bensa C, Louapre C, Benoit J, Landes-Chateau C, Lebrun-Frenay C. Mult Scler. 2023 Aug;29(9):1099-1106. doi: 10.1177/13524585231179669. Epub 2023 Jun 15. PMID: 37322880

Comparison of antibody persistency through one year between one-dose and two-dose regimens of Ad5-nCoV vaccine for COVID-19.
Feng JL, Wang WJ, Jin PF, Zheng H, Jin LR, Xia X, Zhang XY, Li ZP, Li JX, Zhu FC. Hum Vaccin Immunother. 2023 Aug 1;19(2):2230760. doi: 10.1080/21645515.2023.2230760. PMID: 37428653

Acute Rejection Following COVID-19 Vaccination in Penetrating Keratoplasty in a Young Male - A Case Report and Review of Literature.
Marziali E, Pasqualetti R, Bacci G, de Libero C, Caputo R. Ocul Immunol Inflamm. 2023 Aug;31(6):1226-1229. doi: 10.1080/09273948.2022.2106248. Epub 2022 Aug 1. PMID: 35914312

Impact of the COVID-19 pandemic on antimicrobial stewardship support for general practices in England: a qualitative interview study.
Campbell A, Borek AJ, McLeod M, Tonkin-Crine S, Pouwels KB, Roope LS, Hayhoe BW, Majeed A, Walker AS, Holmes A; STEP-UP team. BJGP Open. 2023 Aug 8:BJGPO.2022.0193. doi: 10.3399/BJGPO.2022.0193. Online ahead of print. PMID: 37290780

Corrigendum to "Safety and immunogenicity of mRNA-LNP COVID-19 vaccine CVnCoV in Latin American adults: A phase 2 randomized study" [Vaccine: X 11 (2022) 100189].
Sáez-Llorens X, Lanata C, Aranguren E, Celis CR, Cornejo R, DeAntonio R, Ecker L, Garrido D, Gil AI, Gonzales M, Hess-Holtz M, Leroux-Roels G, Junker H, Kays SK, Koch SD, Lazzaro S, Mann P, Quintini G, Srivastava B, Vahrenhorst D, von Eisenhart-Rothe P, Wolz OO, Oostvogels L. Vaccine X. 2023 Aug;14:100307. doi: 10.1016/j.jvacx.2023.100307. Epub 2023 Apr 28. PMID: 37131960

Is Vaccination Against COVID-19 Associated With Inflammatory Bowel Disease Flare? Self-Controlled Case Series Analysis Using the UK CPRD.
Card TR, Nakafero G, Grainge MJ, Mallen CD, Van-Tam JSN, Williams HC, Abhishek A. Am J Gastroenterol. 2023 Aug 1;118(8):1388-1394. doi: 10.14309/ajg.0000000000002205. Epub 2023 Jan 30. PMID: 36826512

Cryo-EM and cryo-ET of the spike, virion, and antibody neutralization of SARS-CoV-2 and VOCs.
Xu C, Han W, Cong Y. Curr Opin Struct Biol. 2023 Aug 4;82:102664. doi: 10.1016/j.sbi.2023.102664. Online ahead of print. PMID: 37544111

Myocarditis/pericarditis following vaccination with BNT162b2, CoronaVac, and ChAdOx1 among adolescent and adult in Malaysia.
Ab Rahman N, Lim MT, Lee FY, Anak Jam EB, Pearlasamy KM, Sivasampu S; SAFECOVAC study group. Vaccine X. 2023 Aug;14:100303. doi: 10.1016/j.jvacx.2023.100303. Epub 2023 Apr 15. PMID: 37091730

Humoral response after a BNT162b2 heterologous third dose of COVID-19 vaccine following two doses of BBIBP-CorV among healthcare personnel in Peru.
Montero S, Urrunaga-Pastor D, Soto-Becerra P, Cvetkovic-Vega A, Guillermo-Roman M, Figueroa-Montes L, Sagástegui AA, Alvizuri-Pastor S, Contreras-Macazana RM, Apolaya-Segura M, Díaz-Vélez C, Maguiña JL. Vaccine X. 2023 Aug;14:100311. doi: 10.1016/j.jvacx.2023.100311. Epub 2023 May 5. PMID: 37207103

Bilateral Persistent Placoid Maculopathy Following COVID-19 Vaccines: Real or Coincidence?
Chean CS, Ali E, Kulkarni P, Kapoor B, Kumar P. Ocul Immunol Inflamm. 2023 Aug;31(6):1273-1278. doi: 10.1080/09273948.2023.2170889. Epub 2023 Feb 3. PMID: 36737061

Sociocultural and moral narratives influencing the decision to vaccinate among rheumatic disease patients: a qualitative study.
Manrique de Lara A, Colmenares-Roa T, Pascual-Ramos V, Moctezuma-Rios JF, Contreras-Yañez I, Guaracha-Basañez GA, Álvarez-Hernández E, Meza-López Y Olguín G, Peláez-Ballestas I. Clin Rheumatol. 2023 Aug;42(8):2199-2207. doi: 10.1007/s10067-023-06609-5. Epub 2023 May 2. PMID: 37129776

Temporal, age, and geographical variation in vaccine efficacy against infection by the Delta and Omicron variants in the community in France, December 2021 to March 2022.
Blanquart F, Abad C, Ambroise J, Bernard M, Débarre F, Giannoli JM, Rey T, Vieillefond V. Int J Infect Dis. 2023 Aug;133:89-96. doi: 10.1016/j.ijid.2023.04.410. Epub 2023 May 12. PMID: 37182550

Understanding the factors that influence communication about COVID-19 vaccines with patients: Perspectives of Australian immunisation providers.
Abdi I, Bolsewicz K, Bullivant B, Marques MD, Steffens MS. Vaccine X. 2023 Aug;14:100304. doi: 10.1016/j.jvacx.2023.100304. Epub 2023 Apr 17. PMID: 37091729

A questionnaire survey on the prevention of HPV infection among females and males who came of age in Japan under various scenarios of HPV vaccine recommendation.
Ishimoto T, Yagi A, Nakajima K, Okamoto N, Yukimitsu E, Kawasaki M, Kawae Y, Hayasaka S, Ueda Y, Kimura T. Hum Vaccin Immunother. 2023 Aug 1;19(2):2229222. doi: 10.1080/21645515.2023.2229222. PMID: 37462048

Effectiveness of repetitive influenza vaccination against SARS-CoV-2 infection among a cohort of health care workers in Portugal.
Sá Silva S, Severo M, Norton P, Moreira A. Porto Biomed J. 2023 Aug 3;8(4):e223. doi: 10.1097/j.pbj.0000000000000223. eCollection 2023 Jul-Aug. PMID: 37547709

Progressive Observation of Covid-19 Vaccination Effects on Skin-Cellular Structures by Use of Intelligent Laser Speckle Classification (ILSC) Technique.
Orun A, Kurugollu F. J Digit Imaging. 2023 Aug;36(4):1701-1711. doi: 10.1007/s10278-023-00795-z. Epub 2023 Mar 1. PMID: 36859741

Prolonged febrile illness following first dose of ChAdOx1.
Caruana Dingli M, Bugeja L, Camilleri R. BMJ Case Rep. 2023 Aug 3;16(8):e253671. doi: 10.1136/bcr-2022-253671. PMID: 37536942

Immunogenicity, safety and reactogenicity of heterologous (third dose) booster vaccination with a full or fractional dose of two different COVID-19 vaccines: A phase 4, single-blind, randomized controlled trial in adults.

Costa Clemens SA, Marchevsky N, Kelly S, Felle S, Eldawi A, Rajasingam R, Mahmud R, Lambe T, Voysey M, Gonzalez I, Milan EP, Justino MC, Bibi S, Aley P, Clemens R, Pollard AJ. Hum Vaccin Immunother. 2023 Aug 1;19(2):2233400. doi: 10.1080/21645515.2023.2233400. PMID: 37438960

Assessing SARS-CoV-2 vaccine hesitancy among the people living with and without HIV from May to September 2022 in Blantyre, Malawi.
Mchawa C, Zhang SS, Zhang WX, Zhou Y, Wei TT, Du J, Cui F, Lu QB. Hum Vaccin Immunother. 2023 Aug 1;19(2):2222052. doi: 10.1080/21645515.2023.2222052. Epub 2023 Jun 15. PMID: 37318328

Herpes zoster reactivation after mRNA and adenovirus-vectored coronavirus disease 2019 vaccination: Analysis of National Health Insurance Database.
Yoon JG, Kim YE, Choi MJ, Choi WS, Seo YB, Jung J, Hyun HJ, Seong H, Nham E, Noh JY, Song JY, Kim WJ, Kim DW, Cheong HJ. J Infect Dis. 2023 Aug 7:jiad297. doi: 10.1093/infdis/jiad297. Online ahead of print. PMID: 37549237

Effects of a video-based positive side-effect information framing: An online experiment.
Bender FL, Rief W, Brück J, Wilhelm M. Health Psychol. 2023 Aug;42(8):593-602. doi: 10.1037/hea0001263. Epub 2023 Feb 13. PMID: 36780276

COVID-19 Vaccine Strategy Left Small Primary Care Practices On The Sidelines.
Hao S, Rehkopf DH, Velasquez E, Vala A, Bazemore AW, Phillips RL Jr. Health Aff (Millwood). 2023 Aug;42(8):1147-1151. doi: 10.1377/hlthaff.2023.00114. PMID: 37549323

Transplantation of hearts from SARS-CoV-2 positive donors.
Akhyari P, Immohr MB, Bönner F, Reinecke P, Lichtenberg A, Boeken U. ESC Heart Fail. 2023 Aug;10(4):2698-2701. doi: 10.1002/ehf2.14389. Epub 2023 Apr 23. PMID: 37088468

Global research trends related to coronavirus disease 2019 and the aged: a bibliometric analysis.
Carvalho ARB, Sousa Neto AR, Silva MDFD, Freitas DRJ, Moura MEB. Sao Paulo Med J. 2023 Aug 4;142(2):e2022662. doi: 10.1590/1516-3180.2022.0662.R1.190523. eCollection 2023. PMID: 37556683

Multiple Evanescent White Dot Syndrome Following COVID-19 mRNA Vaccination.
Gargouri MA, Yousfi N, Toutain J, Farès S, Lejoyeux R, Gabison E, Cochereau I, Titah C, Azar G. Ocul Immunol Inflamm. 2023 Aug;31(6):1240-1244. doi: 10.1080/09273948.2022.2127782. Epub 2022 Oct 13. PMID: 36228041

Humoral profiling of pediatric patients with cancer reveals robust immunity following anti-SARS-CoV-2 vaccination superior to natural infection.
Martin SD, Nziza N, Miozzo P, Bartsch Y, Farkas EJ, Kane AS, Boal LH, Friedmann A, Alter G, Yonker LM. Pediatr Blood Cancer. 2023 Aug;70(8):e30473. doi: 10.1002/pbc.30473. Epub 2023 May 30. PMID: 37249415

Prioritizing COVID-19 vaccine allocation in resource poor settings: Towards an Artificial Intelligence-enabled and Geospatial-assisted decision support framework.
Shayegh S, Andreu-Perez J, Akoth C, Bosch-Capblanch X, Dasgupta S, Falchetta G, Gregson S, Hammad AT, Herringer M, Kapkea F, Labella A, Lisciotto L, Martínez L, Macharia PM, Morales-Ruiz P,

Murage N, Offeddu V, South A, Torbica A, Trentini F, Melegaro A. PLoS One. 2023 Aug 10;18(8):e0275037. doi: 10.1371/journal.pone.0275037. eCollection 2023. PMID: 37561732

High SARS-CoV-2 seroprevalence in Lagos, Nigeria with robust antibody and cellular immune responses.
Akanmu S, Herrera BB, Chaplin B, Ogunsola S, Osibogun A, Onawoga F, John-Olabode S, Akase IE, Nwosu A, Hamel DJ, Chang CA, Kanki PJ. J Clin Virol Plus. 2023 Aug;3(3):100156. doi: 10.1016/j.jcvp.2023.100156. Epub 2023 Jun 24. PMID: 37388808

Impact of vaccination on infection or death from COVID-19 in individuals with laboratory-confirmed cases: Case-control study.
Hernández Bautista PF, Grajales Muñiz C, Cabrera Gaytán DA, Rojas Mendoza T, Vallejos Parás A, Santacruz Tinoco CE, Alvarado Yaah JE, Anguiano Hernández YM, Sandoval Gutiérrez N, Jaimes Betancourt L. PLoS One. 2023 Aug 3;18(8):e0265698. doi: 10.1371/journal.pone.0265698. eCollection 2023. PMID: 37535644

Protection against COVID-19 hospitalisation conferred by primary-series vaccination with AZD1222 in non-boosted individuals: first vaccine effectiveness results of the European COVIDRIVE study and meta-regression analysis.
Meeraus W, de Munter L, Gray CM, Dwivedi A, Wyndham-Thomas C, Ouwens M, Hartig-Merkel W, Drikite L, Rebry G, Carmona A, Stuurman AL, Chi Nguyen TY, Mena G, Mira-Iglesias A, Icardi G, Otero-Romero S, Baumgartner S, Martin C, Taylor S, Bollaerts K. Lancet Reg Health Eur. 2023 Jul 1;31:100675. doi: 10.1016/j.lanepe.2023.100675. eCollection 2023 Aug. PMID: 37547274

A Case of Neuroretinitis following Inactivated Virion COVID-19 Vaccination.
Nair GS, Khan IA, Rizvi SWA, Shahid S. Ocul Immunol Inflamm. 2023 Aug;31(6):1279-1282. doi: 10.1080/09273948.2023.2173244. Epub 2023 Feb 13. PMID: 36780589

Prophylactic administration of ivermectin attenuates SARS-CoV-2 induced disease in a Syrian Hamster Model.
Uematsu T, Takano T, Matsui H, Kobayashi N, Ōmura S, Hanaki H. J Antibiot (Tokyo). 2023 Aug;76(8):481-488. doi: 10.1038/s41429-023-00623-0. Epub 2023 Apr 25. PMID: 37185581

Influence of epidemiological and clinical factors in the reactogenicity to Comirnaty® vaccine in health care workers of a Spanish university teaching hospital (COVIVAC study).
Risco-Risco C, Martínez-Urbistondo D, Suárez Del Villar R, Ayerbe García-Monzón L, Pérez-Rubio A, Barberán-López J, Andaluz-Ojeda D, Villares Fernández P. Rev Esp Quimioter. 2023 Aug;36(4):400-407. doi: 10.37201/req/017.2023. Epub 2023 Apr 29. PMID: 37119130

Inactivated vaccine fueled adaptive immune responses to Omicron in 2-year COVID-19 convalescents.
Liu M, Zhang J, Li L, Tian J, Yang M, Shang B, Wang X, Li M, Li H, Yue C, Yao S, Lin Y, Guo Y, Zong K, Zhang D, Zhao Y, Cai K, Dong S, Xu S, Zhan J, Gao GF, Liu WJ. J Med Virol. 2023 Aug;95(8):e28998. doi: 10.1002/jmv.28998. PMID: 37548149

Advancements of in vitro transcribed mRNA (IVT mRNA) to enable translation into the clinics.
Kang DD, Li H, Dong Y. Adv Drug Deliv Rev. 2023 Aug;199:114961. doi: 10.1016/j.addr.2023.114961. Epub 2023 Jun 14. PMID: 37321375

Kinetics of cellular and humoral immunogenicity and effectiveness of SARS-CoV-2 booster vaccination in hematologic neoplasms.
Jiménez M, Fernández-Naval C, Navarro V, Novoa S, Martinez-Gallo M, Medina D, Andrés C, Antón A, Peralta S, Pujadas G, Hernández C, Pagès C, Roldán E, Pumarola T, Gironella M, Ruiz-Camps I, Martínez-Gómez X, Valcárcel D, Hernández M, Bosch F, Crespo M, Esperalba J, Abrisqueta P. Am J Hematol. 2023 Aug;98(8):1204-1213. doi: 10.1002/ajh.26951. Epub 2023 May 8. PMID: 37151135

COVID-19 Vaccination as a Trigger of IgA Vasculitis: Truth or Illusion?
Wang G, Luo Y, Li B, Li J. J Rheumatol. 2023 Aug;50(8):1092. doi: 10.3899/jrheum.221189. Epub 2023 Mar 15. PMID: 36921974

Immunoinformatic and reverse vaccinology-based designing of potent multi-epitope vaccine against Marburgvirus targeting the glycoprotein.
Yousaf H, Naz A, Zaman N, Hassan M, Obaid A, Awan FM, Azam SS. Heliyon. 2023 Jul 17;9(8):e18059. doi: 10.1016/j.heliyon.2023.e18059. eCollection 2023 Aug. PMID: 37534001

Homologous or heterologous immunization regimens against SARS-CoV-2 after two doses of inactivated COVID-19 vaccine: Comment.
Mungmunpuntipantip R, Wiwanitkit V. Hum Vaccin Immunother. 2023 Aug 1;19(2):2235957. doi: 10.1080/21645515.2023.2235957. PMID: 37489353

Reactivation of Graves' Disease and Thyroid Eye Disease following COVID-19 Vaccination - A Case Report.
Hung CW, Hung CH. Ocul Immunol Inflamm. 2023 Aug;31(6):1286-1290. doi: 10.1080/09273948.2023.2176889. Epub 2023 Feb 16. PMID: 36796028

COVID-19 vaccine behaviour among citizens of the Métis Nation of Ontario: A qualitative study.
Simms AJ, King KD, Tsui N, Edwards SA, Mecredy G; Métis Nation of Ontario. Vaccine. 2023 Aug 5:S0264-410X(23)00891-5. doi: 10.1016/j.vaccine.2023.07.060. Online ahead of print. PMID: 37550144

SARS-CoV-2 Antibodies in Commercial Immunoglobulin Products Show Markedly Reduced Cross-reactivities Against Omicron Variants.
Lindahl H, Chen P, Åberg M, Ljunggren HG, Buggert M, Aleman S, Smith CIE, Bergman P. J Clin Immunol. 2023 Aug;43(6):1075-1082. doi: 10.1007/s10875-023-01486-8. Epub 2023 Apr 14. PMID: 37058198

Safety evaluation of COVID-19 vaccination during early pregnancy: A single-center prospective cohort study of Chinese pregnant women.
Lu L, Wang L, Feng T, Du X. Hum Vaccin Immunother. 2023 Aug 1;19(2):2226995. doi: 10.1080/21645515.2023.2226995. PMID: 37462023

Examining the Prevailing Negative Sentiments Surrounding Measles Vaccination: Unsupervised Deep Learning of Twitter Posts from 2017 to 2022.
Ng QX, Teo YQJ, Kiew CY, Lim BP, Lim YL, Liew TM. Cyberpsychol Behav Soc Netw. 2023 Aug;26(8):621-630. doi: 10.1089/cyber.2023.0025. Epub 2023 Jun 26. PMID: 37358808

Immunogenicity and safety in pigs of PHH-1V, a SARS-CoV-2 RBD fusion heterodimer vaccine candidate.
Moros A, Prenafeta A, Barreiro A, Perozo E, Fernández A, Cañete M, González L, Garriga C, Pradenas E, Marfil S, Blanco J, Cebollada Rica P, Sisteré-Oró M, Meyerhans A, Prat Cabañas T, March R, Ferrer L. Vaccine. 2023 Aug 7;41(35):5072-5078. doi: 10.1016/j.vaccine.2023.07.008. Epub 2023 Jul 16. PMID: 37460353

Association between COVID-19 Vaccination and Myasthenia Gravis: a Population-based Nested Case Control Study.
Arbel A, Bishara H, Barnett-Griness O, Cohen S, Najjar-Debbiny R, Gronich N, Auriel E, Saliba W. Eur J Neurol. 2023 Aug 8. doi: 10.1111/ene.16025. Online ahead of print. PMID: 37552795

Is a booster dose of COVID-19 vaccines effective on newly dominant omicron subvariants among university students? Comparison between BA.1 and BA.2 dominancy.
Miyauchi S, Hiyama T, Nakano Y, Yoshino A, Miyake Y, Okamoto Y. Am J Infect Control. 2023 Aug;51(8):907-911. doi: 10.1016/j.ajic.2022.11.015. Epub 2022 Nov 24. PMID: 36435404

Viral anti-inflammatory serpin reduces immuno-coagulopathic pathology in SARS-CoV-2 mouse models of infection.
Zhang L, Li YH, Kibler K, Kraberger S, Varsani A, Turk J, Elmadbouly N, Aliskevich E, Spaccarelli L, Estifanos B, Enow J, Zanetti IR, Saldevar N, Lim E, Schlievert J, Browder K, Wilson A, Juan FA, Pinteric A, Garg A, Monder H, Saju R, Gisriel S, Jacobs B, Karr TL, Florsheim EB, Kumar V, Wallen J, Rahman M, McFadden G, Hogue BG, Lucas AR. EMBO Mol Med. 2023 Aug 3:e17376. doi: 10.15252/emmm.202317376. Online ahead of print. PMID: 37534622

Evaluation of the analytical performance of three chemiluminescence serological assays for detecting anti-SARS-CoV-2 antibodies.
Lo Sasso B, Agnello L, Giglio RV, Scazzone C, Massa D, Ciaccio AM, Gambino CM, Vidali M, Ciaccio M. Clin Exp Med. 2023 Aug;23(4):1205-1211. doi: 10.1007/s10238-022-00918-w. Epub 2022 Oct 19. PMID: 36261740

Vaccination schedule for adolescents. Consensus of the AEV, CAV-AEP and SEMA.
García FJÁ, Tejada AMG, Heras IG, de Arce AI, Llop FM, Herreros FN, Martín JJP, Marchuet PS, Rodríguez JV. An Pediatr (Engl Ed). 2023 Aug;99(2):122-128. doi: 10.1016/j.anpede.2023.07.004. Epub 2023 Jul 22. PMID: 37487775

Improving Influenza Vaccine Acceptance in Children Leveraging on COVID-19 Vaccination Lessons.
Ares-Gomez S, Mallah N, Pardo-Seco J, Nartallo-Penas V, Mirás-Carballal S, Rodriguez-Tenreiro-Sánchez C, Rivero-Calle I, Piñeiro-Sotelo M, Durán-Parrondo C, Martinón-Torres F. Arch Bronconeumol. 2023 Aug;59(8):531-533. doi: 10.1016/j.arbres.2023.03.011. Epub 2023 Mar 21. PMID: 37003883

Antibody Fc-binding profiles and ACE2 affinity to SARS-CoV-2 RBD variants.
Haycroft ER, Davis SK, Ramanathan P, Lopez E, Purcell RA, Tan LL, Pymm P, Wines BD, Hogarth PM, Wheatley AK, Juno JA, Redmond SJ, Gherardin NA, Godfrey DI, Tham WH, Selva KJ, Kent SJ, Chung AW. Med Microbiol Immunol. 2023 Aug;212(4):291-305. doi: 10.1007/s00430-023-00773-w. Epub 2023 Jul 21. PMID: 37477828

Notes from the Field: Safety Monitoring of Novavax COVID-19 Vaccine Among Persons Aged ≥12 Years - United States, July 13, 2022-March 13, 2023.
Romanson B, Moro PL, Su JR, Marquez P, Nair N, Day B, DeSantis A, Shimabukuro TT. MMWR Morb Mortal Wkly Rep. 2023 Aug 4;72(31):850-851. doi: 10.15585/mmwr.mm7231a4. PMID: 37535499

Nationwide analysis of the impact of COVID-19 in patients with a cardiovascular, oncological or chronic pulmonary disease in the context of an Eastern European country with a low vaccination rate, Bulgaria: March 2020-April 2022.
Dimitrov G, Valkov T, Batselova H, Kounchev O, Momekov G, Argirova R. BMJ Open. 2023 Aug 2;13(8):e068431. doi: 10.1136/bmjopen-2022-068431. PMID: 37532478

Sleep Disturbance and SARS-CoV-2 Vaccinations in Patients With Chronic Inflammatory Disease.
Pawar N, Taylor KE, Yang M, Deepak P, Kim W, Paley MA, Matloubian M, Carvidi A, Ciorba MA, Demissie E, El-Qunni A, Huang K, Kinnett B, McMorrow LE, Paez D, Poole M, Rose A, Schriefer RE, Kim AHJ, Nakamura M, Katz P, Gensler LS. Arthritis Care Res (Hoboken). 2023 Aug;75(8):1849-1856. doi: 10.1002/acr.25065. Epub 2023 Feb 13. PMID: 36479599

COVID-19 vaccination in correctional systems in the United States.
Martin P, Martin R, DeBritz AA, Kang AW. J Public Health Policy. 2023 Aug 4. doi: 10.1057/s41271-023-00426-5. Online ahead of print. PMID: 37542149

Anamnestic humoral correlates of immunity across SARS-CoV-2 variants of concern.
McNamara RP, Maron JS, Boucau J, Roy V, Webb NE, Bertera HL, Barczak AK, Positives Study Staff T, Franko N, Logue JK, Kemp M, Li JZ, Zhou L, Hsieh CL, McLellan JS, Siedner MJ, Seaman MS, Lemieux JE, Chu HY, Alter G. mBio. 2023 Aug 3:e0090223. doi: 10.1128/mbio.00902-23. Online ahead of print. PMID: 37535402

Parent-reported Barriers and Parental Beliefs Associated with Intentions to Obtain HPV Vaccination for Children in a Primary care Patient Population in Minnesota, USA.
Zhu X, Jacobson RM, MacLaughlin KL, Sauver JS, Griffin JM, Finney Rutten LJ. J Community Health. 2023 Aug;48(4):678-686. doi: 10.1007/s10900-023-01205-9. Epub 2023 Mar 15. PMID: 36920709

Ocular Inflammatory Reactions following an Inactivated SARS-CoV-2 Vaccine: A Four Case Series.
Ren J, Zhang T, Li X, Liu G. Ocul Immunol Inflamm. 2023 Aug;31(6):1128-1133. doi: 10.1080/09273948.2022.2093754. Epub 2022 Jul 12. PMID: 35819841

Covid-19: Payment to general practices to deliver vaccines to be cut by 25.
Mahase E. BMJ. 2023 Aug 7;382:1821. doi: 10.1136/bmj.p1821. PMID: 37549987

Do optimism and moralization predict vaccination? A five-wave longitudinal study.
Delporte M, Luyts M, Molenberghs G, Verbeke G, Demarest S, Hoorens V. Health Psychol. 2023 Aug;42(8):603-614. doi: 10.1037/hea0001272. Epub 2023 Mar 23. PMID: 36951711

Effect of SARS-CoV-2 infection on seizure, anxiety, and depression in 107 patients with epilepsy.
Zhou S, Zhang D, Chang J, Xia Z, Li J, Ni M, Li H. Epilepsy Behav. 2023 Aug;145:109290. doi: 10.1016/j.yebeh.2023.109290. Epub 2023 Jun 15. PMID: 37406559

Effectiveness of previous infection-induced and vaccine-induced protection against hospitalisation due to omicron BA subvariants in older adults: a test-negative, case-control study in Quebec, Canada.
Carazo S, Skowronski DM, Brisson M, Sauvageau C, Brousseau N, Fafard J, Gilca R, Talbot D, Ouakki M, Febriani Y, Deceuninck G, De Wals P, De Serres G. Lancet Healthy Longev. 2023 Aug;4(8):e409-e420. doi: 10.1016/S2666-7568(23)00099-5. Epub 2023 Jul 14. PMID: 37459879

Impact of prior COVID-19 infection on perceptions about the benefit and safety of COVID-19 vaccines.
Thorpe A, Levy AG, Scherer LD, Scherer AM, Drews FA, Butler JM, Fagerlin A. Am J Infect Control. 2023 Aug 4:S0196-6553(23)00546-1. doi: 10.1016/j.ajic.2023.08.002. Online ahead of print. PMID: 37544513

Combination regimen of nirmatrelvir/ritonavir and molnupiravir for the treatment of persistent SARS-CoV-2 infection: A case report and a scoping review of the literature.
Marangoni D, Antonello RM, Coppi M, Palazzo M, Nassi L, Streva N, Povolo L, Malentacchi F, Zammarchi L, Rossolini GM, Vannucchi AM, Bartoloni A, Spinicci M. Int J Infect Dis. 2023 Aug;133:53-56. doi: 10.1016/j.ijid.2023.04.412. Epub 2023 May 5. PMID: 37150351

Response to the coronavirus disease 2019 pandemic of dental hygienists in South Korea-Part III: COVID-19 vaccination intentions.
Kim HN, Kim JH, Min JH. Int J Dent Hyg. 2023 Aug;21(3):648-656. doi: 10.1111/idh.12681. Epub 2023 Apr 17. PMID: 37066829

Assessing the coverage and timeliness of coronavirus vaccination among people experiencing homelessness in Wales, UK: a population-level data-linkage study.
Thomas I, Mackie P. BMC Public Health. 2023 Aug 5;23(1):1494. doi: 10.1186/s12889-023-16432-x. PMID: 37543593

Higher Cell-Mediated Immune Responses in Patients With Inflammatory Bowel Disease on Anti-TNF Therapy After COVID-19 Vaccination.
Caldera F, Farraye FA, Necela BM, Cogen D, Saha S, Wald A, Daoud ND, Chun K, Grimes I, Lutz M, Van Helden SR, Swift MD, Virk A, Bharucha AE, Patel TC, Gores GJ, Chumsri S, Hayney MS, Knutson KL. Inflamm Bowel Dis. 2023 Aug 1;29(8):1202-1209. doi: 10.1093/ibd/izac193. PMID: 36103273

Professional ethics for infectious disease control: moral conflict management in modern public health practice.
Timpka T, Nyce JM. Public Health. 2023 Aug;221:160-165. doi: 10.1016/j.puhe.2023.06.017. Epub 2023 Jul 16. PMID: 37463550

Acceptance or rejection of vaccination against influenza and SARS-CoV2 viruses among primary care professionals in Central Catalonia. A cross-sectional study.
Fuster-Casanovas A, Vidal-Alaball J, Bonet-Esteve A, Muñoz-Miralles R, Catalina QM. Vaccine X. 2023 Aug;14:100290. doi: 10.1016/j.jvacx.2023.100290. Epub 2023 Mar 26. PMID: 37008959

Associations Among Menstrual Cycle Length, Coronavirus Disease 2019 (COVID-19), and Vaccination.
Alvergne A, Boniface E, Darney B, Shea A, Weber K, Ventola C, Vitzthum VJ, Edelman A. Obstet Gynecol. 2023 Aug 10. doi: 10.1097/AOG.0000000000005343. Online ahead of print. PMID: 37562052

The intestinal microbiota predicts COVID-19 severity and fatality regardless of hospital feeding method.
Bucci V, Ward DV, Bhattarai S, Rojas-Correa M, Purkayastha A, Holler D, Qu MD, Mitchell WG, Yang J, Fountain S, Zeamer A, Forconi CS, Fujimori G, Odwar B, Cawley C, Moormann AM, Wessolossky M, Maldonado-Contreras A. mSystems. 2023 Aug 7:e0031023. doi: 10.1128/msystems.00310-23. Online ahead of print. PMID: 37548476

Diminished responses to mRNA-based SARS-CoV-2 vaccines in individuals with rheumatoid arthritis on immune-modifying therapies.
Klebanoff SD, Rodda LB, Morishima C, Wener MH, Yuzefpolskiy Y, Bettelli E, Buckner JH, Speake C, Pepper M, Campbell DJ. JCI Insight. 2023 Aug 8;8(15):e168663. doi: 10.1172/jci.insight.168663. PMID:

[The most common gastrointestinal alterations in patients with post-COVID syndrome].
Angyal K, Tajthy AM, Drácz B, Miheller P, Horváth M, Székely H, Papp V, Czompa D, Szijártó A, Werling K. Orv Hetil. 2023 Aug 6;164(31):1206-1212. doi: 10.1556/650.2023.32839. Print 2023 Aug 6. PMID: 37543972

The Roles of Social Media Use and Medical Mistrust in Black Americans' COVID-19 Vaccine Hesitancy: The RISP Model Perspective.
Nah S, Williamson LD, Kahlor LA, Atkinson L, Upshaw SJ, Ntang-Beb JL. Health Commun. 2023 Aug 8:1-14. doi: 10.1080/10410236.2023.2244169. Online ahead of print. PMID: 37551159

Bivalent COVID-19 mRNA booster vaccination (BA.1 or BA.4/BA.5) increases neutralization of matched Omicron variants.
Springer DN, Bauer M, Medits I, Camp JV, Aberle SW, Burtscher C, Höltl E, Weseslindtner L, Stiasny K, Aberle JH. NPJ Vaccines. 2023 Aug 4;8(1):110. doi: 10.1038/s41541-023-00708-9. PMID: 37542025

Correspondence on outcomes following COVID-19 vaccination and associated factors among healthcare professionals.
Sriwijitalai W, Wiwanitkit V. Hum Vaccin Immunother. 2023 Aug 1;19(2):2219180. doi: 10.1080/21645515.2023.2219180. Epub 2023 Jul 21. PMID: 37477213

Safety and immunogenicity of Ad5-nCoV immunization after three-dose priming with inactivated SARS-CoV-2 vaccine in Chinese adults.
Zhang H, Xu N, Xu Y, Qin P, Dai R, Xu B, Wang S, Ding L, Fu J, Zhang S, Hua Q, Liao Y, Yang J, Hu X, Jiang J, Lv H. Nat Commun. 2023 Aug 8;14(1):4757. doi: 10.1038/s41467-023-40489-2. PMID: 37553338

Pathways to Immunity: Patterns of Excess Death Across the United States and Within Closed Religious Communities.
Stein RE, Colyer CJ, Corcoran KE, Mackay AM. J Relig Health. 2023 Aug;62(4):2820-2835. doi: 10.1007/s10943-023-01838-z. Epub 2023 Jun 1. PMID: 37261578

Modelling the impact of a high-uptake bivalent booster scenario on the COVID-19 burden and healthcare costs in New York City.
Pandey A, Fitzpatrick MC, Moghadas SM, Vilches TN, Ko C, Vasan A, Galvani AP. Lancet Reg Health Am. 2023 Jul 27;24:100555. doi: 10.1016/j.lana.2023.100555. eCollection 2023 Aug. PMID: 37554154

Experiences and challenges of African traditional medicine: lessons from COVID-19 pandemic.
Mutombo PN, Kasilo OMJ, James PB, Wardle J, Kunle O, Katerere D, Wambebe C, Matsabisa MG, Rahmatullah M, Nikiema JB, Mukankubito I, Sheridan R, Sanogo R, Nissapatorn V, Sivakorn C, Tripathy S, Goyal R, Dhobi M. BMJ Glob Health. 2023 Aug;8(8):e010813. doi: 10.1136/bmjgh-2022-010813. PMID: 37558269

Risk reduction analysis of mix-and-match vaccination strategy in healthcare workers during SARS-CoV-2 Omicron variant predominant period: A multi-center cohort study in Taiwan.
Chen YC, Chuang CH, Shen TF, Lin CS, Yang HP, Li HC, Chen CL, Lin IF, Chiu CH. Hum Vaccin Immunother. 2023 Aug 1;19(2):2237387. doi: 10.1080/21645515.2023.2237387. PMID: 37534447

The social vulnerability metric (SVM) as a new tool for public health.
Saulsberry L, Bhargava A, Zeng S, Gibbons JB, Brannan C, Lauderdale DS, Gibbons RD. Health Serv Res. 2023 Aug;58(4):873-881. doi: 10.1111/1475-6773.14102. Epub 2022 Nov 29. PMID: 36401593

Effectiveness of bivalent mRNA vaccines against medically attended symptomatic SARS-CoV-2 infection and COVID-19-related hospital admission among SARS-CoV-2-naive and previously infected individuals: a retrospective cohort study.
Tan CY, Chiew CJ, Pang D, Lee VJ, Ong B, Wang LF, Ren EC, Lye DC, Tan KB. Lancet Infect Dis. 2023 Aug 2:S1473-3099(23)00373-0. doi: 10.1016/S1473-3099(23)00373-0. Online ahead of print. PMID: 37543042

Pandemic-related posttraumatic psychological growth in U.S. military veterans: A 3-year, nationally representative, longitudinal study.
Kang H, Na PJ, Fischer IC, Tsai J, Tedeschi RG, Pietrzak RH. Psychiatry Res. 2023 Aug;326:115370. doi: 10.1016/j.psychres.2023.115370. Epub 2023 Jul 24. PMID: 37499281

Rising to the Occasion: A National Nursing Home Study Documenting Attempts to Address Social Isolation During the COVID-19 Pandemic.
Lapane KL, Lim E, Mack DS, Hargraves JL, Cosenza C, Dubé CE. J Am Med Dir Assoc. 2023 Aug;24(8):1127-1132.e6. doi: 10.1016/j.jamda.2023.05.018. Epub 2023 May 30. PMID: 37355245

Perspective on receptor-associated immune response to Candida albicans single and mixed infections: Implications for therapeutics in oropharyngeal candidiasis.
Yang L, Cheng T, Shao J. Med Mycol. 2023 Aug 2;61(8):myad077. doi: 10.1093/mmy/myad077. PMID: 37533203

Adverse Events Following the BNT162b2 mRNA COVID-19 Vaccine (Pfizer-BioNTech) in Aotearoa New Zealand.
Walton M, Pletzer V, Teunissen T, Lumley T, Hanlon T. Drug Saf. 2023 Aug 9. doi: 10.1007/s40264-023-01332-1. Online ahead of print. PMID: 37556109

The SARS-CoV-2 Spike Protein Mutation Explorer: using an interactive application to improve the public understanding of SARS-CoV-2 variants of concern.
Iannucci S, Harvey WT, Hughes J, Robertson DL, Poyade M, Hutchinson E. J Vis Commun Med. 2023 Aug 1:1-11. doi: 10.1080/17453054.2023.2237087. Online ahead of print. PMID: 37526402

COVID-19 vaccination and gout flare risk in patients with infrequent or frequent flares: a prospective cohort study.
He Y, Xue X, Dalbeth N, Terkeltaub R, Chen Y, Yan F, Pang L, Li X, Yuan X, Cheng X, Li C, Sun M. Arthritis Care Res (Hoboken). 2023 Aug 8. doi: 10.1002/acr.25215. Online ahead of print. PMID: 37553607

Clinical characteristics and comorbidities associated with SARS-CoV-2 breakthrough infection in the University of California Healthcare Systems.
Hogarth M, John D, Li Y, Wang-Rodriguez J, Chakladar J, Li WT, Mehta SR, Jain S, Ongkeko WM. Am J Med Sci. 2023 Aug;366(2):102-113. doi: 10.1016/j.amjms.2023.04.019. Epub 2023 May 3. PMID: 37146904

Current progress in pharmacokinetic studies of vaccines: Impact of carrier, ADME and its modulation on immune responses.
Jha SK, Imran M, Jha LA, Hasan N, Panthi VK, Paudel KR, Almalki WH, Mohammed Y, Kesharwani P. Environ Res. 2023 Aug 3:116823. doi: 10.1016/j.envres.2023.116823. Online ahead of print. PMID: 37543130

Prolonged generalized immune response on ^{18}F-FDG PET/CT following COVID-19 vaccination.
Sawant DA, Razmaria AA, Pandit-Taskar N. Radiol Case Rep. 2023 May 23;18(8):2552-2557. doi: 10.1016/j.radcr.2023.04.046. eCollection 2023 Aug. PMID: 37250482

Autoimmune diabetes mellitus after COVID-19 vaccination in adult population: a systematic review of case reports.
Alsudais AS, Alkanani RS, Fathi AB, Almuntashiri SS, Jamjoom JN, Alzhrani MA, Althubaiti A, Radi S. BMC Endocr Disord. 2023 Aug 4;23(1):164. doi: 10.1186/s12902-023-01424-0. PMID: 37542216

Neutralizing activity of a third dose of CoronaVac against Omicron subvariants within a 20-month follow-up study.
Cao C, Guo Q, Dai Y, Jiang J, Liu M, Ji T, Zhou P, Gong F. Hum Vaccin Immunother. 2023 Aug 1;19(2):2242217. doi: 10.1080/21645515.2023.2242217. PMID: 37529941

Relapsing myocarditis following initial recovery of post COVID-19 vaccination in two adolescent males - Case reports.
Amodio D, Manno EC, Cotugno N, Santilli V, Franceschini A, Perrone MA, Chinali M, Drago F, Cantarutti N, Curione D, Engler R, Secinaro A, Palma P. Vaccine X. 2023 Aug;14:100318. doi: 10.1016/j.jvacx.2023.100318. Epub 2023 May 27. PMID: 37303596

Fifth bivalent omicron BA.4/BA.5 vaccination neutralization of SARS-CoV-2 in heart transplant recipients.
Peled Y, Afek A, Patel JK, Raanani E, Segev A, Ram E, Fardman A, Beigel R, Atari N, Kliker L, Elkader BA, Mandelboim M. J Heart Lung Transplant. 2023 Aug;42(8):1054-1058. doi: 10.1016/j.healun.2023.03.016. Epub 2023 Apr 19. PMID: 37084801

A Brief Peer-Led Intervention to Increase COVID-19 Vaccine Uptake Among People Who Inject Drugs in San Diego County: Results From a Pilot Randomized Controlled Trial.

Strathdee SA, Abramovitz D, Harvey-Vera AY, Stamos-Buesig T, Vera CF, Artamonova I, Logan J, Patterson TL, Servin AE, Bazzi AR. Open Forum Infect Dis. 2023 Jul 21;10(8):ofad392. doi: 10.1093/ofid/ofad392. eCollection 2023 Aug. PMID: 37547856

Epidemiology, course, and outcomes of Sars-CoV-2 infection in patients with acromegaly and Cushing's disease: a monocentric experience in Southern Italy.
Ragonese M, Giuffrida G, Alessi Y, Giandalia A, Giovinazzo S, Cotta OR, Certo R, Casablanca R, Ferraù F, Cannavò S. J Endocrinol Invest. 2023 Aug;46(8):1711-1715. doi: 10.1007/s40618-023-02016-4. Epub 2023 Jan 28. PMID: 36708457

Safety and immunogenicity of a variant-adapted SARS-CoV-2 recombinant protein vaccine with AS03 adjuvant as a booster in adults primed with authorized vaccines: a phase 3, parallel-group study.
de Bruyn G, Wang J, Purvis A, Ruiz MS, Adhikarla H, Alvi S, Bonaparte MI, Brune D, Bueso A, Canter RM, Ceregido MA, Deshmukh S, Diemert D, Finn A, Forrat R, Fu B, Gallais J, Griffin P, Grillet MH, Haney O, Henderson JA, Koutsoukos M, Launay O, Torres FM, Masotti R, Michael NL, Park J, Rivera-Medina DM, Romanyak N, Rook C, Schuerman L, Sher LD, Tavares-Da-Silva F, Whittington A, Chicz RM, Gurunathan S, Savarino S, Sridhar S; VAT00002 booster cohorts study team. EClinicalMedicine. 2023 Jul 22;62:102109. doi: 10.1016/j.eclinm.2023.102109. eCollection 2023 Aug. PMID: 37533419

A large outbreak of the Kappa mutation of COVID-19 in Cork, Ireland, April-May 2021.
Barrett PM, Bruton O, Hanrahan M, White PF, Brennan A, Ertz K, Chu RW, Keogh S, Dean J, O'Mahony MT, O'Sullivan MB, Sheahan A, Murray D; Outbreak Control Team. Ir J Med Sci. 2023 Aug;192(4):1573-1579. doi: 10.1007/s11845-022-03212-6. Epub 2022 Nov 11. PMID: 36369600

Association Between Gut Microbiota and Delirium in Acutely Ill Older Adults.
Garcez FB, Garcia de Alencar JC, Fernandez SSM, Avelino-Silva VI, Sabino EC, Martins RCR, Franco LAM, Lima Ribeiro SM, Possolo de Souza H, Avelino-Silva TJ. J Gerontol A Biol Sci Med Sci. 2023 Aug 2;78(8):1320-1327. doi: 10.1093/gerona/glad074. PMID: 36869725

Routine statins use is associated with less adverse outcome in patients above 70 years of age admitted to hospital with COVID-19.
Izkhakov E, Vilian Y, Buch A, Denysov V, Namouz D, Nathan A, Greenman Y, Ziv-Baran T. BMC Geriatr. 2023 Aug 7;23(1):473. doi: 10.1186/s12877-023-04183-8. PMID: 37550638

Antibody response elicited by the SARS-CoV-2 vaccine booster in patients with multiple sclerosis: Who gains from it?
Schiavetti I, Inglese M, Frau J, Signoriello E, Caleri F, Stromillo ML, Ferrò MT, Rilla MT, Gandoglia I, Gazzola P, Brichetto G, Pasquali L, Grimaldi L, Ulivelli M, Marinelli F, Cordera S, Clerico M, Conte A, Salvetti M, Battaglia MA, Franciotta D, Uccelli A, Sormani MP; CovaXiMS Study Group. Eur J Neurol. 2023 Aug;30(8):2357-2364. doi: 10.1111/ene.15830. Epub 2023 May 28. PMID: 37154406

Longitudinal humoral and cell-mediated immune responses in a population-based cohort in Zurich, Switzerland between March and June 2022 - evidence for protection against Omicron SARS-CoV-2 infection by neutralizing antibodies and spike-specific T-cell responses.
Zens KD, Llanas-Cornejo D, Menges D, Fehr JS, Münz C, Puhan MA, Frei A. Int J Infect Dis. 2023 Aug;133:18-26. doi: 10.1016/j.ijid.2023.04.407. Epub 2023 May 5. PMID: 37149211

Recent Advances in Messenger Ribonucleic Acid (mRNA) Vaccines and Their Delivery Systems: A Review.
Yihunie W, Nibret G, Aschale Y. Clin Pharmacol. 2023 Aug 3;15:77-98. doi: 10.2147/CPAA.S418314. eCollection 2023. PMID: 37554660

The community acceptance of COVID-19 vaccines in Rakhine State: A cross-sectional study in Myanmar.
Simon S, Min KM, Latt TZ, Moe PP, Tun KM. PLOS Glob Public Health. 2023 Aug 3;3(8):e0002162. doi: 10.1371/journal.pgph.0002162. eCollection 2023. PMID: 37535512

Mucosal SARS-CoV-2 Nanoparticle Vaccine Based on Mucosal Adjuvants and Its Immune Effectiveness by Intranasal Administration.
Xiao L, Yu W, Shen L, Yan W, Qi J, Hu T. ACS Appl Mater Interfaces. 2023 Aug 2;15(30):35895-35905. doi: 10.1021/acsami.3c05456. Epub 2023 Jul 19. PMID: 37466148

Sex differences in the efficacy and safety of SARS-CoV-2 vaccination in residents of long-term care facilities: insights from the GeroCovid Vax study.
Trevisan C, Raparelli V, Malara A, Abbatecola AM, Noale M, Palmieri A, Fedele G, Di Lonardo A, Leone P, Schiavoni I, Stefanelli P, Volpato S, Antonelli Incalzi R, Onder G; GeroCovid Vax working group. Intern Emerg Med. 2023 Aug;18(5):1337-1347. doi: 10.1007/s11739-023-03283-y. Epub 2023 Apr 29. PMID: 37120663

Estimation of Intangible Costs for Factors Associated with Oral Antiviral Drugs for COVID-19 Treatment: A Conjoint Analysis in Japan.
Hosogaya N, Takazono T, Kurazono K, Hiroi S, Iwasaki K, Takeshima T, Ha C, Mukae H. Adv Ther. 2023 Aug;40(8):3525-3542. doi: 10.1007/s12325-023-02564-4. Epub 2023 Jun 12. PMID: 37303032

Vaccines for pregnant people: are we missing the forest for the trees?
Metz TD. Lancet Digit Health. 2023 Aug 1:S2589-7500(23)00131-0. doi: 10.1016/S2589-7500(23)00131-0. Online ahead of print. PMID: 37537122

Herpes zoster infection following SARS-CoV-2 vaccine BNT162b2.
Lauro W, Cillo F, Nastro F, Fabbrocini G, Marasca C. Ital J Dermatol Venerol. 2023 Aug;158(4):364-365. doi: 10.23736/S2784-8671.23.07466-2. PMID: 37539506

Comment on "Neuromuscular complications after COVID-19 vaccination: a series of eight patients" by Leemans et al.
Galassi G, Ariatti A. Acta Neurol Belg. 2023 Aug;123(4):1605-1606. doi: 10.1007/s13760-022-02117-6. Epub 2022 Oct 22. PMID: 36273111

Concerns, Perceived Risk and Hesitancy on COVID-19 Vaccine: A qualitative Exploration Among University Students Living in the West-Bank.
Veronese G, Mahamid F, Bdier D. Epidemiol Infect. 2023 Aug 7:1-24. doi: 10.1017/S0950268823001267. Online ahead of print. PMID: 37548186

Screening Hesitancy of a Universal Voluntary-based Rapid Antigen Test for coronavirus disease 2019 (COVID-19) During Omicron Wave in Hong Kong.

Wong EL, Qiu H, Wang K, Sun KS, Yam CH, Cheung AW, Yeoh EK. J Infect Public Health. 2023 Aug;16(8):1306-1312. doi: 10.1016/j.jiph.2023.06.006. Epub 2023 Jun 10. PMID: 37336128

Large library docking for novel SARS-CoV-2 main protease non-covalent and covalent inhibitors.
Fink EA, Bardine C, Gahbauer S, Singh I, Detomasi TC, White K, Gu S, Wan X, Chen J, Ary B, Glenn I, O'Connell J, O'Donnell H, Fajtová P, Lyu J, Vigneron S, Young NJ, Kondratov IS, Alisoltani A, Simons LM, Lorenzo-Redondo R, Ozer EA, Hultquist JF, O'Donoghue AJ, Moroz YS, Taunton J, Renslo AR, Irwin JJ, García-Sastre A, Shoichet BK, Craik CS. Protein Sci. 2023 Aug;32(8):e4712. doi: 10.1002/pro.4712. PMID: 37354015

Comment on urological complications after COVID 19 vaccine.
Kleebayoon A, Wiwanitkit V. World J Urol. 2023 Aug 10. doi: 10.1007/s00345-023-04540-7. Online ahead of print. PMID: 37561131

A strategy to optimize the peptide-based inhibitors against different mutants of the spike protein of SARS-CoV-2.
Priya P, Basit A, Bandyopadhyay P. J Biomol Struct Dyn. 2023 Aug-Sep;41(13):6191-6202. doi: 10.1080/07391102.2022.2103587. Epub 2022 Jul 26. PMID: 35881159

Ionizable polymeric nanocarriers for the codelivery of bi-adjuvant and neoantigens in combination tumor immunotherapy.
Su T, Liu X, Lin S, Cheng F, Zhu G. Bioact Mater. 2023 Aug;26:169-180. doi: 10.1016/j.bioactmat.2023.02.016. Epub 2023 Mar 3. PMID: 36883121

The social value of a SARS-CoV-2 vaccine: Willingness to pay estimates from four western countries.
Costa-Font J, Rudisill C, Harrison S, Salmasi L. Health Econ. 2023 Aug;32(8):1818-1835. doi: 10.1002/hec.4690. Epub 2023 May 7. PMID: 37151130

Seroprevalence of SARS-CoV-2 in Mexican Health Care Workers after Two Years of the Pandemic: The Picture of an Ophthalmic Medical Centre.
Garfias Y, Magaña-Guerrero FS, Buentello-Volante B, Cruz Vega IB, Castro Salas I, Sánchez Cisneros PJ, Aguayo Flores JE, Salas Lais AG, Muñoz Medina JE, Mata-Haro V, Reséndiz-Sandoval M, Vázquez-García VA, Hernández J. Ophthalmic Epidemiol. 2023 Aug;30(4):400-406. doi: 10.1080/09286586.2022.2127789. Epub 2022 Oct 2. PMID: 36184872

Population Attributable Fraction of Non-Vaccination of COVID-19 Due to Vaccine Hesitancy, United States, 2021.
Nguyen KH, Zhao R, Chen S, Vaish AK, Bednarczyk RA, Vasudevan L. Am J Epidemiol. 2023 Aug 8:kwad167. doi: 10.1093/aje/kwad167. Online ahead of print. PMID: 37552958

Throughput-scalable manufacturing of SARS-CoV-2 mRNA lipid nanoparticle vaccines.
Shepherd SJ, Han X, Mukalel AJ, El-Mayta R, Thatte AS, Wu J, Padilla MS, Alameh MG, Srikumar N, Lee D, Weissman D, Issadore D, Mitchell MJ. Proc Natl Acad Sci U S A. 2023 Aug 15;120(33):e2303567120. doi: 10.1073/pnas.2303567120. Epub 2023 Aug 9. PMID: 37556502

Self-assembling SARS-CoV-2 spike-HBsAg nanoparticles elicit potent and durable neutralizing antibody responses via genetic delivery.
Liu C, Wang L, Merriam JS, Shi W, Yang ES, Zhang Y, Chen M, Kong WP, Cheng C, Tsybovsky Y, Stephens T, Verardi R, Leung K, Stein C, Olia AS, Harris DR, Choe M, Zhang B, Graham BS, Kwong PD, Koup RA, Pegu A, Mascola JR. NPJ Vaccines. 2023 Aug 8;8(1):111. doi: 10.1038/s41541-023-00707-w. PMID: 37553406

Safety profile and SARS-CoV-2 breakthrough infections among HCWs receiving anti-SARS-CoV-2 and influenza vaccines simultaneously: an Italian observational study.
Moscara L, Venerito V, Martinelli A, Di Lorenzo A, Toro F, Violante F, Tafuri S, Stefanizzi P. Vaccine. 2023 Aug 4:S0264-410X(23)00874-5. doi: 10.1016/j.vaccine.2023.07.043. Online ahead of print. PMID: 37544827

Enhanced immunogenicity induced by mRNA vaccines with various lipid nanoparticles as carriers for SARS-CoV-2 infection.
Zhang Y, Wang J, Xing H, Liu C, Zha W, Dong S, Jiang Y, Li X. J Mater Chem B. 2023 Aug 9;11(31):7454-7465. doi: 10.1039/d3tb00303e. PMID: 37448376

A Current View of SARS-CoV-2 Vaccine Policies Amongst Pediatric Renal Transplant Centers and Relationships to State Policy.
Littlejohn JB, Pace RL, Curtis KL, Jones-Carr ME, Koller FL. Am Surg. 2023 Aug;89(8):3594-3596. doi: 10.1177/00031348231157895. Epub 2023 Mar 15. PMID: 36919528

Vaccine-Induced Immune Thrombotic Thrombocytopenia Two Years Later: Should It Still Be on the Scientific Agenda?
Petito E, Gresele P. Thromb Haemost. 2023 Aug 7. doi: 10.1055/a-2107-0891. Online ahead of print. PMID: 37285904

How Industrial Policy Could Accelerate Innovation In The Life Sciences.
Robinson JC. Health Aff (Millwood). 2023 Aug;42(8):1045-1053. doi: 10.1377/hlthaff.2023.00047. PMID: 37549321

A microfluidic electrophoretic dual dynamic staining method for the identification and relative quantitation of dsRNA contaminants in mRNA vaccines.
Coll De Peña A, Li N, Vaduva M, Bwanali L, Tripathi A. Analyst. 2023 Aug 7;148(16):3758-3767. doi: 10.1039/d3an00281k. PMID: 37439498

Telemedicine Utilization in an Outpatient Pediatric Neurosurgical Clinic: A Prospective Survey of Patient and Family Preferences.
Anderson MG, Lambert W, Leclair N, Athar D, Martin JE, Bookland MJ, Hersh DS. World Neurosurg. 2023 Aug;176:e557-e568. doi: 10.1016/j.wneu.2023.05.102. Epub 2023 Jun 1. PMID: 37270096

Possible Association between Vogt-Koyanagi-Harada Disease and Coronavirus Disease Vaccine: A Report of Four Cases.

de Queiroz Tavares Ferreira F, Araújo DC, de Albuquerque LM, Bianchini PM, Holanda EC, Pugliesi A. Ocul Immunol Inflamm. 2023 Aug;31(6):1134-1140. doi: 10.1080/09273948.2022.2093756. Epub 2022 Aug 1. PMID: 35914285

Case report of new-onset ulcerative colitis after MVC-COVI1901 vaccine injection for SARS-CoV-2.
Kuo HL, Lin TY, Leong PY. Int J Rheum Dis. 2023 Aug;26(8):1594-1598. doi: 10.1111/1756-185X.14637. Epub 2023 Mar 6. PMID: 36876751

Quantifying the impact of SARS-CoV-2 temporal vaccination trends and disparities on disease control.
Larsen SL, Shin I, Joseph J, West H, Anorga R, Mena GE, Mahmud AS, Martinez PP. Sci Adv. 2023 Aug 2;9(31):eadh9920. doi: 10.1126/sciadv.adh9920. Epub 2023 Aug 2. PMID: 37531439

SARS-CoV-2 Vaccination Effectiveness in Rituximab-Treated Patients Affected by Pemphigus Vulgaris.
Fenizia C, Moltrasio C, Ottobrini L, Utyro O, Genovese G, Vanetti C, Trabattoni D, Marzano AV. J Invest Dermatol. 2023 Aug;143(8):1601-1604. doi: 10.1016/j.jid.2022.12.023. Epub 2023 Jan 28. PMID: 36716924

Ionizable Amino Lipids Distribution and Effects on DSPC/Cholesterol Membranes: Implications for Lipid Nanoparticle Structure.
Dehghani-Ghahnaviyeh S, Smith M, Xia Y, Dousis A, Grossfield A, Sur S. J Phys Chem B. 2023 Aug 10;127(31):6928-6939. doi: 10.1021/acs.jpcb.3c01296. Epub 2023 Jul 27. PMID: 37498794

The effect of the coronavirus disease 2019 vaccine and infection on menstrual cycle length: an analysis of 12 months of continuous menstrual cycle data from 5,314 participants.
Hariton E, Morris JR, Ho K, Chen C, Cui E, Cedars MI. Fertil Steril. 2023 Aug;120(2):387-388. doi: 10.1016/j.fertnstert.2023.05.158. Epub 2023 May 24. PMID: 37230409

Intradermal skin test with mRNA vaccines as a surrogate marker of T cell immunity in immunocompromised patients.
Fallet B, Foglierini M, Porret R, Alcaraz-Serna A, Sauvage C, Jenelten R, Caplanusi T, Gilliet M, Perez L, Fenwick C, Genolet R, Harari A, Bobisse S, Gottardo R, Pantaleo G, Muller YD. J Infect. 2023 Aug;87(2):111-119. doi: 10.1016/j.jinf.2023.06.005. Epub 2023 Jun 14. PMID: 37321353

Immunogenicity of bivalent omicron (BA.1) booster vaccination after different priming regimens in health-care workers in the Netherlands (SWITCH ON): results from the direct boost group of an open-label, multicentre, randomised controlled trial.
Tan NH, Geers D, Sablerolles RSG, Rietdijk WJR, Goorhuis A, Postma DF, Visser LG, Bogers S, van Dijk LLA, Gommers L, van Leeuwen LPM, Boerma A, Nijhof SH, van Dort KA, Koopmans MPG, Dalm VASH, Lafeber M, Kootstra NA, Huckriede ALW, van Baarle D, Zaeck LM, GeurtsvanKessel CH, de Vries RD, van der Kuy PHM; SWITCH ON Research Group. Lancet Infect Dis. 2023 Aug;23(8):901-913. doi: 10.1016/S1473-3099(23)00140-8. Epub 2023 Apr 21. PMID: 37088096

Influence of vaccination on adverse health outcomes after SARS-CoV-2 infection among individuals with alcohol use disorder: a population-based study.
Askgaard G, Osler M, Laursen TM, Hjorthøj C, Benros ME, Ethelberg S, Mølbak K, Nordentoft M, Nilsson SF. Addiction. 2023 Aug;118(8):1482-1492. doi: 10.1111/add.16196. Epub 2023 Apr 15. PMID: 37005828

Comparative antibody and cell-mediated immune responses, reactogenicity, and efficacy of homologous and heterologous boosting with CoronaVac and BNT162b2 (Cobovax): an open-label, randomised trial.
Leung NHL, Cheng SMS, Cohen CA, Martín-Sánchez M, Au NYM, Luk LLH, Tsang LCH, Kwan KKH, Chaothai S, Fung LWC, Cheung AWL, Chan KCK, Li JKC, Ng YY, Kaewpreedee P, Jia JZ, Ip DKM, Poon LLM, Leung GM, Peiris JSM, Valkenburg SA, Cowling BJ. Lancet Microbe. 2023 Aug 4:S2666-5247(23)00216-1. doi: 10.1016/S2666-5247(23)00216-1. Online ahead of print. PMID: 37549680

Tixagevimab/cilgavimab for preventing COVID-19 during the Omicron surge: retrospective analysis of National Veterans Health Administration electronic data.
Young-Xu Y, Epstein L, Marconi VC, Davey V, Korves C, Zwain G, Smith J, Cunningham F, Bonomo RA, Ginde AA. mBio. 2023 Aug 3:e0102423. doi: 10.1128/mbio.01024-23. Online ahead of print. PMID: 37535398

Methodological and statistical considerations: Batch-dependent adverse effects of COVID-19 vaccines.
Scott DAR, Renelle A, Niederer RL. Eur J Clin Invest. 2023 Aug 7:e14073. doi: 10.1111/eci.14073. Online ahead of print. PMID: 37548000

Soil-transmitted helminths: A critical review of the impact of co-infections and implications for control and elimination.
Lebu S, Kibone W, Muoghalu CC, Ochaya S, Salzberg A, Bongomin F, Manga M. PLoS Negl Trop Dis. 2023 Aug 10;17(8):e0011496. doi: 10.1371/journal.pntd.0011496. eCollection 2023 Aug. PMID: 37561673

Investigation of COVID-19 vaccination among maintenance hemodialysis patients in Sichuan, China.
He L, Chen L, Zheng H, Zhang Y, Tang S, Chen H. Jpn J Nurs Sci. 2023 Aug 9:e12556. doi: 10.1111/jjns.12556. Online ahead of print. PMID: 37559431

Combined anti-S1 and anti-S2 antibodies from hybrid immunity elicit potent cross-variant ADCC against SARS-CoV-2.
Grant MD, Bentley K, Fielding CA, Hatfield KM, Ings DP, Harnum D, Wang EC, Stanton RJ, Holder KA. JCI Insight. 2023 Aug 8;8(15):e170681. doi: 10.1172/jci.insight.170681. PMID: 37338994

Poly(vinyl pyrrolidone) derivatives as PEG alternatives for stealth, non-toxic and less immunogenic siRNA-containing lipoplex delivery.
Berger M, Toussaint F, Djemaa SB, Laloy J, Pendeville H, Evrard B, Jerôme C, Lechanteur A, Mottet D, Debuigne A, Piel G. J Control Release. 2023 Aug 2;361:87-101. doi: 10.1016/j.jconrel.2023.07.031. Online ahead of print. PMID: 37482343

Intranasal delivery of an adenovirus-vector vaccine co-expressing a modified spike protein and a genetic adjuvant confers lasting mucosal immunity against SARS-CoV-2.
Jung HE, Ku KB, Kang BH, Park JH, Kim HC, Kim KD, Lee HK. Antiviral Res. 2023 Aug;216:105656. doi: 10.1016/j.antiviral.2023.105656. Epub 2023 Jun 14. PMID: 37327877

Comparison of antibody responses following natural infection with Severe Acute Respiratory Syndrome Coronavirus 2 or receipt of CoronaVac or ChAdOx1 (AZD1222) vaccination in Chiang Mai, Thailand.

Hongjaisee S, Chawansuntati K, Sripan P, Rattanathammethee K, Sakkhachornphop S, Chaiwarith R, Sudjaritruk T, Supparatpinyo K, Wipasa J. Vaccine X. 2023 Aug;14:100305. doi: 10.1016/j.jvacx.2023.100305. Epub 2023 Apr 20. PMID: 37155476

Six-month immune responses to mRNA-1273 vaccine in combination antiretroviral therapy treated late presenter people with HIV according to previous SARS-CoV-2 infection.
Augello M, Bono V, Rovito R, Tincati C, d'Arminio Monforte A, Marchetti G. AIDS. 2023 Aug 1;37(10):1503-1517. doi: 10.1097/QAD.0000000000003585. Epub 2023 May 18. PMID: 37199415

The structure of the RBD-E77 Fab complex reveals neutralization and immune escape of SARS-CoV-2.
Zhang Z, Li X, Xue Y, Yang B, Jia Y, Liu S, Lu D. Acta Crystallogr D Struct Biol. 2023 Aug 1;79(Pt 8):746-757. doi: 10.1107/S2059798323005041. Epub 2023 Jul 10. PMID: 37428848

Designing ferritin nanocage based vaccine candidates for SARS-CoV-2 by *in silico* engineering of its HLA I and HLA II epitope peptides.
Manickavasagam P, Abhishek S, Rajakumara E. J Biomol Struct Dyn. 2023 Aug-Sep;41(13):6121-6133. doi: 10.1080/07391102.2022.2103027. Epub 2022 Jul 27. PMID: 35894946

Reduction in preterm birth among COVID-19 vaccinated pregnant individuals in the United States.
Darwin KC, Kohn JR, Shippey E, Uribe KA, Gaur P, Eke AC. Am J Obstet Gynecol MFM. 2023 Aug 3:101114. doi: 10.1016/j.ajogmf.2023.101114. Online ahead of print. PMID: 37543141

Humoral and cellular immune responses after three or four doses of BNT162b2 in patients with hematological malignancies.
Heftdal LD, Hamm SR, Pérez-Alós L, Madsen JR, Armenteros JJA, Fogh K, Kronborg CC, Vallentin AP, Hasselbalch RB, Møller DL, Hansen CB, Pries-Heje M, Gang AO, Ostrowski SR, Frikke-Schmidt R, Sørensen E, Hilsted L, Bundgaard H, Iversen K, Garred P, Nielsen SD, Grønbaek K. Eur J Haematol. 2023 Aug;111(2):229-239. doi: 10.1111/ejh.13986. Epub 2023 May 8. PMID: 37151174

Soluble SARS-CoV-2 RBD and human ACE2 peptidase domain produced in Drosophila S2 cells show functions evoking virus-cell interface.
Carrión F, Rammauro F, Olivero-Deibe N, Fló M, Portela MM, Lima A, Durán R, Pritsch O, Bianchi S. Protein Sci. 2023 Aug;32(8):e4721. doi: 10.1002/pro.4721. PMID: 37405395

A qualitative assessment of the adverse effects associated with COVID-19 vaccines: a study from Jordan.
Al-Bawab R, Abu-Farha R, El-Dahiyat F, Nassar RI, Zawiah M. J Pharm Policy Pract. 2023 Aug 10;16(1):100. doi: 10.1186/s40545-023-00605-5. PMID: 37563664

Bibliometric analysis of the Vogt–Koyanagi–Harada disease literature.
Li L, Yuan L, Zhou X, Hua X, Yuan X. Int Ophthalmol. 2023 Aug 8. doi: 10.1007/s10792-023-02815-x. Online ahead of print. PMID: 37552428

Humoral and cellular responses after third dose of SARS-CoV-2 vaccine in myeloproliferative neoplasms patients on ruxolitinib therapy.

Atanasio A, Vanni A, Maggi L, Pilerci S, Mazzoni A, Capone M, Crupi F, Cicogna P, Boldrini V, Tekle S, Colao MG, Borella M, Paoli C, Rossolini GM, Vannucchi AM, Annunziato F, Guglielmelli P. Leuk Res. 2023 Aug;131:107330. doi: 10.1016/j.leukres.2023.107330. Epub 2023 May 29. PMID: 37269750

Impact of methotrexate treatment on vaccines immunogenicity in adult rheumatological patients - Lessons learned from the COVID-19 pandemic.
Wroński J, Ciechomska M, Kuca-Warnawin E. Biomed Pharmacother. 2023 Aug 3;165:115254. doi: 10.1016/j.biopha.2023.115254. Online ahead of print. PMID: 37542854

Impact of BNT162b2 and mRNA-1273 Vaccination on Vascular Function in Healthy Adults: A Pilot Study.
Serviente C, Matias A, Calderone M, Enes Erol M, Chipkin SR, Layec G. Circ Res. 2023 Aug 4;133(4):366-368. doi: 10.1161/CIRCRESAHA.122.322862. Epub 2023 Jul 13. PMID: 37439257

Acute pulmonary hypertension due to microthrombus formation following COVID-19 vaccination: a case report.
Nakagawa A, Nakamura N, Torii S, Goto S. Eur Heart J Case Rep. 2023 Jul 26;7(8):ytad353. doi: 10.1093/ehjcr/ytad353. eCollection 2023 Aug. PMID: 37559783

Effects Of An Employee COVID-19 Vaccination Mandate At A Long-Term Care Network.
Golos AM, Buttenheim AM, Ritter AZ, Bair EF, Chapman GB. Health Aff (Millwood). 2023 Aug;42(8):1140-1146. doi: 10.1377/hlthaff.2022.01596. PMID: 37549332

Aerosolized sulfated hyaluronan derivatives prolong the survival of K18 ACE2 mice infected with a lethal dose of SARS-CoV-2.
Pavan M, Fanti CD, Lucia AD, Canato E, Acquasaliente L, Sonvico F, Delgado J, Hicks A, Torrelles JB, Kulkarni V, Dwivedi V, Zanellato AM, Galesso D, Pasut G, Buttini F, Martinez-Sobrido L, Guarise C. Eur J Pharm Sci. 2023 Aug 1;187:106489. doi: 10.1016/j.ejps.2023.106489. Epub 2023 Jun 11. PMID: 37311533

A localizing nanocarrier formulation enables multi-target immune responses to multivalent replicating RNA with limited systemic inflammation.
Kimura T, Leal JM, Simpson A, Warner NL, Berube BJ, Archer JF, Park S, Kurtz R, Hinkley T, Nicholes K, Sharma S, Duthie MS, Berglund P, Reed SG, Khandhar AP, Erasmus JH. Mol Ther. 2023 Aug 2;31(8):2360-2375. doi: 10.1016/j.ymthe.2023.06.017. Epub 2023 Jul 3. PMID: 37403357

Complex Coacervates as a Promising Vehicle for mRNA Delivery: A Comprehensive Review of Recent Advances and Challenges.
Forenzo C, Larsen J. Mol Pharm. 2023 Aug 10. doi: 10.1021/acs.molpharmaceut.3c00439. Online ahead of print. PMID: 37561647

Modulation of the Immune Response to Severe Acute Respiratory Syndrome Coronavirus 2 Vaccination by Nonsteroidal Anti-Inflammatory Drugs.
Skarke C, Lordan R, Barekat K, Naik A, Mathew D, Ohtani T, Greenplate AR, Grant GR, Lahens NF, Gouma S, Troisi E, Sengupta A, Weljie AM, Meng W, Luning Prak ET, Lundgreen K, Bates P, Meng H, FitzGerald GA. J Pharmacol Exp Ther. 2023 Aug;386(2):198-204. doi: 10.1124/jpet.122.001415. Epub 2023 Apr 27. PMID: 37105582

SARS-CoV-2 IgG Spike antibody levels and avidity in natural infection or following vaccination with mRNA-1273 or BNT162b2 vaccines.
Hickey TE, Kemp TJ, Bullock J, Bouk A, Metz J, Neish A, Cherry J, Lowy DR, Pinto LA. Hum Vaccin Immunother. 2023 Aug 1;19(2):2215677. doi: 10.1080/21645515.2023.2215677. Epub 2023 Jun 1. PMID: 37264688

SARS-CoV-2 vaccination and infection in ozanimod-treated participants with relapsing multiple sclerosis.
Cree BAC, Maddux R, Bar-Or A, Hartung HP, Kaur A, Brown E, Li Y, Hu Y, Sheffield JK, Silva D, Harris S. Ann Clin Transl Neurol. 2023 Aug 7. doi: 10.1002/acn3.51862. Online ahead of print. PMID: 37550942

Socio-demographic characteristics associated with COVID-19 vaccination uptake in Switzerland: longitudinal analysis of the CoMix study.
Reichmuth ML, Heron L, Riou J, Moser A, Hauser A, Low N, Althaus CL. BMC Public Health. 2023 Aug 10;23(1):1523. doi: 10.1186/s12889-023-16405-0. PMID: 37563550

Community efforts to promote vaccine uptake in a rural setting: a qualitative interview study.
Nanyonjo A, Nelson D, Sayers E, Lall P, Vernon-Wilson E, Tetui M, Grindrod K, Kane R, Gussy M, Siriwardena N. Health Promot Int. 2023 Aug 1;38(4):daad088. doi: 10.1093/heapro/daad088. PMID: 37549195

Remitting seronegative symmetrical synovitis with pitting edema syndrome postsecond COVID-19 vaccination: a case report.
Hodifa Y, Khalayli N, Hodaifa A, Kudsi M. Ann Med Surg (Lond). 2023 Jun 20;85(8):4118-4120. doi: 10.1097/MS9.0000000000001015. eCollection 2023 Aug. PMID: 37554915

A Curious Case of Occlusive Retinal Vasculitis in a Young Individual Associated with COVID-19 Vaccination.
Chandrasekaran PR. Ocul Immunol Inflamm. 2023 Aug;31(6):1254-1260. doi: 10.1080/09273948.2022.2137046. Epub 2022 Oct 28. PMID: 36306426

Analysis of the N-glycosylation profiles of the spike proteins from the Alpha, Beta, Gamma, and Delta variants of SARS-CoV-2.
Wang D, Baudys J, Osman SH, Barr JR. Anal Bioanal Chem. 2023 Aug;415(19):4779-4793. doi: 10.1007/s00216-023-04771-y. Epub 2023 Jun 24. PMID: 37354227

Broadly neutralizing humanized SARS-CoV-2 antibody binds to a conserved epitope on Spike and provides antiviral protection through inhalation-based delivery in non-human primates.
Hermet P, Delache B, Herate C, Wolf E, Kivi G, Juronen E, Mumm K, Žusinaite E, Kainov D, Sankovski E, Virumäe K, Planken A, Merits A, Besaw JE, Yee AW, Morizumi T, Kim K, Kuo A, Berriche A, Dereuddre-Bosquet N, Sconosciuti Q, Naninck T, Relouzat F, Cavarelli M, Ustav M, Wilson D, Ernst OP, Männik A, LeGrand R, Ustav M Jr. PLoS Pathog. 2023 Aug 2;19(8):e1011532. doi: 10.1371/journal.ppat.1011532. eCollection 2023 Aug. PMID: 37531329

Political quarrel overshadows vaccination advocacy: How the vaccine debate on Brazilian Twitter was framed by anti-vaxxers during Bolsonaro administration.

Verjovsky M, Barreto MP, Carmo I, Coutinho B, Thomer L, Lifschitz S, Jurberg C. Vaccine. 2023 Aug 5:S0264-410X(23)00921-0. doi: 10.1016/j.vaccine.2023.07.075. Online ahead of print. PMID: 37550146

Delivery and Expression of mRNA in the Secondary Lymphoid Organs Drive Immune Responses to Lipid Nanoparticle-mRNA Vaccines after Intramuscular Injection.
Takanashi A, Pouton CW, Al-Wassiti H. Mol Pharm. 2023 Aug 7;20(8):3876-3885. doi: 10.1021/acs.molpharmaceut.2c01024. Epub 2023 Jul 26. PMID: 37491979

Prolonged infective SARS-CoV-2 omicron variant shedding in a patient with diffuse large B cell lymphoma successfully cleared after three courses of remdesivir.
Nakamura K, Sugiyama M, Ishizuka H, Sasajima T, Minakawa Y, Sato H, Miyazawa M, Kitakawa K, Fujita S, Saito N, Kashiwabara N, Kohata H, Hara Y, Kanari Y, Shinka T, Kanemitsu K. J Infect Chemother. 2023 Aug;29(8):820-824. doi: 10.1016/j.jiac.2023.05.003. Epub 2023 May 12. PMID: 37182841

Modelling the potential public health impact of different vaccination strategies with an omicron-adapted bivalent vaccine in Malaysia.
Thakkar K, Spinardi J, Kyaw MH, Yang J, Mendoza CF, Dass M, Law W, Ozbilgili E, Yarnoff B. Expert Rev Vaccines. 2023 Aug 7. doi: 10.1080/14760584.2023.2245465. Online ahead of print. PMID: 37548520

Dynamical changes of SARS-CoV-2 spike variants in the highly immunogenic regions impact the viral antibodies escaping.
Di Rienzo L, Miotto M, Desantis F, Grassmann G, Ruocco G, Milanetti E. Proteins. 2023 Aug;91(8):1116-1129. doi: 10.1002/prot.26497. Epub 2023 Apr 20. PMID: 37078559

Morning Vaccination Compared with Afternoon/Evening Vaccination on Humoral Response to SARS-CoV-2 Adenovirus Vector-Based Vaccine in Hemodialysis Patients.
Lin TY, Hung SC. Clin J Am Soc Nephrol. 2023 Aug 1;18(8):1077-1079. doi: 10.2215/CJN.0000000000000207. Epub 2023 May 23. PMID: 37220168

SARS-CoV-2 neutralizing antibody epitopes are overlapping and highly mutated which raises the chances of escape variants and requires development of broadly reactive vaccines.
Joseph J, Darpe S, Kulkarni G, Raj VS. Proteins. 2023 Aug;91(8):1021-1031. doi: 10.1002/prot.26488. Epub 2023 Mar 21. PMID: 36912191

SARS-CoV-2 virus-like-particles *via* liposomal reconstitution of spike glycoproteins.
McColman S, Shkalla K, Sidhu P, Liang J, Osman S, Kovacs N, Bokhari Z, Forjaz Marques AC, Li Y, Lin Q, Zhang H, Cramb DT. Nanoscale Adv. 2023 Jul 14;5(16):4167-4181. doi: 10.1039/d3na00190c. eCollection 2023 Aug 8. PMID: 37560413

Plain Language vs Standard Format for Youth Understanding of COVID-19 Recommendations: A Randomized Clinical Trial.
Stallwood L, Sammy A, Prebeg M, Relihan J, Baba A, Charide R, Sayfi S, Elliott SA, Hartling L, Munan M, Richards DP, Mathew JL, Kredo T, Mbuagbaw L, Motilall A, Scott SD, Klugar M, Lotfi T, Stevens AL, Pottie K, Schünemann HJ, Butcher NJ, Offringa M; RecMap Members. JAMA Pediatr. 2023 Aug 7:e232686. doi: 10.1001/jamapediatrics.2023.2686. Online ahead of print. PMID: 37548983

[Detection of antibodies against SARS-CoV-2 in CHUAC emergency staff after the administration of the Comirnaty vaccine (Pfizer-BioNTech): a retrospective study].
Rodríguez Buyo IM, González Vázquez A, Rey Paraños I, Seijas González A. Aten Primaria. 2023 Aug;55(8):102675. doi: 10.1016/j.aprim.2023.102675. Epub 2023 May 9. PMID: 37247534

Secondary immunoglobulin A nephropathy with gross hematuria leading to rapidly progressive glomerulonephritis following severe acute respiratory syndrome coronavirus 2 vaccination: a case report.
Fukuda M, Kaneko T, Kawai T, Ishii H, Shimizu A. BMC Nephrol. 2023 Aug 8;24(1):232. doi: 10.1186/s12882-023-03287-y. PMID: 37553599

Postvaccination Symptoms After SARS-CoV-2 mRNA Vaccination Among Patients With Inflammatory Bowel Disease: A Prospective, Comparative Study.
Mujukian A, Kumar R, Li D, Debbas P, Botwin GJ, Cheng S, Ebinger J, Braun J, McGovern D, Melmed GY; CORALE-IBD Study Group. Inflamm Bowel Dis. 2023 Aug 9:izad114. doi: 10.1093/ibd/izad114. Online ahead of print. PMID: 37556401

Intradermal administration of DNA vaccine targeting Omicron SARS-CoV-2 via pyro-drive jet injector provides the prolonged neutralizing antibody production via germinal center reaction.
Hayashi H, Sun J, Yanagida Y, Otera T, Tai JA, Nishikawa T, Yamashita K, Sakaguchi N, Yoshida S, Baba S, Chang CY, Shimamura M, Okamoto S, Amaishi Y, Chono H, Mineno J, Rakugi H, Morishita R, Nakagami H. Sci Rep. 2023 Aug 10;13(1):13033. doi: 10.1038/s41598-023-40172-y. PMID: 37563266

Response to "Efficacy of COVID-19 vaccination in adult patients with sickle cell disease: Comment".
Cheminet G, Derdevet J, Arlet JB. Eur J Haematol. 2023 Aug 9. doi: 10.1111/ejh.14067. Online ahead of print. PMID: 37555364

Bivalent mRNA-1273.214 vaccine effectiveness against SARS-CoV-2 omicron XBB* infections.
Chemaitelly H, Ayoub HH, AlMukdad S, Faust JS, Tang P, Coyle P, Yassine HM, Al Thani AA, Al-Khatib HA, Hasan MR, Al-Kanaani Z, Al-Kuwari E, Jeremijenko A, Kaleeckal AH, Latif AN, Shaik RM, Abdul-Rahim HF, Nasrallah GK, Al-Kuwari MG, Butt AA, Al-Romaihi HE, Al-Thani MH, Al-Khal A, Bertollini R, Abu-Raddad LJ. J Travel Med. 2023 Aug 9:taad106. doi: 10.1093/jtm/taad106. Online ahead of print. PMID: 37555656

Proliferative glomerulonephritis with monoclonal immunoglobulin deposits and atypical pathological findings treated with corticosteroid and rituximab.
Mori M, Tanaka A, Maeda K, Saito S, Furuhashi K, Maruyama S. CEN Case Rep. 2023 Aug 7. doi: 10.1007/s13730-023-00813-7. Online ahead of print. PMID: 37548878

Periodic Mesoporous Organosilica as a Nanoadjuvant for Subunit Vaccines Elicits Potent Antigen-Specific Germinal Center Responses by Activating Naive B Cells.
Li F, Feng X, Huang J, Zhang M, Liu W, Wang X, Zhu R, Wang X, Wang P, Yu B, Li W, Qiao ZA, Yu X. ACS Nano. 2023 Aug 8. doi: 10.1021/acsnano.3c00991. Online ahead of print. PMID: 37552584

Omicron breakthrough infections in wild-type SARS-CoV-2 vaccinees elicit high levels of neutralizing antibodies against pangolin coronavirus GX_P2V.

Lu S, Luo S, Bai B, Fan Z, Hong B, Xu W, Ma H, Chen W, Fan H, Tong Y, Song L. J Med Virol. 2023 Aug;95(8):e29031. doi: 10.1002/jmv.29031. PMID: 37561639

The variable conversion of neutralizing anti-SARS-CoV-2 single chain antibodies to IgG provides insight into RBD epitope accessibility.
Chang MR, Ke H, Miguéns LL, Coherd C, Nguyen K, Kamkaew M, Johnson R, Storm N, Honko A, Zhu Q, Griffiths A, Marasco WA. Protein Eng Des Sel. 2023 Aug 10:gzad008. doi: 10.1093/protein/gzad008. Online ahead of print. PMID: 37561410

Bilateral Relentless Placoid Chorioretinitis Following Pfizer-BioNTech COVID-19 Vaccination: Specific Antigenic Trigger or Nonspecific Immune Activation?
Dutt DDCS, Lam J, Richards J. Ocul Immunol Inflamm. 2023 Aug 8:1-6. doi: 10.1080/09273948.2023.2239338. Online ahead of print. PMID: 37552853

Immunogenicity and safety of fractional doses of 17D-213 yellow fever vaccine in children (YEFE): a randomised, double-blind, non-inferiority substudy of a phase 4 trial.
Juan-Giner A, Namulwana ML, Kimathi D, Grantz KH, Fall G, Dia M, Bob NS, Sall AA, Nerima C, Sahani MK, Mulogo EM, Ampeire I, Hombach J, Nanjebe D, Mwanga-Amumpaire J, Cummings DAT, Bejon P, Warimwe GM, Grais RF. Lancet Infect Dis. 2023 Aug;23(8):965-973. doi: 10.1016/S1473-3099(23)00131-7. Epub 2023 Apr 28. PMID: 37127047

Advances in mRNA therapeutics for cancer immunotherapy: From modification to delivery.
Han G, Noh D, Lee H, Lee S, Kim S, Yoon HY, Lee SH. Adv Drug Deliv Rev. 2023 Aug;199:114973. doi: 10.1016/j.addr.2023.114973. Epub 2023 Jun 25. PMID: 37369262

Cross-sectional Characterization of SARS-CoV-2 Antibody Levels and Decay Rates Following Infection of Unvaccinated Elderly Individuals.
Whelan M, Galipeau Y, White-Al Habeeb N, Konforte D, Abou El Hassan M, Booth RA, Arnold C, Langlois MA, Pelchat M. Open Forum Infect Dis. 2023 Jul 20;10(8):ofad384. doi: 10.1093/ofid/ofad384. eCollection 2023 Aug. PMID: 37547857

Bilateral Acute Macular Neuroretinopathy after COVID-19 Vaccination and Infection.
Bellur S, Zeleny A, Patronas M, Jiramongkolchai K, Kodati S. Ocul Immunol Inflamm. 2023 Aug;31(6):1222-1225. doi: 10.1080/09273948.2022.2093753. Epub 2022 Aug 1. PMID: 35914286

Identification of alpha-linolenic acid as a broad-spectrum antiviral against zika, dengue, herpes simplex, influenza virus and SARS-CoV-2 infection.
Feng Y, Yang Y, Zou S, Qiu S, Yang H, Hu Y, Lin G, Yao X, Liu S, Zou M. Antiviral Res. 2023 Aug;216:105666. doi: 10.1016/j.antiviral.2023.105666. Epub 2023 Jul 8. PMID: 37429528

The Use of Travel as an Appeal to Motivate Millennial Parents on Facebook to Get Vaccinated Against COVID-19: Message Framing Evaluation.
Arshanapally S, Starr T, Elsberry LB, Rinker R. JMIR Form Res. 2023 Aug 1;7:e43720. doi: 10.2196/43720. PMID: 37437085

Saliva antiviral antibody levels are detectable but correlate poorly with serum antibody levels following SARS-CoV-2 infection and/or vaccination.
Faustini SE, Cook A, Hill H, Al-Taei S, Heaney J, Efstathiou E, Tanner C, Townsend N, Ahmed Z, Dinally M, Hoque M, Goodall M, Stamataki Z, Plant T, Chapple I, Cunningham AF, Drayson MT, Shields AM, Richter AG; PITCH consortium. J Infect. 2023 Aug 3:S0163-4453(23)00439-5. doi: 10.1016/j.jinf.2023.07.018. Online ahead of print. PMID: 37543310

Inhibitory effects of 190 compounds against SARS-CoV-2 M$^{pr\ o}$ protein: Molecular docking interactions.
Souza GB, Sens L, Hammerschmidt SJ, de Sousa NF, de Carvalho MAG, Dos Santos CVD, Tizziani T, Moreira MA, Pollo LAE, Martin EF, Neto JSS, Biavatti MW, de Assis FF, Ngadjui BT, Simo IK, Ambassa P, Scotti MT, Scotti L, Braga AL, Schirmeister T, Sandjo LP. Arch Pharm (Weinheim). 2023 Aug;356(8):e2300207. doi: 10.1002/ardp.202300207. Epub 2023 May 31. PMID: 37255416

Safety and immunogenicity of a ChAdOx1 vaccine against Rift Valley fever in UK adults: an open-label, non-randomised, first-in-human phase 1 clinical trial.
Jenkin D, Wright D, Folegatti PM, Platt A, Poulton I, Lawrie A, Tran N, Boyd A, Turner C, Gitonga JN, Karanja HK, Mugo D, Ewer KJ, Bowden TA, Gilbert SC, Charleston B, Kaleebu P, Hill AVS, Warimwe GM. Lancet Infect Dis. 2023 Aug;23(8):956-964. doi: 10.1016/S1473-3099(23)00068-3. Epub 2023 Apr 13. PMID: 37060917

Exploration of mRNA nanoparticles based on DOTAP through optimization of the helper lipids.
Ma X, Wu F, Peng C, Chen H, Zhang D, Han T. Biotechnol J. 2023 Aug 7:e2300123. doi: 10.1002/biot.202300123. Online ahead of print. PMID: 37545293

Repetitive mRNA vaccination is required to improve the quality of broad-spectrum anti-SARS-CoV-2 antibodies in the absence of CXCL13.
Azarias Da Silva M, Nioche P, Soudaramourty C, Bull-Maurer A, Tiouajni M, Kong D, Zghidi-Abouzid O, Picard M, Mendes-Frias A, Santa-Cruz A, Carvalho A, Capela C, Pedrosa J, Castro AG, Loubet P, Sotto A, Muller L, Lefrant JY, Roger C, Claret PG, Duvnjak S, Tran TA, Tokunaga K, Silvestre R, Corbeau P, Mammano F, Estaquier J. Sci Adv. 2023 Aug 4;9(31):eadg2122. doi: 10.1126/sciadv.adg2122. Epub 2023 Aug 4. PMID: 37540749

Salivary antibodies induced by BA.4/BA.5-convalescence or bivalent booster Immunoglobulin vaccination protect against novel SARS-COV-2 variants of concern.
Diem G, Dichtl S, Zaderer V, Lass-Flörl C, Reindl M, Lupoli G, Dächert C, Muenchhoff M, Graf A, Blum H, Keppler OT, Wilflingseder D, Posch W. Microbiol Spectr. 2023 Aug 8:e0179323. doi: 10.1128/spectrum.01793-23. Online ahead of print. PMID: 37551989

Increased Risk of Herpes Zoster in Adult Patients with Inflammatory Bowel Disease After SARS-CoV2 Infection: A Propensity-Matched Cohort Study.
Desai A, Soni A, Hayney MS, Hashash JG, Kochhar GS, Farraye FA, Caldera F. Inflamm Bowel Dis. 2023 Aug 4:izad162. doi: 10.1093/ibd/izad162. Online ahead of print. PMID: 37540900

Conducting a phase III clinical trial in children during the COVID- 19 pandemic: Experience and lessons learnt from a clinical research facility of Nepal.

Chapagain RH, Maharjan J, Adhikari S, Thapa P, Kunwar K, Giri BR, Shrestha NJ, Shrestha AK, Shrestha SK, Tamang SM, Cho H, Park EL, Lee J, Lee J, Kim DR, Yang JS, Saluja T, Wartel A, Lynch J, Song KR. Hum Vaccin Immunother. 2023 Aug 1;19(2):2239680. doi: 10.1080/21645515.2023.2239680. PMID: 37539816

Patentes registradas en Patentscope

Estrategia de búqueda: *Vaccine in the title or abstract AND 20230801:20230810 as the publication date 74 records*

1.WO/2023/142191VACCINE SYSTEM FOR PREVENTION OR TREATMENT OF CANCER ON BASIS OF WHOLE-CELL COMPONENTS OF ONE OR MORE CANCER CELLS AND/OR TUMOR TISSUE OR MIXTURES THEREOF
WO - 03.08.2023
Clasificación Internacional A61K 39/00 Nº de solicitud PCT/CN2022/076908 Solicitante SUZHOU ERSHENG BIOPHARMACEUTICAL CO., LTD. Inventor/a LIU, Mi
Disclosed are a vaccine system for the prevention or treatment of cancer on the basis of whole-cell components of one or more cancer cells and/or tumor tissue or mixtures thereof, and a preparation method therefor and the use thereof. Water-soluble components and/or water-insoluble components of whole-cell components of one or more cancer cells and/or tissue are delivered using modified nano-particles or micro-particles for the preparation of a vaccine for the prevention and treatment of cancer. Both the water-soluble parts and/or the water-insoluble parts are loaded in nano-particles or micro-particles, that is, both the mutated proteins or polypeptides are loaded in the nano-vaccine or micro-vaccine. The substances with immunogenicity in the whole-cell components or mixtures thereof can be used for the prevention and treatment of cancer. Adding modification processes such as adding chemical modifications and adding charged substances in the vaccine preparation process increases the amount of an antigen so that the effect of the vaccine can be better. The vaccine system can prevent and/or treat cancer.

2.20230241204POLYPEPTIDE VACCINE COUPLED WITH TLR7 AGONIST FOR NOVEL CORONAVIRUS AND USE THEREOF
US - 03.08.2023
Clasificación Internacional A61K 39/215 Nº de solicitud 18008826 Solicitante SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES Inventor/a Likun GONG
Disclosed are a polypeptide vaccine coupled with a TLR7 agonist for novel coronavirus and the use thereof. Specifically, the present invention provides a vaccine polypeptide for novel coronavirus pneumonia based on the basis of the analytical study of the RBD sequence and structural information of the S protein of SARS-CoV-2, wherein the vaccine polypeptide has the following structural formula: Z-(J-U)n, where in the formula, Z, J, U, n, etc. are as defined in the description. Also provided in the present invention are a vaccine composition containing the vaccine polypeptide and the use thereof.

3.WO/2023/142786CORONAVIRUS VACCINE COMPOSITION, METHODS, AND USES THEREOF
WO - 03.08.2023
Clasificación Internacional C07K 19/00 Nº de solicitud PCT/CN2022/140514 Solicitante SICHUAN CLOVER BIOPHARMACEUTICALS, INC. Inventor/a LIANG, Peng
Provided is an immunogenic composition comprising a recombinant peptide and protein. The recombinant peptide and protein comprise a coronavirus antigen and immunogen, for example, an S

protein peptide of a SARS-CoV-2 coronavirus beta (B.1.351) variant or a fragment, a variant or a mutant thereof, such as a chimeric antigen and immunogen comprising a receptor-binding domain of the beta variant and an S protein peptide sequence of an original strain or other variants. The immunogenic composition comprises a secreted fusion protein, the secreted fusion protein comprising a soluble coronavirus antigen. The soluble coronavirus antigen protein is connected, by means of an in-frame fusion, to a C-terminal moiety of a collagen capable of self-trimerization to form a disulfide bond-linked trimeric fusion protein. The provided immunogenic composition can be used for generating an immune response, for example, used as a vaccine for the prevention of coronavirus infections, such as infections by SARS-CoV-2 original (Hu-1), alpha, beta, gamma, delta, omicron strains and/or other strains. The provided immunogenic composition can be used in a vaccine composition, for example, as part of a prophylactic and/or therapeutic vaccine. Also provided are methods for producing the recombinant peptide and protein, methods for the prevention, treatment and/or diagnosis, and a related kit.

4.WO/2023/142201METHOD FOR INDUSTRIAL PRODUCTION OF VACCINE AGAINST PSEUDOMONAS AERUGINOSA
WO - 03.08.2023
Clasificación Internacional A61K 39/104 Nº de solicitud PCT/CN2022/076983 Solicitante WESTVAC BIOPHARMA CO., LTD. Inventor/a WANG, Zhenling
A method for the industrial production of a vaccine against Pseudomonas aeruginosa. By using a series of standardized, programmed and digital settings, it is ensured that a vaccine with stable quality containing whole Pseudomonas aeruginosa and multiple immunogenic components in Pseudomonas aeruginosa is produced. The obtained vaccine has good immunogenicity, can prevent infectious diseases caused by multiple types of Pseudomonas aeruginosa, and also has weak side effects and high safety.

5.WO/2023/143600NOVEL IONIZABLE LIPID FOR NUCLEIC ACID DELIVERY, AND LNP COMPOSITION AND VACCINE THEREOF
WO - 03.08.2023
Clasificación Internacional C07C 217/08 Nº de solicitud PCT/CN2023/073789 Solicitante CANSINO BIOLOGICS INC. Inventor/a YAN, Zhihong
The present invention provides a novel cationic lipid, a lipid nanoparticle, and a nucleic acid vaccine. According to the present invention, a specific cationic lipid is selected to prepare a lipid nanoparticle mRNA vaccine, and the lipid nanoparticle mRNA vaccine is found to have better in-vitro stability and immunogenicity as compared with the prior art.

6.WO/2023/143601NOVEL IONIZABLE LIPID USED FOR NUCLEIC ACID DELIVERY AS WELL AS LNP COMPOSITION AND VACCINE THEREOF
WO - 03.08.2023
Clasificación Internacional C07C 219/06 Nº de solicitud PCT/CN2023/073791 Solicitante CANSINO BIOLOGICS INC. Inventor/a WANG, Haomeng
Provided in the present invention are a novel cationic lipid, a lipid nanoparticle and a nucleic acid vaccine. In the present invention, a specific cationic lipid is selected for preparing a lipid nanoparticle mRNA vaccine, which is found to have better in-vitro stability and can stimulate a stronger immunoreaction compared with LNPs prepared from cationic lipids in the prior art.

7.WO/2023/147337LARGE-SCALE FLAVIVIRAL VACCINE PRODUCTION AND MANUFACTURE
WO - 03.08.2023
Clasificación Internacional B01D 15/36 Nº de solicitud PCT/US2023/061230 Solicitante TAKEDA VACCINES, INC. Inventor/a SANTANGELO, Joseph David

The present invention provides methods for large-scale flaviviral vaccine production and manufacture. The methods provided herein are specifically contemplated for large-scale production and manufacture of live, attenuated flaviviral vaccines such as live, attenuated, dengue virus vaccines. Further, the methods provided herein pertain to formulation of live, attenuated, monovalent, divalent, trivalent, or tetravalent viral vaccine products.

8.20230241199PROTEIN-BASED NANOPARTICLE VACCINE FOR METAPNEUMOVIRUS
US - 03.08.2023
Clasificación Internacional A61K 39/145 Nº de solicitud 18126140 Solicitante Icosavax, Inc. Inventor/a Andrew Lawrence Feldhaus
Provided are virus-like particle vaccines for human metapneumovirus (hMPV) in which the ectodomain of hMPV F protein is linked to, and thereby displayed on, a symmetric protein-based virus-like particle. For example, the vaccine antigen may be a N-terminal fusion of the ectodomain of hMPV F protein to a protein having a multimerization domain for a one- or two-component virus-like particle, such as a two-component icosahedral virus-like particle. Further provided are vaccine compositions, methods of manufacturing, and methods of use, e.g., immunizing a subject to generate a protective immune response to hMPV.

9.WO/2023/147091CORONAVIRUS VACCINE
WO - 03.08.2023
Clasificación Internacional A61K 39/12 Nº de solicitud PCT/US2023/011790 Solicitante BIONTECH SE Inventor/a CHE, Ye
This disclosure relates to the field of RNA to prevent or treat coronavirus infection. In particular, the present disclosure relates to methods and agents for vaccination against coronavirus infection and inducing effective coronavirus antigen-specific immune responses such as antibody and/or T cell responses. Specifically, in one embodiment, the present disclosure relates to methods comprising administering to a subject RNA encoding a peptide or protein comprising an epitope of SARS-CoV-2 spike protein (S protein) for inducing an immune response against coronavirus S protein, in particular S protein of SARS-CoV-2, in the subject, i.e., vaccine RNA encoding vaccine antigen.

10.WO/2023/142885POLYHEDRAL NANOSTRUCTURE-BASED SARS-COV-2 VACCINE, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF
WO - 03.08.2023
Clasificación Internacional A61K 39/215 Nº de solicitud PCT/CN2022/143936 Solicitante SOOCHOW UNIVERSITY Inventor/a HU, Xiaolong
Disclosed in the present invention are a polyhedral nanostructure-based SARS-CoV-2 vaccine, a construction method therefor, and an application thereof. A polyhedral nanostructure is used to wrap a SARS-CoV-2 spike protein receptor binding domain (RBD) to achieve the preparation of a SARS-CoV-2 vaccine immunogen. By means of the construction of an in-vitro recombinant baculovirus vector for the expression of a fusion protein of a polyhedrin and an RBD, and the characteristic that the first 110 amino acid residues of a polyhedrin protein can form a nanocrystal structure, fusion expression of a polyhedrin and an RBD is realized, and an RBD protein can be wrapped by polyhedrin protein crystals, wherein the protein crystals can be separated and purified only by simple centrifugation in a laboratory.

11.WO/2023/144355*EX VIVO* HUMAN MODEL DESIGNED TO EVALUATE THE VACCINE POTENTIAL OF A COMPOSITION
WO - 03.08.2023
Clasificación Internacional G01N 33/50 Nº de solicitud PCT/EP2023/052096 Solicitante GENOSKIN Inventor/a SCHOLAERT, Manon

The present invention relates to an ex vivo method designed to evaluate the vaccine potential of a composition, the method comprising the steps of: ia) transcutaneously administering the composition to a skin explant comprising the epidermis, the dermis and the epidermal appendages, as well as a thickness of at least 5 millimetres of hypodermis; ib) determining the activation status of the antigen-presenting cells within the skin explant; and ii) determining the vaccine potential of the composition.

12.20230241193mRNA VACCINE DESIGN USING MULTIPLE INTERACTING IMMUNO-STIMULATORY PATHWAYS, FOR CANCER AND INFECTIOUS DISEASES
US - 03.08.2023
Clasificación Internacional A61K 39/00 Nº de solicitud 18163333 Solicitante MicroVAX, LLC Inventor/a Albert B. Deisseroth
An immunotherapeutic mRNA vaccine comprises a first translation unit comprising a secretable first fusion protein comprising a co-stimulatory molecule fused to a first TAA, adapted to generate a first TAA specific adaptive immune response by way of a first immunostimulatory pathway. The immunotherapeutic mRNA vaccine also comprises a second translation unit comprising a non-secretable second fusion protein comprising an identical co-stimulatory molecule fused to a second TAA identical to the first TAA, adapted to generate a second TAA specific adaptive immune response by way of a second immunostimulatory pathway, whereby the at least two immune response interact at one or more locations downstream to amplify the first TAA specific adaptive immune response.

13.WO/2023/147092CORONAVIRUS VACCINE
WO - 03.08.2023
Clasificación Internacional A61K 39/12 Nº de solicitud PCT/US2023/011791 Solicitante BIONTECH SE Inventor/a CHE, Ye
This disclosure relates to the field of RNA to prevent or treat coronavirus infection. In particular, the present disclosure relates to methods and agents for vaccination against coronavirus infection and inducing effective coronavirus antigen-specific immune responses such as antibody and/or T cell responses. Specifically, in one embodiment, the present disclosure relates to methods comprising administering to a subject RNA encoding a peptide or protein comprising an epitope of SARS-CoV-2 spike protein (S protein) for inducing an immune response against coronavirus S protein, in particular S protein of SARS-CoV-2, in the subject, i.e., vaccine RNA encoding vaccine antigen.

14.4216996IMPFSTOFFZUSAMMENSETZUNGEN FÜR MUKOSALE IMMUNANTWORT
EP - 02.08.2023
Clasificación Internacional A61K 39/215 Nº de solicitud 21873652 Solicitante NANT HOLDINGS IP LLC Inventor/a SOON-SHIONG PATRICK
Vaccine compositions are provided that comprise a lyophilized, adenovirus-based expression vector, and a stabilizing compound, such as such as aragonite. Further provided are compositions that include a solid dosage form made from aragonite for loading and delivery of a vaccine composition.

15.WO/2023/143591NOVEL IONIZABLE LIPID USED FOR NUCLEIC ACID DELIVERY AND LNP COMPOSITION THEREOF AND VACCINE
WO - 03.08.2023
Clasificación Internacional C07C 219/06 Nº de solicitud PCT/CN2023/073756 Solicitante CANSINO BIOLOGICS INC. Inventor/a LI, Jin
The present invention provides a novel cationic lipid, a lipid nanoparticle and a nucleic acid vaccine. It is found that the lipid nanoparticle mRNA vaccine prepared in the present invention by selecting a specific cationic lipid has better in-vitro stability and immunogenicity than LNPs prepared from cationic lipids in the prior art.

16.WO/2023/142219A METHOD FOR LARGE-SCALE PREPARATION OF HIGH-PURITY EXOSOMES
WO - 03.08.2023
Clasificación Internacional C12N 5/071 Nº de solicitud PCT/CN2022/079004 Solicitante NATIONAL VACCINE & SERUM INSTITUTE Inventor/a AN, Wenlin
Provided is a method for large-scale isolation of high-purity exosomes. This isolation method includes the following steps: pre-treatment of samples containing exosomes; crude extraction of exosomes via tangential flow microfiltration; exosomes purification by washing through repeated dilution and re-concentration of exosomes crude extracts to remove impurities; exosomes storage in buffer containing the stabilizer taurine (final concentration ranges from 4 to 100mM) at -80°C or as lyophilized powders. The method for large-scale preparation of exosomes has the advantages of cost effective, time saving, high purity, high yield, and suitable for the isolation and purification of exosomes from a wide range of biological materials.

17.WO/2023/147342LARGE-SCALE FLAVIVIRAL VACCINE PRODUCTION AND MANUFACTURE
WO - 03.08.2023
Clasificación Internacional B01D 15/36 Nº de solicitud PCT/US2023/061238 Solicitante TAKEDA VACCINES, INC. Inventor/a KHOO, Gary
The present invention provides methods for large-scale flaviviral vaccine production and manufacture. The methods provided herein are specifically contemplated for large-scale production and manufacture of live, attenuated flaviviral vaccines such as live, attenuated, dengue virus vaccines. Further, the methods provided herein pertain to formulation of live, attenuated, monovalent, divalent, trivalent, or tetravalent viral vaccine products.

18.20230241190VACCINE FOR TREATING MULTIPLE SCLEROSIS
US - 03.08.2023
Clasificación Internacional A61K 39/00 Nº de solicitud 18157484 Solicitante RESEARCH & BUSINESS FOUNDATION SUNGKYUNKWAN UNIVERSITY Inventor/a Jaeyun KIM
The present disclosure relates to a vaccine composition for treating multiple sclerosis. The vaccine composition of the present disclosure induces immune tolerance and suppresses autoimmune response itself, thus can be usefully applied to the treatment of multiple sclerosis.

19.WO/2023/150588A mRNA VACCINE DESIGN USING MULTIPLE INTERACTING IMMUNO-STIMULATORY PATHWAYS, FOR CANCER AND INFECTIOUS DISEASES
WO - 10.08.2023
Clasificación Internacional A61K 39/00 Nº de solicitud PCT/US2023/061805 Solicitante MICROVAX, LLC Inventor/a DEISSEROTH, Albert, B.
An immunotherapeutic mRNA vaccine comprises a first translation unit comprising a secretable first fusion protein comprising a co-stimulatory molecule fused to a first TAA, adapted to generate a first TAA specific adaptive immune response by way of a first immunostimulatory pathway. The immunotherapeutic mRNA vaccine also comprises a second translation unit comprising a non-secretable second fusion protein comprising an identical co-stimulatory molecule fused to a second TAA identical to the first TAA, adapted to generate a second TAA specific adaptive immune response by way of a second immunostimulatory pathway, whereby the at least two immune response interact at one or more locations downstream to amplify the first TAA specific adaptive immune response.

20.20230241202Adenovirus-Based SARS-CoV-2 Vaccine
US - 03.08.2023
Clasificación Internacional A61K 39/215 Nº de solicitud 17927548 Solicitante University of Pittsburgh - Of the Commonwealth System of Higher Education Inventor/a Andrea A. Gambotto

A recombinant coronavirus vaccine is provided. Methods of making and delivering the coronavirus vaccine also are provided along with a method of generating and anti-coronavirus immune response. A microneedle array is provided, along with methods of making and using the microneedle array.

21.WO/2023/150771PHARMACEUTICAL COMPOSITION FOR TREATMENT AND PREVENTION OF CORONAVIRUS INFECTION
WO - 10.08.2023
Clasificación Internacional A61K 39/215 Nº de solicitud PCT/US2023/062083 Solicitante OBI PHARMA, INC. Inventor/a LAI, Ming-Tain
Here we developed a COVID-19 vaccine using delta strain spike protein as the antigen to provide a more comprehensive protection against delta strain, and possibly certain degree of protection against other known variants. In combination with a saponin based ISCOM (immune stimulating complex) adjuvant in nanoparticle format, which provides better immunogenicity towards T cell responses than traditional Q.S-21. The vaccine candidate that shows the best immunogenicity would be further developed to enter clinical trial.

22.WO/2023/150457METHODS AND MATERIALS FOR IDENTIFYING AND TREATING VACCINE-INDUCED IMMUNE THROMBOTIC THROMBOCYTOPENIA
WO - 10.08.2023
Clasificación Internacional G01N 33/53 Nº de solicitud PCT/US2023/061341 Solicitante MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH Inventor/a PADMANABHAN, Anand
Methods and materials for identifying and/or treating mammals (e.g., humans) as having vaccine-induced immune thrombotic thrombocytopenia (VITT) are provided herein. In some cases, the methods and materials provided herein can be used to differentiate between VITT and spontaneous HIT.

23.WO/2023/149849AUTOMATIC ORAL CENTRAL DRINKER SYSTEM WITH VACCINE AND DRUG DOSING INTEGRATION FOR RODENT ANIMALS
WO - 10.08.2023
Clasificación Internacional A01K 7/02 Nº de solicitud PCT/TR2022/050165 Solicitante CUKUROVA UNIVERSITESI REKTORLUGU Inventor/a TEKELIOGLU, Bilge Kaan
The invention is designed for collective irrigation, drug and vaccine application to cages in facilities where mice, rats, rabbits, guinea pigs, etc., rodents are housed collectively, and to be used when necessary. It can be used in the administration of all oral (PO) viral, bacterial and mycotic vaccines. It can also be used for the application of water- soluble drugs in all infections and infestations, viral, bacterial, mycotic and parasitic (including protozoal and coccidia). It is related to the irrigation system, which is designed to be dosed in accordance with the type of rodent animal and delivered to the animals through the water system in certain periods and at the determined dose, and has the ability to do its own mechanical cleaning.

24.20230241194PRE-ERYTHROCYTIC MALARIA VACCINES
US - 03.08.2023
Clasificación Internacional A61K 39/015 Nº de solicitud 18011914 Solicitante Michael THEISEN Inventor/a C. Richter King
Pre-erythrocytic malaria vaccines with good preservation stability and immunostimulatory action are provided. According the present invention, combination use of a pharmaceutical composition comprising (4E,8E,12E,16E,20E)-N-{2-[{4-[(2-amino-4-{[(3S)-1-hydroxyhexan-3-yl]amino}-6-methylpyrimidin-5-yl)methyl]benzyl}(methyl)amino]ethyl}-4,8,12,17,21,25-hexamethylhexacosa-4,8,12,16,20,24-hexaeneamide, or a pharmaceutically acceptable salt thereof, as a vaccine adjuvant with enhanced specific immune response against antigens and good preservation stability and a malaria vaccine with

biological activity allow for the provision of pre-erythrocytic malaria vaccines with good preservation stability and immunostimulatory action.

25.4216982VARIANTE STAPHYLOCOCCUS AUREUS LUKA- UND LUKB-POLYPEPTIDE UND IMPFSTOFFZUSAMMENSETZUNGEN
EP - 02.08.2023
Clasificación Internacional A61K 38/16 Nº de solicitud 21873641 Solicitante JANSSEN PHARMACEUTICALS INC Inventor/a MORROW BRIAN
The present disclosure relates to *Staphylococcus* aureus leukocidin A (LukA) and leukocidin B (LukB) variant polypeptides, and polynucleotides encoding the LukA, LukB and LukAB variant polypeptides. The present disclosure further relates to vaccine compositions comprising these LukA and LukB variants, and methods of generating an immune response against *Staphylococcus aureus* in a subject.

26.20230241197PROTEIN MOLECULE USEFUL FOR ANTI-PSEUDOMONAS AERUGINOSA VACCINE
US - 03.08.2023
Clasificación Internacional A61K 39/104 Nº de solicitud 17927199 Solicitante KYOTO PREFECTURAL PUBLIC UNIVERSITY CORPORATION Inventor/a Teiji SAWA
The present invention provides a protein molecule effective for an anti-*Pseudomonas aeruginosa* vaccine. A protein molecule comprising PcrV antigen domain and at least one domain selected from the group consisting of OprF antigen domains and Exotoxin A antigen domains.

27.20230241198COMBINATION PORCINE VACCINE
US - 03.08.2023
Clasificación Internacional A61K 39/02 Nº de solicitud 18003056 Solicitante BOEHRINGER INGELHEIM ANIMAL HEALTH USA INC. Inventor/a Edgar Diaz
The present invention relates to a vaccine comprising an antigen of *Lawsonia intracellularis* and one or more antigens of at least one further pathogen selected from the group of porcine circovirus (PCV), *Mycoplasma hyopneumoniae* (*M. hyo*.) and porcine respiratory and reproductive syndrome virus (PRRSV), wherein the antigen of *Lawsonia intracellularis* is live *Lawsonia intracellularis*.

28.WO/2023/142999NUCLEIC ACID NANO VACCINE DERIVED FROM BACTERIAL OUTERMEMBRANE VESICLE AND USE THEREOF
WO - 03.08.2023
Clasificación Internacional C12N 15/88 Nº de solicitud PCT/CN2023/071288 Solicitante NATIONAL CENTER FOR NANOSCIENCE AND TECHNOLOGY Inventor/a NIE, Guangjun
A nano vaccine used for delivering an mRNA antigen and derived from a bacterial outermembrane vesicle and the use thereof. Specifically provided is a technology for displaying nucleic acid on the outer surface of a vesicle.

29.20230241195MICROENCAPSULATED ORAL STERNE VACCINE
US - 03.08.2023
Clasificación Internacional A61K 39/07 Nº de solicitud 18009095 Solicitante THE TEXAS A&M UNIVERSITY SYSTEM Inventor/a Jamie B. Felix
Methods and compositions for the immunization of animals and humans using an oral immunization or vaccine that comprises *B. anthracis* Sterne strain 34F2 spores suspended in alginate and coated with a shell containing poly-L-lysine (PEL), a vitelline protein B (VpB), or both and an external coating of alginate in an amount sufficient to protect an animal or human from a lethal dose of anthrax.

30.20230241111NOVEL IMMUNOTHERAPY AGAINST NEURONAL AND BRAIN TUMORS
US - 03.08.2023

Clasificación Internacional A61K 35/17 Nº de solicitud 18166936 Solicitante Immatics Biotechnologies GmbH Inventor/a Toni WEINSCHENK
The present invention relates to peptides, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated cytotoxic T cell (CTL) peptide epitopes, alone or in combination with other tumor-associated peptides that serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses. The present invention relates to 11 novel peptide sequences and their variants derived from HLA class I and class II molecules of human tumor cells that can be used in vaccine compositions for eliciting anti-tumor immune responses.

31.WO/2023/144231NEW METHOD FOR IDENTIFYING HERV-DERIVED EPITOPES
WO - 03.08.2023
Clasificación Internacional A61P 35/00 Nº de solicitud PCT/EP2023/051839 Solicitante ERVACCINE TECHNOLOGIES Inventor/a DEPIL, Stéphane
The present invention relates to methods for identifying HERV-derived T cell epitopes associated with cancer, and peptides comprising or consisting of epitopes identified by said method, expression vectors encoding said peptides, cytotoxic T lymphocytes (CTLs) of a subject treated with said peptides or vectors and engineered T cells expressing T-cell receptors recognizing said peptides. The present invention also relates to the use of said peptides, expression vectors, CTLs or engineered T cells as a vaccine or a medicament, and in particular the use of said peptides, expression vectors, CTLs or engineered T cells for use in preventing or treating cancer in a subject in need thereof.

32.20230242604B*44 RESTRICTED PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST CANCERS AND RELATED METHODS
US - 03.08.2023
Clasificación Internacional C07K 14/47 Nº de solicitud 18170154 Solicitante Immatics Biotechnologies GmbH Inventor/a Colette SONG
The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

33.WO/2023/147307VACCINE AGAINST LEPTOSPIROSIS
WO - 03.08.2023
Clasificación Internacional C07K 14/20 Nº de solicitud PCT/US2023/061173 Solicitante YALE UNIVERSITY Inventor/a WUNDER, Elsio
The disclosure provides a composition comprising an effective amount of a plurality of leptospiral proteins, or immunogenic fragments thereof. The disclosure further provides a method of generating an immune response against leptospirosis using a composition comprising the plurality of leptospiral proteins, or immunogenic fragments thereof, and an adjuvant.

34.WO/2023/144202A MURINE CYTOMEGALOVIRUS VACCINE VECTOR FOR ADMINISTRATION IN A NON-MOUSE SUBJECT
WO - 03.08.2023

Clasificación Internacional A61K 39/00 Nº de solicitud PCT/EP2023/051800 Solicitante HELMHOLTZ-ZENTRUM FÜR INFEKTIONSFORSCHUNG GMBH Inventor/a CICIN-SAIN, Luka
The invention relates to a replication-deficient murine Cytomegalovirus (MCMV) vector for use in inducing an antigen-specific immune response in a subject, wherein the subject is not a mouse, and wherein said vector expresses a disease antigen. The invention further relates to a pharmaceutical composition comprising a replication-deficient murine Cytomegalovirus (MCMV) vector suitable to induce an antigen-specific immune response in a subject, wherein said vector expresses a disease antigen, and wherein the composition is configured for administration to a non-mouse subject. In embodiments, the vector has a disrupted immediate-early 2 (ie2) gene causing a replication deficiency of said vector in a non-mouse subject. The invention further relates to a pharmaceutical composition for use in inducing an antigen-specific immune response in a non-mouse subject to the expressed disease antigen.

35.WO/2023/145417ADJUVANT COMPOSITION AND VACCINE COMPOSITION
WO - 03.08.2023
Clasificación Internacional A61K 39/39 Nº de solicitud PCT/JP2023/000336 Solicitante SHIN NIPPON BIOMEDICAL LABORATORIES, LTD. Inventor/a HARUTA, Shunji
An adjuvant composition containing an adjuvant and a complex including microparticles of a biodegradable polymer and/or cyclodextrin, wherein the adjuvant is incorporated into the microparticles of the biodegradable polymer and/or is clathrated in the cyclodextrin.

36.20230241108PEPTIDES AND COMBINATION OF PEPTIDES OF NON-CANONICAL ORIGIN FOR USE IN IMMUNOTHERAPY AGAINST DIFFERENT TYPES OF CANCERS
US - 03.08.2023
Clasificación Internacional A61K 35/17 Nº de solicitud 18164407 Solicitante Immatics Biotechnologies GmbH Inventor/a Heiko SCHUSTER
The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

37.20230241112PEPTIDES AND COMBINATION OF PEPTIDES OF NON-CANONICAL ORIGIN FOR USE IN IMMUNOTHERAPY AGAINST DIFFERENT TYPES OF CANCERS
US - 03.08.2023
Clasificación Internacional A61K 35/17 Nº de solicitud 18170690 Solicitante Immatics Biotechnologies GmbH Inventor/a Heiko SCHUSTER
The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

38.20230241115PEPTIDES AND COMBINATION OF PEPTIDES OF NON-CANONICAL ORIGIN FOR USE IN IMMUNOTHERAPY AGAINST DIFFERENT TYPES OF CANCERS
US - 03.08.2023
Clasificación Internacional A61K 35/17 Nº de solicitud 18173177 Solicitante Immatics Biotechnologies GmbH Inventor/a Heiko SCHUSTER
The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

39.20230241109PEPTIDES AND COMBINATION OF PEPTIDES OF NON-CANONICAL ORIGIN FOR USE IN IMMUNOTHERAPY AGAINST DIFFERENT TYPES OF CANCERS
US - 03.08.2023
Clasificación Internacional A61K 35/17 Nº de solicitud 18164413 Solicitante Immatics Biotechnologies GmbH Inventor/a Heiko SCHUSTER
The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

40.20230241114PEPTIDES AND COMBINATION OF PEPTIDES OF NON-CANONICAL ORIGIN FOR USE IN IMMUNOTHERAPY AGAINST DIFFERENT TYPES OF CANCERS
US - 03.08.2023
Clasificación Internacional A61K 35/17 Nº de solicitud 18173174 Solicitante Immatics Biotechnologies GmbH Inventor/a Heiko SCHUSTER
The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

41.20230241110PEPTIDES AND COMBINATION OF PEPTIDES OF NON-CANONICAL ORIGIN FOR USE IN IMMUNOTHERAPY AGAINST DIFFERENT TYPES OF CANCERS
US - 03.08.2023
Clasificación Internacional A61K 35/17 Nº de solicitud 18164418 Solicitante Immatics Biotechnologies GmbH Inventor/a Heiko SCHUSTER

The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

42.20230241113PEPTIDES AND COMBINATION OF PEPTIDES OF NON-CANONICAL ORIGIN FOR USE IN IMMUNOTHERAPY AGAINST DIFFERENT TYPES OF CANCERS
US - 03.08.2023
Clasificación Internacional A61K 35/17 Nº de solicitud 18170698 Solicitante Immatics Biotechnologies GmbH Inventor/a Heiko SCHUSTER
The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

43.WO/2023/142285ATTENUATION METHOD FOR INFLUENZA VIRUSES, ATTENUATED INFLUENZA VIRUS STRAIN, AND USE
WO - 03.08.2023
Clasificación Internacional C12N 7/01 Nº de solicitud PCT/CN2022/090199 Solicitante ZHEJIANG DIFFERENCE BIOTECHNOLOGY CO., LTD. Inventor/a SUN, Huimin
Provided are an attenuation method for influenza viruses, an attenuated influenza virus strain, and the use. The attenuation method comprises: deleting bases of an arbitrary number at random positions on an influenza virus conserved region M2 protein transmembrane domain and a cytoplasmic domain to obtain attenuated influenza viruses having corresponding base deletion. The attenuated influenza virus strain obtained by means of the attenuation method has good growth characteristics on an MDCK cell line expressing M2 protein. The virus strain of a high dose can grow in MDCK cells or chicken embryos and has high chicken erythrocyte agglutination titer. Balb/C mouse immunization by means of nasal instillation shows that: compared with parental virus IAV PR8, said strain is non-pathogenic to the mice. The random base deletion mode reduces the virulence of the influenza viruses, and lays a foundation for screening of a safer and more effective live attenuated IAV vaccine.

44.20230241240MULTIFUNCTIONAL IMMUNOTHERAPEUTIC MONOCLONAL ANTIBODY COMPLEXES AND CONJUGATES
US - 03.08.2023
Clasificación Internacional A61K 47/68 Nº de solicitud 18001542 Solicitante Shimon Slavin Inventor/a Shimon Slavin
Immunotherapeutic Monoclonal Antibody Complexes or Conjugates (IMAC) comprising readily accessible antibodies designed and approved for clinical use are provided using a one-step method that combines killing of existing cancer cells in parallel with induction of long-lasting anti-cancer vaccination. Methods for their use, alone or in combination with cancer killer cells including intentionally mismatched

donor T cells, NK cells concomitantly with additional anti-cancer or immune activating agents, or activation of patient's own immune system for personalized treatment of cancer and elimination of undesirable non-malignant cells are also provided. In addition, treatment method based on IMAC can be applied for in vivo vaccination against cancer using an existing malignant lesion as internal anti-cancer vaccine by engagement of patients antigen presenting cells for induction of long-lasting anti-cancer vaccination in situ against residual or recurrent disease.

45.2615177Coronavirus vaccine
GB - 02.08.2023
Clasificación Internacional A61K 39/215 Nº de solicitud 202217951 Solicitante BIONTECH SE Inventor/a ALEXANDER MUIK
The invention relates to a composition comprising a RNA sequence encoding the SARS-CoV-2 S protein of the Omicron variant or an immunogenic fragment thereof. Preferably the protein comprises the S1 subunit or the receptor binding domain (RBD) of the S protein. The Omicron variant could be BA.4, BA.5, BA.1, BA.2, XBB, XBB.1 or BQ.1.1. The composition is an immunogenic composition and further comprises lipid nanoparticles, modified uridines, a poly-A sequence and a linker. The immunogenic composition comprises a first and second RNA which can be formulated in separate or the same lipid nanoparticles. The immunogenic composition is used to induce immune response against SARS-CoV-2 in a subject, the response can be against Omicron, Beta, Alpha or Delta variants or the Wuhan strain. Also disclosed is an antigen that is not a BA.1 Omicron variant of SARS-CoV-2. An immunogenic composition comprising a first RNA encoding a SARS-CoV-2 S protein of a Wuhan strain, an Alpha, Beta or Delta variant and a second RNA that isn't a BA.1 Omicron variant. An immunogenic composition comprising a first RNA encoding a SARS-CoV-2 S protein of a Wuhan strain, an Alpha, Beta, Delta or BA.1 variant and a second RNA which is antigenically distinct.

46.4217066BCG-IMPFUNGEN ZUR PRÄVENTION VON COVID-19 UND ANDEREN INFEKTIONSKRANKHEITEN
EP - 02.08.2023
Clasificación Internacional A61P 31/06 Nº de solicitud 21873441 Solicitante MASSACHUSETTS GEN HOSPITAL Inventor/a FAUSTMAN DENISE L
The invention relates, in part, to a method for the prophylactic treatment of a coronavirus infection in a human adult subject comprising administering at least two doses of a Bacillus Calmette-Guerin (BCG) vaccine to the subject, wherein the subject is a type I diabetic.

47.WO/2023/142284NUCLEIC ACID-LOADED LIPID NANOPARTICLE FREEZE-DRIED PREPARATION AS WELL AS PREPARATION METHOD THEREFOR AND USE THEREOF
WO - 03.08.2023
Clasificación Internacional A61K 9/127 Nº de solicitud PCT/CN2022/090197 Solicitante SHENZHEN RHEGEN BIOTECHNOLOGY CO., LTD. Inventor/a HU, Yong
Provided are a nucleic acid-loaded lipid nanoparticle freeze-dried preparation as well as a preparation method therefor and the use thereof. A freeze-drying method for nucleic acid-loaded lipid nanoparticles comprises the steps of: preparing a buffer solution containing nucleic acid-loaded lipid nanoparticles and a freeze-drying protective agent; lowering temperature for pre-freezing same; and under a vacuum condition, raising temperature for drying same so as to reduce the water content of a system to 3% or less, such that a dried preparation of the nucleic acid-loaded lipid nanoparticles is prepared. The prepared dried preparation of the nucleic acid-loaded lipid nanoparticles can be stored for a long time at room temperature, still maintains a stable nanoparticle size and a zeta potential after being re-dissolved,

exhibits quite high nucleic acid entrapment efficiency and biological activity, and is particularly suitable for preparing mRNA vaccine freeze-dried powder preparations for novel coronaviruses.

48.WO/2023/150757IMMUNOGENIC MRNA DELIVERY VEHICLES
WO - 10.08.2023
Clasificación Internacional A61K 9/51 Nº de solicitud PCT/US2023/062063 Solicitante CORNER THERAPEUTICS, INC. Inventor/a CORNFORTH, Andrew N.
The present disclosure relates to lipid-based delivery vehicles for mRNA vaccines, which include a lysophosphatidylcholine (LPC) compound for enhancing vaccine immunogenicity. The present disclosure also relates to methods for use of the mRNA vaccines.

49.20230241209METHOD FOR PREPARING COMBINATION VACCINE ADJUANT BASED ON CARBOXYL MODIFIED ALUMINUM OXYHYDROXIDE NANOPARTICLES
US - 03.08.2023
Clasificación Internacional A61K 39/39 Nº de solicitud 18002822 Solicitante DALIAN UNIVERSITY OF TECHNOLOGY Inventor/a Changying XUE
A method for preparing a combination adjuvant is based on carboxyl modified aluminum oxyhydroxide nanoparticles. The preparation method uses carboxylated hydroxyl oxide nanoparticles as a carrier, but is not limited to the role of a carrier. The carboxylated hydroxyl oxide nanoparticles are combined with a novel CpG-ODN adjuvant, such that the half-life period of a CpG adjuvant is prolonged. The combination of adjuvants shows a synergistic effect, such that the Th2 type immune stimulation ability is enhanced, and the possibility of Th1 type immunity is also given to the adjuvant.

50.20230241208Glyconjugate Vaccines
US - 03.08.2023
Clasificación Internacional A61K 39/385 Nº de solicitud 17052485 Solicitante London School of Hygiene & Tropical Medicine Inventor/a Brendan WREN
This invention relates to the use of *S. pneumoniae* protein antigens, such as NanA, PiuA and Sp0148, as carriers for immunogenic *S. pneumoniae* capsular polysaccharide. This may be useful for example in glycoconjugate vaccines able to generate a protective immune response against multiple capsular serotypes. Glycoconjugates, vaccine compositions and methods of manufacture and use are provided.

51.4219524NEUARTIGE PEPTIDE UND KOMBINATION AUS PEPTIDEN ZUR VERWENDUNG IN DER IMMUNTHERAPIE GEGEN AML UND ANDERE KARZINOME
EP - 02.08.2023
Clasificación Internacional C07K 7/06 Nº de solicitud 22211062 Solicitante IMMATICS BIOTECHNOLOGIES GMBH Inventor/a MAHR ANDREA
The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

52.4218808ADJUVANS- UND IMPFSTOFFZUSAMMENSETZUNGEN
EP - 02.08.2023
Clasificación Internacional A61K 39/39 Nº de solicitud 23153466 Solicitante ADVANCED BIOADJUVANTS LLC Inventor/a GERBER JAY D

Methods are provided for preparing and delivering an adjuvant for vaccines including lecithin, polymer and one or more additives. The polymer is preferably polyacrylic acid-based. The additive is preferably one or more of a glycoside and a sterol. The method of preparation includes hydrating lecithin and a polymer in saline or water and mixing the lecithin and polymer to form the adjuvant. Additives can be included prior to or after hydration of the lecithin and polymer.

53.WO/2023/144527INTRADERMAL VACCINE COMPLEMENT
WO - 03.08.2023
Clasificación Internacional A61K 39/09 Nº de solicitud PCT/GB2023/050159 Solicitante VAN DE VELDE, Nicolas Inventor/a VAN DE VELDE, Nicolas
The invention relates to intradermal immunogenic compositions, methods of administering such compositions, methods of use of the compositions in combination with pneumococcal vaccines, and kits comprising intradermal delivery devices and pre-filled syringes of the compositions.

54.WO/2023/147090PHARMACEUTICAL COMPOSITIONS FOR DELIVERY OF HERPES SIMPLEX VIRUS ANTIGENS AND RELATED METHODS
WO - 03.08.2023
Clasificación Internacional A61K 31/7105 Nº de solicitud PCT/US2023/011789 Solicitante BIONTECH SE Inventor/a SAHIN, Ugur
The present disclosure provides pharmaceutical compositions for delivery of HSV antigens (e.g., an HSV vaccine) and related technologies (e.g., components thereof and/or methods relating thereto).

55.20230241107NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST EPITHELIAL OVARIAN CANCER AND OTHER CANCERS
US - 03.08.2023
Clasificación Internacional A61K 35/17 Nº de solicitud 18047236 Solicitante Immatics Biotechnologies GmbH Inventor/a Heiko SCHUSTER
The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

56.4217484NUKLEINSÄURENANOSTRUKTUREN ZUR ZUFÜHRUNG VON NUKLEINSÄURESEQUENZEN AN ZELLEN
EP - 02.08.2023
Clasificación Internacional C12N 15/11 Nº de solicitud 21801602 Solicitante UCL BUSINESS LTD Inventor/a HOWORKA STEFAN
Improved nucleic acid nanostructures provide a platform for stable and effective intra-cellular delivery of nucleic acids, suitably coding nucleic acids such as mRNA or ssDNA. A nucleic acid nanostructure is provided that comprises a first single stranded nucleic acid sequence that defines a scaffold sequence, wherein the scaffold sequence comprises at least one open reading frame that encodes a first gene product; and a plurality of single stranded nucleic acid sequences that define a plurality of staple sequences, wherein the plurality of staple sequences are capable of hybridising with one or more regions of the scaffold sequence in order to induce the formation of a geometrically defined higher order structure. The nanostructure may further comprise at least one membrane binding moiety, wherein the

membrane binding moiety is configured to associate with a cell membrane. The nanostructures may be used in pharmaceutical compositions, such as vaccine compositions, and in methods of treating subjects in need thereof.

57.20230241106NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST EPITHELIAL OVARIAN CANCER AND OTHER CANCERS
US - 03.08.2023
Clasificación Internacional A61K 35/17 Nº de solicitud 18047234 Solicitante Immatics Biotechnologies GmbH Inventor/a Heiko SCHUSTER
The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

58.20230242940METHODS OF MAKING AND USING A VACCINE AGAINST CORONAVIRUS
US - 03.08.2023
Clasificación Internacional C12N 15/86 Nº de solicitud 17918878 Solicitante Massachusetts Eye and Ear Infirmary Inventor/a Luc H. Vandenberghe
Provided herein are vaccines against coronavirus that utilize adeno-associated virus (AAV) for delivery.

59.4218807ZIKA-VIRUS-IMPFSTOFF
EP - 02.08.2023
Clasificación Internacional A61K 39/12 Nº de solicitud 23152481 Solicitante VALNEVA AUSTRIA GMBH Inventor/a BARBERO CALZADO JANA
Described herein are Zika virus vaccines and compositions and methods of producing and administering said vaccines to subjects in need thereof.

60.20230242594ENGINEERED CORONAVIRUS SPIKE (S) PROTEIN AND METHODS OF USE THEREOF
US - 03.08.2023
Clasificación Internacional C07K 14/005 Nº de solicitud 18000112 Solicitante BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM Inventor/a Jason MCLELLAN
Provided herein are engineered Coronavirus S proteins, such as engineered SARS-CoV-2 S proteins. In some aspects, the engineered S proteins exhibit enhanced conformational stability and/or antigenicity. Methods are also provided for use of engineered proteins as diagnostics, in screening platforms and/or in vaccine compositions.

61.WO/2023/143606FULLY HUMAN ENDOGENOUS GENE DELIVERY SYSTEM
WO - 03.08.2023
Clasificación Internacional C12N 15/12 Nº de solicitud PCT/CN2023/073840 Solicitante INNOVEC BIOTHERAPEUTICS Inventor/a WANG, Cheng
Provided is a fully human endogenous gene delivery system, which comprising a human endogenous enveloping protein, a human endogenous capsid protein, and a gene of interest. The endogenous gene delivery can be applied to CRISPR system, gene therapy,vaccine manufacturing and the like.

62.WO/2023/142286GROUP OF ATTENUATED STRAINS OF INFLUENZA A VIRUS BASED ON SYNONYMOUS MUTATION AND/OR DELETION MUTATION, AND PREPARATION METHOD THEREFOR AND USE THEREOF
WO - 03.08.2023
Clasificación Internacional C12N 7/04 Nº de solicitud PCT/CN2022/090204 Solicitante ZHEJIANG DIFFERENCE BIOTECHNOLOGY CO., LTD Inventor/a YU, Fei
Provided are a group of attenuated strains of the influenza A virus based on synonymous mutation and/or deletion mutation, and a preparation method therefor and the use thereof. The attenuated strains are obtained by modifying an M2 gene; the modification comprises performing synonymous mutation on an overlapping part of the M2 gene and an M1 gene in an M gene of the influenza A virus to ensure that the amino acid sequence of M1 is complete and unchanged; or the modification comprises performing synonymous mutation on the overlapping part of the M2 gene and the M1 gene in the M gene of the influenza A virus to ensure that the amino acid sequence of M1 is complete and unchanged, and deleting some nucleotide sequences from the M2 gene. The attenuated strains have strong stability, do not undergo reverse mutation after multiple instances of subculturing, have high safety, do not have a strong dependence on a cell line, and have relatively high advantages in a vaccine production process.

63.20230241196GONORRHEA SUBUNIT VACCINE
US - 03.08.2023
Clasificación Internacional A61K 39/095 Nº de solicitud 17790360 Solicitante Oregon State University Inventor/a Aleksandra E. Sikora
Methods are disclosed for inducing an immune response to Neisseria gonorrhoeae in a mammalian subject. These methods include administering to the mammalian subject an effective amount of a MetQ protein and an effective amount of a K-type CpG oligodeoxynucleotide, thereby inducing the immune response. Also disclosed are immunogenic compositions including an effective amount of a MetQ protein and an effective amount of a K-type CpG oligodeoxynucleotide.

64.4217006VERBINDUNG ZUR ERHÖHUNG DER WIRKSAMKEIT VON VIRALEN VEKTOREN
EP - 02.08.2023
Clasificación Internacional A61K 47/64 Nº de solicitud 21778157 Solicitante ABLEVIA BIOTECH GMBH Inventor/a SMRZKA OSKAR
The present invention provides a compound for the sequestration of undesirable neutralizing antibodies against viral vectors (as used in vaccines and in gene therapy) in a patient. The compound comprises an inert biopolymer scaffold and at least a first peptide n-mer of the general formula P (— S — P)$_{(n-1)}$ and a second peptide n-mer of the general formula P (— S — P)$_{(n-1)}$; wherein, independently for each occurrence, P is a peptide with a sequence length of 2-13 amino acids and S is a non-peptide spacer, wherein, independently for each of the peptide n-mers, n is an integer of at least 1, wherein each of the peptide n-mers is bound to the biopolymer scaffold. Independently for each occurrence, P has an amino-acid sequence comprising a sequence fragment with a length of at least six amino acids of a capsid protein sequence of a viral vector. Also provided are pharmaceutical compositions comprising the compound, as well as a method of sequestering one or more antibodies present in an individual and a method of inhibiting an undesirable immune reaction to a treatment with a vaccine or a gene therapy composition.

65.WO/2023/149846AN IMMUNOGENIC COMPOSITION OF DISEASE-ASSOCIATED ANTIGENS FOR USE IN A VACCINE, ANTIBODY PRODUCTION AND IMMUNODIAGNOSTIC TESTS
WO - 10.08.2023

Clasificación Internacional C07K 14/005 Nº de solicitud PCT/TR2022/050090 Solicitante SAHIN, Fikret Inventor/a SAHIN, Fikret
The invention is based on the deletion of 21 amino acids from the C-terminal region of the S2 subunit of SARS-CoV2-S protein and transporting the S1 subunit, which is fused to S2 to the cell membranes. In this way, the presentation of the antigenic S1 subunit of SARS-CoV2-S protein in large amounts and in its natural structure in the cell membrane and its use as a whole cell or cell membrane has been determined as a new vaccination protocol for the SARS-CoV-2. Designing the S2 subunit of SARS-CoV2-S protein as a carrier, fusing any bacterial, viral, and tumor proteins with antigenic properties and transpoting it to the cell membrane will be a comprehensive vaccination protocol that will cover all bacteriae, viruses and even tumors.

66.WO/2023/148256INACTIVATED SARS-COV-2 VIRUS VACCINE
WO - 10.08.2023
Clasificación Internacional A61K 39/12 Nº de solicitud PCT/EP2023/052534 Solicitante VALNEVA AUSTRIA GMBH Inventor/a
Described herein are SARS-CoV-2 vaccines and compositions and methods of producing and administering said vaccines to subjects in need thereof.

67.4219706AUTOMATISIERTE DSDNA-SYNTHESE UNTER VERWENDUNG EINES DIGITAL-BIOLOGISCHEN WANDLERS
EP - 02.08.2023
Clasificación Internacional C12N 15/00 Nº de solicitud 22215974 Solicitante SYNTHETIC GENOMICS INC Inventor/a VENTER J CRAIG
The present invention provides a system for receiving biological sequence information and activating the synthesis of a biological entity. The system has a receiving unit for receiving a signal encoding biological sequence information transmitted from a transmitting unit. The transmitting unit can be present at a remote location from the receiving unit. The system also has an assembly unit connected to the receiving unit, and the assembly unit assembles the biological entity according to the biological sequence information. Thus, according to the present invention biological sequence information can be digitally transmitted to a remote location and the information converted into a biological entity, for example a protein useful as a vaccine, immediately upon being received by the receiving unit and without further human intervention after preparing the system for receipt of the information. The invention is useful, for example, for rapidly responding to viral and other biological threats that are specific to a particular locale.

68.4219525VON FOXM1 ABGELEITETES PEPTID UND IMPFSTOFF DAMIT
EP - 02.08.2023
Clasificación Internacional C07K 7/06 Nº de solicitud 23150049 Solicitante ONCOTHERAPY SCIENCE INC Inventor/a YAMASHITA SACHIKO
The present invention provides FOXM1-derived epitope peptides having the ability to induce cytotoxic T cells. The present invention further provides polynucleotides encoding the peptides, antigen-presenting cells presenting the peptides, and cytotoxic T cells targeting the peptides, as well as methods of inducing the antigen-presenting cells or CTLs. The present invention also provides compositions and pharmaceutical compositions containing them as an active ingredient. Further, the present invention provides methods of treating and/or preventing cancer, and/or preventing postoperative recurrence thereof, using the peptides, polynucleotides, antigen-presenting cells, cytotoxic T cells or pharmaceutical compositions of the present invention. Methods of inducing an immune response against cancer are also provided.

69.WO/2023/142647NEW TYPE THERAPEUTIC NUCLEIC ACID VACCINE FOR HPV

WO - 03.08.2023
Clasificación Internacional C12N 15/62 Nº de solicitud PCT/CN2022/134851 Solicitante BEIJING AEONVITAL BIOMEDICINE RESEARCH CO., LTD. Inventor/a ZHANG, Xiujun
Provided is a nucleic acid sequence for the treatment and prevention of HPV infection diseases, wherein the nucleic acid sequence comprises an HPV16-AVLS1 sequence and an HPV16-AVLC1 sequence at a ratio of 1 : 1; and an HPV18-AVLS1 sequence and an HPV18-AVLC1 sequence at a ratio of 1 : 1. The sequence AVLS1 and the sequence AVLC1 respectively include two E6 proteins connected in series, two L1 short peptides, two L2 short peptides, two E7 proteins connected in series, a PADRE sequence and an adjuvant sequence; the N terminus of the sequence AVLS1 has a mouse IgK secretory peptide sequence; and the N terminus of the sequence AVLC1 has an ubiquitin sequence. The nucleic acid sequence can not only induce anti-E6/E7 antibodies, but also induce functional cellular immunity, and shows an effect for preventing and treating HPV-related tumors.

70.2023902297Wearable animal vaccine insulation apparatus
AU - 03.08.2023
Clasificación Internacional Nº de solicitud 2023902297 Solicitante Fisher, Marnie Inventor/a Fisher, Marnie

71.WO/2023/148333CO-VACCINATION WITH CD4 AND CD8 ANTIGENS
WO - 10.08.2023
Clasificación Internacional A61K 39/00 Nº de solicitud PCT/EP2023/052687 Solicitante CECAVA GMBH & CO. KG Inventor/a ZELBA, Henning
The present invention relates to a vaccine composition comprising a first peptide being an MHC I antigen and a second peptide being an MHC II antigen, wherein the sequence of the first peptide is comprised in the sequence of the second peptide. The present invention further relates to a kit of parts comprising the same. Instant compositions and kits are particularly useful in the methods of inducing or increasing an immune response in a subject. Instant compositions are further useful in the methods of treatment or prevention of a disease or a disorder in a subject, in particular an infectious disease or a cancer disease.

72.20230241328PRE-FILLED MULTI-FLUID MEDICAL DELIVERY ASSEMBLIES
US - 03.08.2023
Clasificación Internacional A61M 5/34 Nº de solicitud 18119114 Solicitante Koska Family Limited Inventor/a Marc Koska
A pre-filled medical delivery system can have a blow-fill-seal (BFS) module and a mixing assembly. The BFS module can have first and second chambers, first and second sealed ports, and first and second actuation members. Each chamber can have a respective liquid agent therein. Each sealed port and each actuation member can be in fluid communication with a respective one of the chambers. The mixing assembly can be constructed for coupling to the BFS module. When coupled to the BFS module, the mixing assembly can breach the seals of the first and second ports and provide fluid communication therebetween. The disclosed systems, when assembled, can combine the liquid agents from the first and second chambers of the BFS component and deliver the combination as a single dose of a therapeutic agent (e.g., vaccine, drug, medicament, etc.) to a patient.

73.WO/2023/142283SARS-COV-2 MRNA VACCINE, AND PREPARATION METHOD THEREFOR AND USE THEREOF
WO - 03.08.2023
Clasificación Internacional C12N 15/50 Nº de solicitud PCT/CN2022/090196 Solicitante SHENZHEN RHEGEN BIOTECHNOLOGY CO., LTD. Inventor/a HU, Yong

An mRNA molecule capable of encoding a target polypeptide. The target polypeptide comprises an NTD-RBD natural domain in a SARS-CoV-2 spike protein, wherein the NTD-RBD natural domain comprises an NTD fragment, an RBD fragment and a linker therebetween, and the linker is a natural amino acid sequence derived from the spike protein.

74.WO/2023/150638OMICRON CORONAVIRUS VACCINE CONSTRUCTS AND METHODS OF MAKING AND USING SAME
WO - 10.08.2023
Clasificación Internacional A61K 39/215 Nº de solicitud PCT/US2023/061878 Solicitante WASHINGTON UNIVERSITY Inventor/a DIAMOND, Michael
Provided herein are adenoviral vectors encoding spike protein variants of SARS-CoV2 coronavirus, and compositions comprising the vectors. Also provided are methods of prevention and treatment of SARS-CoV2 using the compositions provided.

NOTA ACLARATORIA: Las noticias y otras informaciones que aparecen en este boletín provienen de sitios públicos, debidamente referenciados mediante vínculos a Internet que permiten a los lectores acceder a las versiones electrónicas de sus fuentes originales. Hacemos el mayor esfuerzo por verificar de buena fe la objetividad, precisión y certeza de las opiniones, apreciaciones, proyecciones y comentarios que aparecen en sus contenidos, pero este boletín no puede garantizarlos de forma absoluta, ni se hace responsable de los errores u omisiones que pudieran contener. En este sentido, sugerimos a los lectores cautela y los alertamos de que asumen la total responsabilidad en el manejo de dichas informaciones; así como de cualquier daño o perjuicio en que incurran como resultado del uso de estas, tales como la toma de decisiones científicas, comerciales, financieras o de otro tipo.

Edición: Annia Ramos Rodríguez aramos@finlay.edu.cu
Randelys Molina Castro rmolina@finlay.edu.cu
Irina Crespo Molina icrespo@finlay.edu.cu
Yamira Puig Fernández yamipuig@finlay.edu.cu

FINLAY EDICIONES